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By Joshua A. Gunn 
 
 
Development and validation of ultra performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) methodologies for the purpose of detecting and quantifying 
common drugs of abuse in human meconium specimens is described. Meconium is the first stool 
passed by a newborn infant. Meconium formation occurs over several months of gestation and 
subsequent toxicological analysis of the specimens can be useful for identifying drugs and other 
xenobiotics indicative of prenatal drug exposure.  
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique 
which draws upon the principles of chromatography to run separations at higher flow rates for 
increased speed, while simultaneously achieving superior resolution and sensitivity. Tandem 
mass spectrometry experiments were performed using a triple quadrupole mass spectrometer 
equipped with an electrospray ionization (ESI) source operating in positive ion mode. 
Methodologies were developed and validated to detect and quantify amphetamine, 
methamphetamine, cocaine, benzoylecgonine, morphine, codeine, hydromorphone, and 6-
monoacetylmorphine (6-MAM) in authentic meconium specimens.  
Analytes were extracted from the meconium matrix using either a mixed mode solid 
phase extraction (SPE), or a supported-liquid extraction (SLE) employing columns containing a 
modified form of diatomaceous earth. Data acquisition was performed using multiple reaction 
monitoring (MRM) and quantitation of each analyte was performed using a working standard 
 
 
calibration curve. The analytical methodologies were fully validated for the meconium matrix, 
where linearity, matrix equivalence, selectivity, accuracy, precision, sensitivity, stability, and 
recovery were evaluated.  
Equivalence studies indicated that in all cases, certified drug free whole blood was a 
suitable matrix for the preparation of working calibration curves. Blank meconium specimens 
containing analytes at the LOQ, were spiked with various exogenous interferences and analyzed 
to assess the selectivity of the analytical method. All methodologies were deemed highly 
selective for the analyte of interest even in the presence of exogenous compounds commonly 
encountered in forensic specimens. Accuracy, precision, stability, and recovery were assessed at 
three different analyte concentrations corresponding to the LOQ, the ULOQ, and a concentration 
point midway between the two. Mean accuracies ranged from 94.6% to 99.6% over the three 
concentrations for the cocaine/benzoylecgonine methodology while the amphetamine and opiate 
assays also exhibited high accuracies with mean ranges of 93.6% to 98.4% and 93% to 99.6%, 
respectively. Inter and intra batch precision data indicated enhanced method precision and 
reproducibility relative to existing techniques. Intra-batch CV values ranged from 1.6 to 11.8% 
for the cocaine/benzoylecgonine methodology while inter-batch CV values ranged from 3.9% to 
6.2%. Intra-batch CV values ranged from 0.7% to 8.5% for the amphetamine/methamphetamine 
methodology while inter-batch CV values ranged from 1.9% to 6.2%. The opiate methodology 
was also highly precise with intra-batch CV values ranging from 1.2% to 10.7% while inter-
batch CV values ranged from 0.5% to 6.1% across the four analytes. While mean analyte 
recoveries ranged from 9.3% for benzoylecgonine to 76.3% for 6-monoacetylmorphine, the 
consistency and reproducibility of the extraction was acceptable for all analytes. Stability studies 
indicated that all analytes are stable in the meconium matrix when stored at 4°C and subjected to 
 
 
multiple freeze-thaw cycles over a 72 hour period. Limits of detection ranged from 250 pg/mL 
for methamphetamine, to 2.5 ng/mL for all four opiate analytes. Linear calibration for the 
cocaine/benzoylecgonine, amphetamine/methamphetamine, and opiate methodologies was 
achieved over the range of 10 – 250 ng/mL, 5 – 500 ng/mL, and 10 – 500 ng/mL, respectively.  
Recent technological advances made in the field of particle chemistry mean that liquid 
chromatographic separations can be performed at higher flow rates for increased speed without 
sacrificing resolution or sensitivity. The increased speed, resolution, sensitivity, and separation 
efficiency afforded by UPLC combined with the inherent selectivity and sensitivity of the 
tandem mass spectrometer allowed for the accurate quantitation of all 8 analytes in the 
meconium matrix in a time and cost effective manner. Development and validation of such 
analytical methodologies will prove beneficial for the identification of prenatal substance abuse 
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Chapter 1: Introduction to Prenatal Substance Abuse and Its Clinical and 
Forensic Significance 
1.1 Introduction 
Prenatal substance abuse is an ongoing concern due to the characteristic physical and 
mental developmental problems that result from drug abuse during pregnancy. Illicit drug 
consumption continues to increase across geographical, social, and cultural groups worldwide 
and in 2000 The World Drug Report estimated 180 million people, or 3% of the worlds 
inhabitants to be drug users[1]. Substance abuse in the United States has reached epidemic 
proportions during the past two decades and in 2006 an estimated 20.4 million Americans aged 
12 years or older were users of illicit drugs[2, 3]. This estimation represents 8.3% of the 
American population aged 12 years or older[2]. Females constitute approximately 30% of the 
substance addicted population in the United States and most are of childbearing age[4]. Among 
pregnant women aged 15 to 44 years who participated in the 2006 National Survey on Drug Use 
and Health (NSDUH), 4.0% reported having used illicit drugs within 1 month of the survey[2]. 
National findings from the 2006 survey indicate that the rate of illicit drug use among pregnant 
women aged 15 to 44 years has remained steady since 2003[2].  
Estimating the prevalence of drug use among pregnant women based on maternal history 
or broad scale surveys often proves unreliable due to guilt, embarrassment, fear of reprisal, or of 
loss of custody[5]. As a result, identification of the drug exposed neonate is a difficult task and 
even in the case of maternal admission, information regarding the type and/or extent of drug use 
is often inaccurate[6]. One survey based on maternal report estimated that the prevalence of drug 
abuse among pregnant women ranged between 0.4% and 27%[6, 7]. A survey conducted on 
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infants delivered at a tertiary perinatal center illustrated the inaccuracy of estimations based on 
maternal history. While only 10.5% of infants were birthed to mothers suspected of drug use 
based on maternal history, subsequent drug testing revealed that 42% of infants had been 
exposed to illicit drugs[8]. Another study of 3000 infants illustrated the inaccuracies associated 
with maternal self-report. Of the 3000 infants monitored in the study, 43% were found to be 
positive for illicit substances through toxicological analysis, while only 11% of these were 
reported by the mother[9].  
A study conducted on the prevalence of cocaine use during pregnancy in the early 1990s 
reported that 37 out of 600 (6.25%) infants born across three metropolitan hospital nurseries in 
the Toronto area tested positive for cocaine[10]. These findings were consistent with estimations 
made by Birchfield et al who concluded that rates of infants exposed prenatally to cocaine range 
between 2.6% and 11% of all live births[11]. A nationwide survey carried out in the early 1990s 
at urban teaching hospitals indicated that 10-45% of the women cared for at those hospitals use 
cocaine during pregnancy[12]. A separate survey of 36 hospitals reported that 11% of the women 
studied had used illicit drugs during pregnancy[7]. A follow up report by the same authors in 
1992 estimated that between 500,000 and 750,000 newborns are exposed to illicit drugs each 
year[13].  
 Various neonatal health and developmental problems are thought to be directly related to 
fetal exposure to drugs, alcohol, chemical agents, or other xenobiotics [6, 14-16]. Despite 
extensive research and continued evidence of fetal and neonatal health risks, a large number of 
pregnant women are involved in illicit drug use[5]. Drug use during gestation is associated with 
higher risks for poor obstetrical outcomes, including placental abruption, premature labor, low 
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birth weight, microcephaly, congenital anomalies, necrotizing enterocolitis, neonatal withdrawal, 
neurobehavioral effects, subarachnoid and intracerebral hemorrhage, and fetal death[17-25].  
Due to the detrimental effects resulting from prenatal exposure to illicit substances, 
correct diagnosis of drug use during pregnancy is essential. Correct diagnosis and early 
intervention will allow the child to receive the specialized treatment and the care required to 
ensure that their development is not further compromised. Successful diagnosis of drug abuse 
during pregnancy will also assist in preventing the same mother from giving birth to subsequent 
drug-exposed children[26]. It is extremely important to ensure that the early diagnosis of drug 
abuse during pregnancy not only brings about beneficial changes in the environment of the 
infant, but also aids in the successful rehabilitation of substance addicted mothers[27]. Although 
the early identification of prenatal substance abuse will aid in the long term wellbeing of the 
infant, without the implementation of a well defined intervention road map, such diagnosis also 
have the potential to cause harm to mothers, children, and families alike[28]. Careful 
consideration of the circumstances surrounding each and every positive result will ensure that a 
mother who has used drugs or alcohol at some time during pregnancy is not mislabeled as a 
substance abuser in the absence of true abuse. Review of positive results with mothers suspected 
of substance abuse will help to ensure that infants are not separated from their mothers and 
placed in living situations that offer no benefit[28].  
Traditional identification of neonatal drug exposure is accomplished using a combination 
of maternal history, newborn clinical symptoms and laboratory toxicology testing of the mother 
and the infant[27]. Generally, toxicological testing of the mother and infant will only occur if the 
consulting physician has reason to believe that prenatal substance abuse may be an issue based 
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on maternal history, or if the infant’s physical features meet certain criteria which are commonly 
associated with prenatal exposure to drugs.  
Many states mandate toxicology testing of all mothers and infants regardless of maternal 
history or certain physical features of the infant. Indiana’s Maternal & Children’s Special Health 
Care (MCSHC) department mandates laboratory testing of meconium specimens to detect the 
presence of controlled substances for those infants born in Indiana who meet selected criteria at 
birth. Toxicology testing is performed on high-risk newborns (1) whose weight is less than 2500 
grams and whose head circumference is smaller than the 10th percentile for the infant’s 
gestational age when there is no other medical explanation for these conditions; or (2) when 
there is maternal history of current or past drug use; or; (3) mother had no or inconsistent 
prenatal care (frequently missed appointments, hospital hopping); or (4) infant shows 
signs/symptoms suggestive of drug effects or withdrawal; or (5) unexpected abruption 
placentae[29]. Approximately 1,600 newborn infants meet one or more of these criteria in 
Indiana alone and many additional meconium specimens are submitted for analysis based on 
recommendations from the consulting physician[29]. 
1.2 Drug Transfer in the Maternal-Fetal Complex 
The placenta is a specialized organ which not only plays a lead role in fetal protection 
during intrauterine life but also continuously adapts itself to meet developmental and nutritional 
requirements of the fetus while in the uterus[30]. The role of the placenta as a transport organ is 
crucial for fetal development as it is responsible for transferring oxygen and nutrients to the fetus 
while simultaneously allowing for the efficient removal of fetal metabolism products by the 
mother[30, 31]. Essential nutrients such as amino acids, vitamins, phosphate, iron, mono- and 
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dicarboxylates, and glucose among others are transferred to the fetus throughout intrauterine life 
via very specific transport mechanisms present within in the placenta[31].  
The developing fetus is not only provided with essential nutrients and oxygen via specific 
placental transport mechanisms but is also effectively protected through the placentas ability to 
prevent the entry of various xenobiotics from the maternal blood supply[31]. Excluding drugs of 
large molecular weight, such as heparin or insulin, most drugs are thought to cross the placental 
membrane during pregnancy and are associated with varying degrees of fetal exposure[32]. In 
general, un-ionized molecules with low molecular weights and high lipid solubility will diffuse 
across the placental membrane more readily than large hydrophilic drug molecules[33]. Drugs 
that are highly bound to proteins or contain ionized functional groups in plasma (pH 7.4) will 
exhibit a much lower degree of placental diffusion than unionized, unbound drugs.  
The placenta also facilitates the passage of various xenobiotics form the fetus to the 
mother for elimination should they initially permeate the placental membrane. It is well 
documented that various licit and illicit drugs can indeed cross the placental membrane which 
represents the primary physiological link between mother and fetus [34-38].  
While most xenobiotics cross the placental membrane and enter the fetal bloodstream via 
passive diffusion, other potential transport mechanisms include facilitated diffusion, active 
transport, and filtration. The mechanism by which certain drugs permeate the placental 
membrane and enter the fetal bloodstream is dependent on the physicochemical properties of the 
compounds such as molecular size, polarity, and pKa, as well as lipid solubility and protein 
binding ability[32]. Maternal pharmacokinetics including the volume of distribution, rate of 
metabolism and excretion, and the effect of haemodynamic changes in the mother during 
pregnancy all impact the degree and severity of in utero drug exposure[32]. Maternal blood pH, 
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which dictates the state of ionizable functional groups, will also play a significant role in the 
drugs ability to cross the placenta[34].  
Numerous transport systems which recognize a wide variety of pharmacologically active 
drugs as substrates have been identified in the placenta, along with several additional transport 
systems whose role in the placenta remains an enigma[31]. There is strong evidence to suggest 
that several placental transport systems are direct targets for common drugs of abuse including 
cocaine, amphetamines, nicotine, and cannabinoids[31]. Interference of drugs of abuse with the 
transport function of the placenta can occur following a direct interaction of the drug with 
specific transporters, or through an indirect modification of cell signaling pathways or 
transmembrane ion gradients which subsequently influences transporter function[31].  
Accompanying the recognition that drugs of abuse significantly affect placental transport 
is the realization that maternal use of such drugs compromises the normal physiological function 
of the placenta. Unnatural changes in placental physiology resulting from maternal drug use 
produces deleterious effects in the mother as well as in the developing fetus[31].  
1.3 Traditional Testing Procedures 
Toxicological analysis of maternal and neonatal specimens is an objective means of 
identifying prenatal drug exposure. Analysis of biological specimens obtained from the neonate 
is necessary to document proof of the infant’s exposure to illicit drugs, even if the mother admits 
to the use of illicit substances[39]. Positive toxicology testing in the infant facilitates court action 
in the cases where authorities have recommended the child be removed from the mothers care 
and placed in foster care[39].  
Traditional toxicological analyses aimed at identifying prenatal exposure to illicit 
substances have utilized various maternal and neonatal specimens over the years. Maternal blood 
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is routinely analyzed for the presence of illicit substances in the mother. However, due to the 
relatively short retention time of most drugs in blood, and the invasiveness of sample collection, 
blood analysis is somewhat limited. Toxicological analysis of neonatal blood is rarely performed 
as serum drug levels in the infant largely depend on the time interval between the mother’s last 
drug intake and the subsequent collection of the neonatal blood. This time interval can be 
substantial and as a result drug levels in the neonatal blood will likely fall below detection limits 
for common screening techniques[39].  
Neonatal urine is the most widely analyzed biological fluid for the determination of in 
utero drug exposure and offers several distinct advantages over blood. Drug concentrations in 
neonatal urine will be higher than those in corresponding blood (serum) specimens due to the 
concentrating ability of the kidneys[40]. Neonatal urine also offers a slightly longer window of 
detection than blood and should indicate the presence of any substances that the neonate was 
exposed to in the last 3-7 days prior to delivery[41]. Urine also offers a larger volume for 
collection than blood and from a toxicological standpoint it is easier to analyze than blood 
because it is devoid of protein and cellular constituents that can complicate extraction and/or 
analysis techniques[40].  
Although neonate urine has been the most widely analyzed biological fluid for the 
identification of in utero exposure to drugs, it does have several disadvantages which can 
complicate collection and subsequent analyses. Neonatal urine collection is difficult, invasive 
and must be performed as close to birth as possible as appreciable levels of drugs and/or 
metabolites are expected to be present in the first specimen only[39, 41]. Drugs present in the 
infant’s urine represent recent drug use by the mother and depending on the physicochemical 
properties of the drug, the urine may test negative if the mother is an infrequent user or abstained 
8 
 
from use in the days leading up to delivery[39, 41]. Another common drawback to neonatal urine 
analysis is the fact that most laboratories adopt pre-existing urine-based methodologies to screen 
the infant’s urine for drugs of abuse. Unfortunately, neonatal urine is far from an ideal specimen 
for such analyses. Pre-existing urine-based methodologies have been widely developed and 
validated for use in workplace or forensic drug analysis[42]. Such screening techniques adopt 
cutoff levels deemed suitable for their intended purpose and will most likely be too high for the 
drug concentrations in clinical samples such as neonatal urine. Drug concentrations in neonatal 
urine following in utero exposure would be expected to be lower than concentrations seen in 
positive workplace or forensic samples due to maternal-fetal transfer kinetics, maternal 
abstinence or infrequent use, and compromised sample collection at the time of birth. As a result 
of these factors, several workplace drug testing thresholds have been shown to be too high for 
clinical samples. The consequence of such false negatives is an underestimation of drug exposure 
in the clinical setting. Multiple studies indicated that adopting lower cutoff levels for such assays 
can dramatically improve detection rates[43, 44]. Due to the relative short detection window 
offered by neonatal urine and a lack of recommended cutoff levels which take into account the 
pharmacokinetics of drug transfer and elimination, the incidence of false-negative results in 
neonatal urine analysis is high and can range from 32%-63%[41, 45]. 
Recently, meconium has become the specimen of choice for the detection of prenatal 
exposure to several drugs of abuse[26, 46]. Meconium is the first blackish tarlike material passed 
from the rectum by the newborn and is not fully evacuated until 125 hours post natal [47-49]. 
Meconium is a dark-green mass of water, epithelial cells, mucopolysaccharides, bile pigments, 
and other lipids which begins to form between the 12th and 16th week of gestation and 
accumulate until birth. Formation of meconium occurs in the fetal gut and results from 
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swallowed amniotic fluid and sloughed gastrointestinal epithelial cells[50]. Accumulation of 
drugs and other xenobiotics occurs in the meconium as a result of fetal swallowing. This 
phenomenon occurs when the fetus releases urine, containing drugs and metabolites, into the 
amniotic fluid where it is subsequently swallowed and deposited into the meconium. Subsequent 
exposure, excretion and reabsorption through fetal swallowing, combined with maternal 
metabolism and elimination, and placental transfer results in the concentration of drugs and their 
metabolites in meconium[51, 52]. At approximately the 16th week of gestation, the fetus 
possesses fully functional liver enzymes capable of metabolizing drugs, allowing for excretion 
into the bile and urine. Meconium is one of the most sensitive matrices for the detection of 
prenatal drug exposure due to the accumulation of substances over several months of gestation.  
The usefulness of meconium as an alternative toxicological specimen was first 
demonstrated by Ostrea et al[53] in the late 1980’s, and its popularity as a tool for the 
identification of prenatal exposure has continued to increase over the past two decades for 
several reasons. The first reason is the relatively simple and non-invasive procedure used to 
collect meconium samples, making it more successful than urine collection[54]. Meconium 
analysis also extends the window of drug detection to approximately the last 20 weeks of 
gestation as well as extending the window for specimen collection.  
Meconium analysis has become an extremely important tool for the identification of 
prenatal exposure to drugs of abuse. While the analysis of maternal and newborn blood or urine 
can be useful for identifying recent (1-4 days) drug use, mothers who have abstained from use in 
previous days will likely go undetected using these traditional matrices. However, due to nature 
of meconium formation, which occurs over several months of gestation, isolated drug use during 
the second and third trimesters will still be detectable through meconium analysis long after 
10 
 
drugs have been metabolized and excreted from the blood and urine. While blood and/or urine 
analysis proves useful for the identification of recent or chronic drug use, the extended detection 
window afforded by meconium analysis aids in identifying infants exposed to drugs through 
more isolated or recreational drug use which has previously gone undetected.  
1.4 History of Meconium Analysis 
The biochemical analysis of meconium for medical, clinical, and forensic purposes has 
been widely reported in the scientific literature for over a century. While this review will focus 
on the analysis of meconium for the purpose of identifying prenatal exposure to xenobiotics, 
various scientific reports have utilized meconium analysis for alternative purposes. Meconium 
analysis has been reported for the purpose of determining its metallic content[55], elucidating its 
chemical composition in relation to blood-group-specific polysaccharides and abnormalities in 
cases of meconium ileus[56], determining its tryptic activity in cases of congenital intestinal 
obstruction[57], and isolating and preparing blood group substances for the purposes of 
immunization studies[58].  
One of the first reported uses of meconium as an alternate toxicological specimen was 
published in 1956 by Kinsella and coworkers who wished to study the enteric excretion of 
metabolites of steroid hormones in the human[59]. Although the estrogenic activity of meconium 
had been previously reported by Gsell-Busse and coworkers[60], this was the first report of the 
successful isolation and detection of estrogens in meconium. The authors theorized that the 
isolation and detection of estriol should be possible due to the fact that meconium constitutes a 
concentrate and a record of enteric excretion of metabolites throughout the fetal life. Results 
indicated that estriol is present in the human intestinal content both as a free compound and as a 
glucuronide conjugate, and its isolation and detection from meconium is feasible. The authors 
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conclude that meconium should prove to be a fruitful biological material not only for the further 
investigation of steroid hormone metabolism but for other compounds of pharmacological 
interest[59].  
Four years later, the same authors applied a similar methodology for the isolation and 
determination of dehydroepiandrosterone from meconium[61]. While the determination of 
dehydroepiandrosterone supported the authors earlier theory that meconium constitutes a record 
of enteric excretion over the fetal lifetime, the absence of androsterone, a subsequent metabolite 
of dehydroepiandrosterone, indicated that vast differences may exist between fetal and adult 
intermediary metabolism.  
The potential value of meconium, not only as an alternate biological material for 
metabolic investigations, but also as a diagnostic tool to better understand the endocrinology of 
the fetus was being realized by the early 1960s thanks largely in part to the work of Kinsella et 
al. Following this work, several reports appeared in the scientific literature describing analytical 
methodologies for the isolation and determination of steroid hormones and their conjugates in 
human meconium for the purpose of endocrinology research [62-65]. Green and Shwachman 
proposed the use of presumptive testing for the purpose of identifying cystic fibrosis on the basis 
of high serum protein in meconium specimens[66]. The authors highlight the ongoing use of 
protein analysis for the identification of meconium ileus and suggest that abnormal serum protein 
levels in meconium may be a useful biomarker of cystic fibrosis in patients who did not have the 
complication of meconium ileus[66].  
Meconium was also utilized for the successful determination of listeria monocytogenes 
for the purpose of identifying listeriosis in the newborn infant[67]. In 1968, Miettinen and 
coworkers published one of the first studies on the application of gas chromatography and mass 
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spectrometry for the detection of sterols in several fetal specimens including vernix caseosa, 
amniotic fluid, and meconium[68].  
The first reported use of meconium as an alternative toxicological specimen for the 
detection of drug of abuse was published in 1987 by Ostrea et al who successfully detected 
heroin, cocaine, and cannabinoid metabolites in the stools of infants born to drug dependant 
mothers[69]. In the following year, Ostrea and coworkers described a method for the rapid 
isolation and detection of morphine and benzoylecgonine in meconium using a simple liquid 
extraction followed by radioimmunoassay screening and suggested that such a technique would 
prove superior for the detection of drug metabolites in meconium due to the low incidence of 
false positive results which tend to be common in urine analysis[41, 53].  
Ostrea continued to publish methodologies for the detection of drugs of abuse in 
meconium as alternatives to the more traditional urine analysis and in 1989 he and coworkers 
analyzed 20 meconium specimens obtained from drug dependant mothers to compare the 
analytical results with those obtained by urine analysis[45]. Of the 20 meconium specimens 
analyzed in the study, all were positive for at least one drug metabolite using radioimmunoassay 
(RIA) techniques. The widespread popularity of cocaine in the late 1980s was evident with 80% 
of the specimens screening positive for benzoylecgonine while 55% of the specimens were 
positive for morphine and 60% were indicative of cannabinoid use. Meconium specimens were 
analyzed over the first three days of evacuation and while drug concentrations were highest 
during the first two days of collection, positive determinations were still reported on the third day 
of collection. Analysis of the urine only yielded positive results for 37% of the infants using 
fluorescent polarization immunoassay (FPIA) and when paired urine and meconium specimens 
were analyzed using RIA, higher concentrations of drug metabolites were detected in meconium. 
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Interestingly, eight of the urine samples screened negative despite having a positive meconium 
result indicating that meconium constitutes a very useful matrix for drug screening in the 
neonate[45].  
Maynard and Amoruso also investigated the usefulness of meconium as a matrix for 
identifying prenatal exposure to drugs in abuse in 28 specimens collected from neonates born to 
women suspected of drug abuse[70]. Urine collected from the newborn, the mother, or both, 
along with meconium specimens were analyzed for the presence of cocaine, morphine, codeine 
and marijuana. Results obtained through the analysis of meconium specimens were concordant 
with urine analysis in 86% of the cases and in three cases meconium analysis yielded positive 
results for cocaine while the newborn urine specimens were negative. The authors conclude that 
due to the ease and reliable nature of meconium collection and the compatibility of this type of 
screen testing with high throughput commercial laboratories, meconium is a useful specimen for 
the detection of drugs in newborns[70].  
In 1991, Ostrea and Welch reviewed current analytical methodologies for the 
identification of maternal drug abuse and highlighted the importance of utilizing alternate 
specimens such as meconium or hair as recent literature suggested that urine analysis may 
seriously under diagnose the prevalence of fetal exposure to various drugs[71]. In the following 
year, Ostrea and coworkers published the first large-scale, prospective, epidemiological study 
into the prevalence and characteristics of maternal drug use in a high-risk, urban population by 
analyzing the meconium from more than 3000 neonates delivered in a single perinatal center 
over a ten month period[8]. Meconium specimens were analyzed were cocaine, morphine and 
cannabinoids using RIA. Of the 3010 subjects, 44% were positive for one or more of the drug 
classes while only 335 (11%) of the mothers actually admitted to maternal drug use. Of the 335 
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mothers who admitted drug use, 52% of their newborns returned positive urine samples while 
88% of the infants tested positive through meconium analysis. Due to the often normal 
appearance of infants who have been prenatally exposed to drugs and whose mothers deny such 
use, there is a growing need to more effectively identify the drug exposed child. The authors 
conclude that improved identification of exposed newborns is possible with meconium drug 
analysis[8].  
Callahan and coworkers evaluated the sensitivity of meconium analysis compared 
directly to hair and urine analysis for the detection of gestational exposure to cocaine[47]. The 
meconium, hair, and urine of 59 infants who had been prenatally exposed to cocaine were 
collected and analyzed using GC/MS, RIA and immunoassay, respectively. The authors 
determined the most sensitive matrices for the identification of prenatal drug exposure to be 
meconium or hair as traditional immunoassay analysis of the infants urine failed to identify 60% 
of the cocaine-exposed infants. GC/MS analysis of the meconium or RIA analysis of the infants 
hair appears to be capable of providing sufficient sensitivity required to identify fetal cocaine 
exposure which occurred during the last two trimesters of pregnancy[47].  
In 1992, Dahlem and colleagues published the results of yet another comparative study 
aimed at assessing the suitability of meconium relative to infant urine for the identification of in 
utero drug exposure[72]. The suitability of meconium relative to urine was assessed to identify 
the most accurate way of determining maternal drug use as maternal admissions often prove 
unreliable. Meconium and urine specimens were collected from twenty infants born to drug 
dependant mothers and analyzed using RIA. Nineteen of the twenty infants (95%) tested positive 
for drugs in meconium while only thirteen (65%) tested positive through immunoassay analysis 
of the urine. Urine analysis failed to detect the presence of morphine in three specimens, cocaine 
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in two specimens, and cannabinoids in three specimens. Results indicated that meconium is not 
only easier and less invasive to collect, but it also constitutes a reliable alternate matrix to urine 
for the detection of drugs in the neonate[72].  
Yawn and coworkers employed meconium screening in combination with urine analysis 
for the purpose of assessing substance use in rural Midwestern pregnant women[73]. Meconium 
specimens screened positive for cannabinoids in 1.1% of subjects, opiates in 0.6% of subjects, 
and cocaine in 0.1% of samples indicating that while substance use was relatively low in this 
particular rural area, meconium analysis provides a reliable technique for the detection of such 
use[73].  
By the mid 1990s, meconium was widely recognized as a sensitive matrix for the 
determination of prenatal drug exposure. The toxicological analysis of meconium specimens 
became more common in studies aimed at determining rates of maternal substance use rather 
than simply assessing the suitability of meconium for such analysis. In 1993, Dusick and 
coworkers employed meconium analysis to determine the association between prenatal cocaine 
exposure and intracranial ultrasonographic abnormalities, among other perinatal outcomes[74]. 
HPLC and GC/MS analysis of meconium specimens collected from 323 consecutively born very 
low birth weight infants enabled the researchers to assign infants to either a cocaine-exposed 
group, or a cocaine-nonexposed group to further study the relationship between prenatal 
substance abuse and adverse perinatal outcomes. Studies indicated that while cocaine does not 
appear to increase the incidence or severity of intracranial hemorrhage or periventricular 
leukomalacia, it does increase the risk of abruptio placentae, surgical ligation of a patent ductus 
arteriosus and seizures in very low birth weight infants. Meconium analysis will prove 
instrumental in identifying infants predisposed to such outcomes[74].  
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Rosengren and colleagues utilized meconium analysis to determine the prevalence of 
cocaine use and assess the perceptions and pitfalls associated with current predictors of maternal 
use[75]. Results indicated that meconium analysis is necessary to positively identify cocaine 
exposed infants as the more traditional predictors, such as the opinion of the nurse, can be 
frequently inaccurate. Lombarderoa and colleagues reported a sensitive GC/MS methodology for 
the detection of cocaine, benzoylecgonine and ecgonine methyl ester (EME) in meconium 
extracts taken directly from diapers of exposed infants[76]. The authors report a LOD of 11 
ng/mL and conclude that GC/MS analysis of meconium provides an attractive alternative to 
urine for the detection of cocaine and its metabolites as meconium collection is less invasive and 
less discomforting for the neonate[76].  
In 1994, following the publication of several methodologies for the detection of drugs in 
meconium specimens, Wingert and colleagues conducted a large scale study aimed at comparing 
meconium, maternal urine, and neonatal urine as matrices for the detection of maternal drug use 
during pregnancy[77]. Meconium, maternal urine and neonatal urine were collected from 423 
consecutive deliveries at a large, metropolitan obstetric hospital. Specimens were screened for 
cocaine, cannabinoids, codeine, morphine, and methadone using EMIT and positive screens were 
confirmed using GC/MS. Of the three matrices under investigation, meconium proved more 
reliable than maternal or neonatal urine for the detection of benzoylecgonine and was equally 
effective for the determination of codeine, morphine, cannabinoids and methadone[77]. Similar 
publications highlighting the usefulness of meconium for the sensitive detection of drugs of 
abuse lead to the widespread application of meconium analysis in both academic and health 
institutions worldwide [44, 46, 78-88].  
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Many early methodologies employed GC/MS for the determination of analytes in 
meconium. This was largely due to the complex nature of the meconium matrix which meant that 
chromatographic separation was required to isolate the analytes and mass spectral information 
was required for unequivocal identification. Chromatographic techniques coupled to mass 
spectrometric detectors have continued to find widespread use in forensic toxicology laboratories 
for the detection of drugs of abuse in meconium.  
1.4.1 Instrumental Methodologies Employed for the Analysis of Meconium 
A large majority of analytical methodologies reported in the literature describing the 
detection of xenobiotics in meconium have utilized GC/MS. Recent advances in analytical 
technologies have allowed for the application of even more sensitive and selective assays to the 
problem of identifying prenatal drug exposure in the neonate. In 2003, Pichini et al described a 
sensitive methodology for the detection of arecoline in meconium using high performance liquid 
chromatography (HPLC) coupled to a quadrupole mass spectrometer which was equipped with 
an electrospray ionization (ESI) source[89]. Chromatographic separation was achieved using a 
reversed phase column and the mass spectrometer was operated in single ion monitoring (SIM) 
mode allowing for a lower limit of quantitation (LLOQ) of 5 ng/g.  
One of the earliest applications of tandem mass spectrometry for the detection of xenobiotics was 
published in 2005 by Choo and coworkers who employed LC-APCI-MS/MS for the 
quantification of methadone and its metabolites following solid phase extraction (SPE) from 
human meconium[90]. The authors report a LLOQ of 5 ng/g, highlighting the enhanced 
sensitivity of the tandem mass spectrometer.  
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In 2006, Kato and colleagues reported a HPLC-MS/MS methodology employing isotope dilution 
and an on-line SPE for the sensitive determination of phthalate metabolites in meconium[91]. 
The efficiency of the solid phase extraction combined with the inherent sensitivity of tandem 
mass spectrometry enabled the authors to achieve LLOQs of between 0.2 and 0.7 ng/g. Since the 
appearance of these early studies in the scientific literature, tandem mass spectrometry has 
allowed for the low level detection of various analytes of forensic interest such as codeine, 
morphine, hydrocodone, hydromorphone, oxycodone, 6-acetylmorphine[92], amphetamine, 4-
hydroxy-3-methoxyamphetamine, 4-hydroxy-3-methoxymethamphetamine, methamphetamine, 
3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, 3,4-
methylenedioxymethamphetamine, norephedrine, p-hydroxyamphetamine, p-
hydroxymethamphetamine[93], alpha-hydroxyalprazolam, alpha-hydroxyethylflurazepam, alpha-
hydroxytriazolam, alprazolam, desalkylflurazepam, diazepam, lorazepam, midazolam, 
nordiazepam, oxazepam, temazepam, clonazepam, 7-aminoclonazepam[94], nicotine, cotinine, 
trans-3'-hydroxycotinine, nornicotine, norcotinine[95], buprenorphine, and 
norbuprenorphine[96].  
While meconium analysis is today performed largely for the purpose of identifying prenatal drug 
exposure, it also finds widespread application in the early identification of cystic fibrosis, 
identifying prenatal exposure to neurotoxicants such as organic pesticides, detection of 






Chapter 2: Introduction to the Laboratory Analysis of Toxicological 
Specimens 
2.1 Introduction 
The analytical methodology employed for the toxicological analysis of biological 
specimens depends largely on whether the testing aims to provide qualitative or quantitative 
information. Although the specifics of testing procedures may vary slightly from laboratory to 
laboratory, the process of measurement is usually divided into an initial screening test followed 
by a confirmation test. Most laboratories perform an initial screening test when asked to analyze 
any specimen for the presence of a certain drug or drug class. Screening tests provide the analyst 
with a relatively quick and cost effective way to determine whether a drug or drug class is likely 
to be present in a given specimen. Screening tests may be designed to detect the presence of a 
certain drug class, such as benzodiazepines, or may be a broad drug screen performed on a 
GC/MS which enables the analyst to screen for many drugs based on retention times and mass 
spectral data. Following a positive screen result, the presence of a drug or drug class should be 
confirmed using a second technique which draws on a different chemical principle. Confirmatory 
tests should be more selective for the target analyte than the initial screen. 
Forensic toxicology laboratories routinely offer specific testing panels aimed at detecting 
and quantifying specific drugs such as ‘drugs of abuse’, ‘analgesic medications’, ‘drug facilitated 
sexual assault (DFSA) drugs’, or ‘drugs capable of causing impairment’. Obviously the total 
number of drugs encountered in any one forensic case can be large and while certain drugs will 
provide important toxicological information, many of the drugs will not be relevant to the case at 
hand. By offering panels consisting of selected analytes, forensic toxicology laboratories can 
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provide the most relevant information without the cost of testing for additional analytes with 
little significant to the case.  
Confirmation assays are designed to identify and quantify only target analytes. The 
number of analytes included in each confirmation assay is often less than the number of 
compounds capable of generating a positive screen. Confirmation assays are generally designed 
to identify and quantify all analytes included in a specific panel. While positive screening results 
are possible due to cross reacting interferences, positive confirmations only arise when one or 
more target analytes are present in the sample. Table 1 outlines the common analytes and testing 












Table 1: Common analytes detected during ‘drugs of abuse’ screening and confirmation analysis. 
Drug class Analytes detected in screen testing Analytes detected in 
confirmation testing 
Amphetamines • Amphetamine derivatives 




Cannabinoids • Cannabinoids (THC and metabolites) 
• Cross reactants (pantoprazole, omeprazole)
• TCH 
• THC-COOH 
Cocaine • Cocaine and metabolites 




Methadone • Methadone and metabolites 
• Cross reactants (doxylamine)
• Methadone 
• EDDP 
Barbiturates • Barbiturates and metabolites 







Benzodiazepines • Benzodiazepines and metabolites 







Opiates • Opiate derivatives 









Mass spectrometry (MS) has long been the recommended technique for confirmatory 
testing and should be employed where possible and practical. Mass spectrometry provides the 
analyst with unique structural information making the unequivocal identification of individual 
drugs possible, even in the presence of chemically similar compounds. Confirmation analysis 
employing mass spectrometry is generally performed following a positive immunoassay screen. 
Both instrumentation and sample preparation procedures required for mass spectrometric 
analysis can be cost ineffective. Initial presumptive screening employing more cost effective 
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immunoassay techniques identifies a large majority of negative samples. This reduces the 
number of required confirmations and therefore the overall cost of analysis. 
Mass spectrometers coupled to either gas chromatographic (GC/MS) or liquid 
chromatographic (LC/MS) systems are the most commonly employed analytical techniques for 
confirmatory testing in the toxicology laboratory. Gas chromatography coupled with mass 
spectrometry has long been the most commonly employed confirmation technique in the 
toxicology laboratory. In recent years however, the coupling of liquid chromatography with mass 
spectrometry has found widespread use due to its decreased sample preparation requirements and 
increased sensitivity. Liquid chromatography also alleviates thermal complications associated 
with GC analysis. Many compounds do not naturally lend themselves to GC analysis as they are 
either too polar or insufficiently volatile. By chemically derivatizing the target analyte to either 
increase its overall volatility or decrease its polarity, it is possible to increase the suitability of a 
certain compound for GC analysis. While chemical derivatization alleviates some of the thermal 
complications associated with GC analysis, sample preparation requirements and long run times 
can prove time and cost ineffective in high throughput toxicology laboratories. Thermal stability 
also presents a problem when analyzing small drug molecules, as thermally labile compounds 
may undergo degradation in the injection port of the GC.  
Liquid chromatography offers the analyst the advantage of introducing samples in 
aqueous solvents and eliminates the need for chemical derivatization, thus greatly reducing 
sample preparation time and cost. Liquid chromatography employing tandem mass spectrometry 
has recently become the preferred technique for toxicological analyses due to its superior 
selectivity and sensitivity which enables the analyst to quantify lower levels of analyte in more 
complex matrices with reduced sample preparation. 
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2.2 Sample Preparation Techniques 
Sample preparation refers to a series of steps which are performed to transform a sample 
into a form that is suitable for analysis. There are numerous ways to prepare samples for 
chemical analysis and the method of choice depends on the nature of the sample, the method of 
chemical analysis that will follow preparation, and whether the testing is presumptive or 
confirmatory. Sample analysis in the forensic toxicology laboratory is typically chromatographic 
which requires more extensive sample cleanup than immunoassay or spectrophotometric based 
techniques.  
Due to the complex nature of biological specimens and the low concentrations of drug 
commonly encountered in forensic analysis, analytes of interest are often isolated or extracted 
from the sample matrix and concentrated prior to instrumental analysis[100]. Direct 
chromatographic analysis of biological specimens is not practical due to the large number of 
naturally occurring compounds present in specimens such as whole blood, urine, and meconium. 
Biological specimens are so rich in endogenous interfering species that any attempts to identify 
or quantify low levels of xenobiotics without prior isolation would prove inaccurate. Isolation 
and concentration of an analyte from a biological matrix prior to chromatographic analysis 
allows for a more accurate identification/quantitation and ensures instrument longevity.  
Chemical extractions, for the purpose of isolating and concentrating an analyte of interest 
from a biological matrix, are most commonly achieved using either liquid-liquid extractions 
(LLE) or solid-phase extractions (SPE).  
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2.2.1 Liquid – Liquid Extraction (LLE) 
Liquid-liquid extractions utilize differences in the pH and solubility characteristics of an 
analyte to effectively remove the compound from an aqueous matrix such as blood or urine. 
Liquid-liquid extractions are achieved by introducing an immiscible organic solvent to an 
appropriately buffered aqueous specimen. Compounds in a non-ionized form will prefer the 
lipophilic environment of the organic solvent while ionized species will remain the aqueous 
environment of the biological sample. By appropriately buffering the biological sample 
according the pH characteristics of the analyte, and introducing an immiscible organic solvent, 
un-ionized drug molecules will transfer to the organic layer while many of the biological 
components such as proteins remain in the aqueous layer. It is on this basis that liquid-liquid 
extractions allow for the effective removal of analytes from the surrounding biological 
matrix[100].  
Developing an efficient LLE requires knowledge of the physicochemical properties of the 
target analyte. Basic compounds are routinely extracted into organic solvents by first buffering 
the sample with an appropriate base or basic buffer solution. Under alkaline conditions, basic 
compounds will be unionized and will readily transfer into the organic environment of solvents 
such as hexane, toluene, dichloromethane or chloroform. Similarly, acidic analytes may be 
extracted into such solvents by first buffering the aqueous sample with an acid or acidic buffer 
solution to ensure that the target analyte is present in an un-ionized form. Target analytes are 
generally extracted into organic solvents with densities less than that of the aqueous layer to 
allow for easy transfer and subsequent concentration of the analyte through simple dry down and 
reconstitution steps.  
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2.2.2 Solid Phase Extractions (SPE) 
Solid phase extractions also aim to isolate and concentrate target analytes by removing 
sample impurities. Solid-phase extractions (SPE) were originally developed for the purpose of 
alleviating some of the time-related problems associated with multi-step liquid-liquid 
extractions[100]. In SPE, appropriately buffered samples are applied to a silica gel based packing 
material which is contained within a syringe barrel cartridge. Extractions are based on the 
physicochemical interaction between the packing material and the target analyte.  
Sample preparation using SPE usually consists of four basic steps; which include column 
conditioning, sample loading, wash steps, and analyte elution. The first step of a solid phase 
extraction is referred to as column conditioning which aims to make the subsequent extraction 
easier and more efficient. Conditioning the column with a non-polar solvent not only removes 
any impurities in the cartridge but also ensures maximum contact of the liquid and solid phases. 
Conditioning of the column with a solvent similar in nature to the sample solvent ensures that the 
sample will experience similar pH conditions when loaded onto the column. Failure to condition 
the column can result in poor recoveries and irreproducible results[101].  
Following column conditioning, the sample is loaded onto the SPE column in a solvent 
that is weak for the sorbent being used[101]. If the solvent is too strong for the analyte of 
interest, the analyte will not be retained on the sorbent and will simply pass through the column 
into waste. Once the sample has been loaded onto the column, several wash steps are generally 
performed to wash all remaining sample onto the sorbent and remove any undesirable sample 
components. Wash steps are generally performed with a weak solvent similar in nature to the 
loading solvent to ensure that no analyte is eluted during the wash process. Analyte elution is the 
final step of SPE and is achieved using a solvent that is strong for the sorbent being used.  
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While all SPE are performed using a similar sequence of events as the ones described 
above, the nature of the packing material may be varied to provide different retention 
mechanisms. Normal phase SPE involves the use of a solid phase consisting of polar functionally 
bonded silica with short carbon chains. In normal phase SPE, the polar sorbent acts to retain 
polar analytes while less polar components are washed through the sorbent into waste. Analyte 
elution is then achieved with a highly polar solvent. Reversed phase SPE utilizes a non-polar 
solid sorbent which generally consists of silicon derivatized with hydrocarbon chains. Retention 
is based on the hydrophobic effect and only non-polar or weakly polar analytes will retain on the 
sorbent surface. Analyte elution is achieved using non-polar organic solvents which disrupt the 
hydrophobic interaction between the sorbent and the analyte. 
While normal phase and reversed phase SPE separate analytes based on polarity, ion-
exchange SPE separates analyte based on electrostatic interaction existing between a charged or 
ionized analyte and a charged sorbent. Ion-exchange SPE requires that both the analyte of 
interest and the functional groups bonded to the solid phase are charged. Special consideration 
must therefore be given to the solvents of choice and their respective pH.  
Anion exchange sorbents are derivatized with positively charged functional groups and 
act to retain negatively charged analytes. Anion exchange SPE is well suited for the extraction of 
acidic compounds following buffering with a base to ensure that the analyte is negatively 
charged. Sample elution is performed through the addition of an organic solvent containing a 
concentrated acid (1-2% v/v) which acts to neutralize the molecule and increase its solubility in 
the organic elution solvent.  
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Cation exchange sorbents are derivatized with negatively charged functional groups and 
act to retain positively charged analytes. Cation exchange SPE is well suited for the extraction of 
basic compounds following buffering with an acid to ensure that the analyte is positively 
charged. Sample elution is performed through the addition of an organic solvent containing a 
concentrated base (1-2% v/v) which acts to neutralize the molecule and increase its solubility in 
the organic elution solvent.  
2.3 Chromatographic Separations in Forensic Toxicology 
The term chromatography defines the analytical separation technique in which the 
components of a mixture are carried through a stationary phase by the flow of a mobile phase. 
Subsequent separation of the individual components is based on the differences in migration 
rates among the sample components[102]. The two general categories of chromatography most 
commonly employed in forensic toxicology are liquid chromatography (LC) and gas 
chromatography (GC). In the former, the mobile phase is a liquid; in the latter it is a gas. 
Chromatographic separations play an integral role in forensic toxicology as traditional 
toxicological specimens commonly encountered in post mortem analysis require extensive 
sample separation to isolate the compound of interest from matrix interferences and other drugs. 
Gas chromatographic separations are performed by vaporizing and injecting a small 
volume of sample (typically 1µL) onto the head of a chromatographic column. The sample 
components are swept along the stationary phase by an inert carrier gas such as helium and the 
differing degrees of interaction between the gaseous analytes and the stationary phase causes the 
individual sample components to elute at different times. Stationary phases are comprised of a 
microscopic layer of liquid or polymer coated onto an inert solid support and contained within a 
metal capillary column maintained in a temperature-regulated oven[103]. Following injection of 
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a sample mixture onto the chromatographic column, each component partitions between the 
stationary phase and the mobile phase as it is continuously swept toward the detector. Sample 
components that have a high affinity for the stationary phase spend more time in that phase and 
take longer to reach the detector. As the individual components begin to elute from the 
chromatographic column, the detector produces a signal that is proportional to the amount of 
substance that passed through it[103]. Individual components that elute from the column are 
identified by a characteristic retention time which is a reproducible measure of the time interval 
between sample injection onto the column and peak detector response. Gas chromatographs are 
commonly interfaced with mass spectrometers because the low flow rates employed for capillary 
GC allow the column eluent to be directly fed into the ionization chamber of the mass 
spectrometer making for easy coupling. 
Liquid chromatographic separations are achieved by injecting a small volume of sample 
onto a column which is tightly packed with stationary phase particles. Sample components are 
carried through the column by a continuous flow of a liquid mobile phase solution. Individual 
compounds pass through the column at different rates due to the differences in their partitioning 
behavior between the mobile liquid phase and the stationary phase. Unlike gas chromatographic 
separations where there is no direct interaction between the mobile phase (carrier gas) and the 
analyte, each sample component experiences differing degrees of both chemical and physical 
interactions with the stationary phase and mobile phase as it traverses the LC column. Analytes 
are identified by a characteristic retention time which is an accurate measure of the time interval 
between sample injection onto the column and peak detector response.  
Before the development and implementation of sophisticated LC/MS interfaces, high 
performance liquid chromatography (HPLC) was the fastest growing and most widely employed 
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analytical separation technique due to its suitability for separating nonvolatile or thermally labile 
species not amendable to GC. Traditional HPLC systems were coupled to one of several 
detection systems that proved compatible with the liquid phase separation technique such as 
refractive index detectors, UV/VIS (fixed wavelength, variable wavelength, diode array) 
detectors, fluorescence detectors, and electrochemical detectors. The successful coupling of 
liquid chromatography to mass spectrometry required the development of sophisticated 
interfaces capable of combining the liquid phase separation technique, with the gas phase mass 
spectrometry technique carried out under vacuum.  
2.4 Ultra Performance Liquid Chromatography (UPLC) 
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique 
which draws upon the principles of chromatography to run separations at higher flow rates for 
increased speed, while simultaneously achieving superior resolution and sensitivity. Ultra 
performance liquid chromatography was developed through the recognition that a reduction in 
the stationary phase particle size will have the greatest benefit to any chromatographic 
process[104-106]. While the increased efficiency of small particle chromatography has long been 
recognized, development of techniques utilizing this science is complicated by the large 
increases in system backpressures encountered when pumping mobile phase through sub 2µm 
particles. Traditional HPLC systems are unable to operate at backpressures typically afforded by 
small particle chromatography. While there is no single separation parameter that distinguishes 
between ‘high performance’ and ‘ultra performance’ liquid chromatography, UPLC refers to 




The evolution of packing materials designed and employed to directly affect 
chromatographic separations has been based on the underlying principles of the van Deemter 
equation (Equation 1)[104] [107].  
H = A + B/µ + Cµ         Equation 1 
The van Deemter equation is an empirical formula that describes the relationship between mobile 
linear velocity (µ) and column efficiency (HETP or H) (Equation 1)[104]. The van Deemter plot 
(Figure 1) illustrates the principles of the van Deemter equation and is used to predict and 
determine the mobile phase flow rate where column efficiencies will be maximized[108].  
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Figure 1 illustrates how particle diameter can significantly reduce the HETP resulting in higher 
separation efficiencies. The extended minimum of the sub 2 µm particles seen in Figure 1 
indicates that increases in mobile phase flow rates do not have the same negative influences on 
separation efficiency as seen with the larger particles. This means that increased efficiencies are 
available over a much wider range of flow rates and the speed of analysis can be increased 
without sacrificing efficiency or resolution[104, 106]. 
Column efficiency is used to evaluate the performance of a stationary phase through its ability to 
accomplish particular separations. Such evaluation entails how well the column is packed and its 
kinetic performance. Column efficiency is commonly measured by the number of theoretical 
plates (N) in a stationary phase. This measure of column efficiency is easily calculated by 
obtaining an analytes retention time (tR) and peak standard deviation (σ) from a chromatogram 
and substituting the values into Equation 2.  
N = (tR/σ)2         Equation 2 
The more theoretical plates a column has, the more efficient it is deemed. Although plate number 
is still an accurate way to determine column efficiency, a more appropriate parameter for 
measuring efficiency is the plate height or the height equivalent to a theoretical plate (HETP) 
which is calculated from the column length (L) and the number of theoretical plates (N) 
(Equation 3).  
H = L/N         Equation 3 
Measuring column efficiency based on the height equivalent to a theoretical plate (HETP) allows 
for the normalization of plate number for columns of different lengths. Plate height is 
traditionally measured in millimeters and as plate height decreases, column efficiency increases 
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as there will be more equilibrations along the column length, leading to a more efficient 
separation.  
Efficiency is the primary separation parameter behind UPLC since it relies on the same 
selectivity and retentivity as HPLC[107]. Review of the fundamental resolution (Rs) equation 
(Equation 4) reveals that chromatographic resolution is directly proportional to the square root of 
column efficiency.  
Rs = (√N)/4 ((α-1)/α) (k/(k+1))      Equation 4 
Increasing column efficiency will not only result in greater resolving power but also gives rise to 
narrower peaks due to the fact that column efficiency is inversely proportional to the square root 
of the peak width (Equation 5).  
N α 1/w2          Equation 5 
Narrower peak width would be expected to contribute to increased resolving power because 
narrower peaks are easier to separate[107]. Increased efficiency also leads to an increase in 
sensitivity, according to Equation 6, which states that peak height, and therefore sensitivity, is 
inversely proportional to peak width (Equation 6).  
H α 1/w         Equation 6 
Yet another benefit to the chromatographer is the concomitant increase in peak capacity 
per unit time in gradient separations that accompanies the taller, narrower peaks[105]. 
Recognition that increases in column efficiency lead to subsequent increases in resolution and 
sensitivity has long existed and as a result analysts commonly employ various methods to 
maximize column efficiency. According to Equations 2 and 3, gains in column efficiency can be 
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achieved by increasing the number of theoretical plates or by reducing the height of the 
theoretical plates. Increasing the number of theoretical plates through the employment of longer 
columns may not always be desirable as this leads to increases in retention time and band 
broadening. This especially holds true for high throughput forensic toxicological analysis where 
sample run time must be minimized to minimize sample turnaround time, and losses in 
sensitivity through band broadening are not affordable due to the already low concentrations of 
analyte present in typical samples. As a result, increases in column efficiency are more 
commonly achieved through the reduction of theoretical plate height.  
The van Deemter equation describes the relationship between linear flow velocity (µ) and 
column efficiency (H), where A, B, and C are constants related to the mechanistic components of 
band broadening (Equation 1). Maximizing separation efficiencies through the reduction of 
theoretical plate height (H) requires a thorough understanding of the van Deemter equation and 
its individual components which all contribute to band broadening.  
Eddie diffusion, also known as multiple flow path diffusion, is a phenomenon which 
contributes to zone spreading and is represented by the constant ‘A’ in the van Deemter equation. 
When a mobile phase moves through a porous medium such as a packed column, parts of the 
stream take a more tortuous path than others. Zone spreading is the result because some solute 
molecules take longer paths and lag behind the average, while others take shorter paths and move 
ahead of the average[109]. Longitudinal diffusion is another phenomenon which contributes to 
band broadening and can is represented by the constant ‘B’ in the van Deemter equation. When 
solutes are contained in a fluid such as a mobile phase stream, they will naturally diffuse and 
spread based on the concentration gradient that exists. Regardless of how discrete the solute 
band, once in the mobile phase, solutes will diffuse from the center of the band to more dilute 
34 
 
regions resulting in zone spreading. Due to the fact that diffusion coefficients of mobile phases 
are orders of magnitude smaller in liquids than they are in gases, the longitudinal diffusion 
constant (B/µ) approaches zero in the van Deemter equation as it is directly proportional to the 
mobile phase diffusion coefficient. Mass transfer processes that occur in the mobile phase also 
result in zone broadening and this phenomenon is represented by the constant ‘C’ in the van 
Deemter equation. Such broadening occurs because both the flowing stream of the mobile phase, 
and the stationary phase particles have finite widths and time is required for solute molecules to 
diffuse from the interior of these phases to the interfaces which is where transfer can occur. As a 
result, analyte molecules at the front of the band are swept ahead before they have time to 
equilibrate with the stationary phase and molecules at the trailing edge of the band are left behind 
by fast moving mobile phase[109]. Table 2 outlines the components of the Van deemter equation 
and their relationship to column and analyte properties. 
Table 2: Components of the Van deemter equation and their relationship to column and analyte 
properties 
Process Term in equation Relationship to column and analyte 
properties 
Eddie diffusion A A = 2λdp 
Longitudinal diffusion B/µ B/µ = (2γDM)/µ 
Mass transfer in mobile phase CMµ CMµ = (fM(k’)d2pµ)/DM 
 
Careful examination of the relationships existing between the three diffusion phenomena and the 
column properties, leads to the conclusion that a reduction in the diameter of stationary phase 
particles will have the greatest impact on theoretical plate height, and therefore separation 
efficiency. Zone spreading, as a result of Eddie diffusion and mass transfer effects, is directly 
proportional to stationary phase particle diameter. Reducing the diameter of the stationary phase 
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particle will maximize separation efficiency through the reduction of Eddy diffusion and 
diffusion resulting from mass transfer effects. Although stationary phase particle diameter does 
not directly affect the phenomena of longitudinal diffusion, the higher linear velocities affordable 
with smaller particles (see below) act to minimize longitudinal diffusion effects and further 
maximize separation efficiency.  
Reducing stationary phase particle size has been exploited as the driving force for 
increasing separation efficiencies for more than forty years, however until the introduction of 
UPLC, the scope of this technique was somewhat limited. Not only are traditional HPLC system 
designs unable to operate at the high backpressures associated with small particle 
chromatography, but traditional detection systems lack the speed required to generate sufficient 
data when working with peaks that may only be a few seconds wide[107]. 
Examination of some fundamental chromatographic equations helps to illustrate the new 
levels of speed, sensitivity and resolution provided by the three fold decrease in particle size 
from 5µm (HPLC scale) to 1.7µm (UPLC scale). According to the van Deemter plot, (Figure 1) 
column efficiency (N) is inversely proportional to particle size (dp) (Equation 7) due to 
decreased zone broadening with smaller particles.  
N α 1/dp         Equation 7 
As a result, a decrease in particle size from 5µm to 1.7µm will result in a threefold increase in 
efficiency. The fundamental resolution equation (Equation 4) tells us that resolution is 
proportional to the square root of efficiency meaning that the threefold increase in efficiency 
afforded by the 1.7µm particles also provides a 70% increase in resolution. Efficiency is also 
inversely proportional to the square root of peak width (Equation 5) meaning that peak widths 
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will be 70% narrower as a result of the reduced particle size. A 70% reduction in peak width 
results in a 70% increase in peak height and therefore sensitivity. Reduced peak width also 
provide the chromatographer with a greater peak capacity per unit time in gradient 
separations[107]. Smaller particles also enable extraordinary increases in analysis speed without 
sacrificing resolution[110]. According to Equation 8 column length can be reduced 
proportionally as particle size is decreased without losing efficiency[110].  
N = L/dp         Equation 8 
This enables the chromatographer to perform separations in one third of the analysis time. 
Moreover, van Deemter theory states that the optimum flow rate (Fopt), corresponding to 
maximum separation efficiencies, increases as particle size decreases, according to Equation 9.  
Fopt α 1/dp         Equation 9 
As can be seen from the van Deemter plot (Figure 1), as particle size decreases, the 
corresponding HETP also decreases, resulting in higher efficiencies. It is also evident from the 
van Deemter plot that the highest efficiencies are available over a much wider range of flow rates 
with smaller particles than with larger particles.  
The separation efficiency of HPLC increased as the particle size of column packing 
decreased from 10 µm in the 1970s down to 3.5 µm in the 1990s[111]. One consistent 
observation with all of these particles sizes, as well as the 2.5 µm particles used in the early 
2000s was that HETP decreased to a minimum value and then increased with increasing flow 
rate[111] (Figure 1). When employing 1.7 µm stationary phase particles such as those used in 
UPLC, the resulting van Deemter plot not only exhibits a decreased HETP relative to the larger 
particles but also offers an extended minimum over a wider range of linear velocities[104, 111]. 
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As a result, flow rate or speed of analysis can be optimized without sacrificing resolution. This 
means that when transitioning from 5µm to 1.7µm particles, not only can column length be 
reduced by a factor of 3, but the separation can be run at three times the flow rate. This translates 
to a nine fold increase in throughput with no loss in efficiency or resolution[110].  
Since backpressure is proportional to flow rate, achieving small particle, high peak 
capacity separations requires fully redesigned HPLC systems capable of operating at 
backpressures beyond the capabilities of today’s system designs[112]. To take full advantage of 
the increased speed, superior resolution and sensitivity afforded by smaller particles, instrument 
technology had to be fully redesigned[112].  
To fully realize the potential speed, sensitivity and resolution of UPLC separations, new 
pressure – tolerant reversed phase particle had to be developed. Production of extremely small, 
efficient particles with high mechanical strength would allow the analyst to surpass the 
performance standards of current HPLC column technology. Early investigations into the use of 
sub 2 µm particles for ultrahigh-pressure reversed phase chromatography were reported by 
MacNair and coworkers who employed 1.5 µm nonporous octadecyl-silane-modified silica 
particles to achieve theoretical plate counts as high as 300,000 for lightly retained 
compounds[113]. In more recent years, Waters Corporation has utilized a bridged 
ethylsiloxane/silica hybrid (BEH) structure with a narrow particle size distribution, produced by 
the condensation of 1,2-bis(triethoxysilyl)ethane and tetraethoxysilane[114]. This new hybrid 
material was developed in a 1.7 µm particle to improve efficiency, ruggedness, pH range, peak 
shape and loading capacity, as well as the ability to run at elevated backpressures and 
temperatures[112, 114]. The interconnection of silica atoms with ethyl groups whilst maintaining 
a silica backbone has proven to be a key success factor for Waters UPLC columns because it 
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means maintaining the strength of silica, while achieving reduced silanol activity and improved 
resistance to alkaline conditions[114]. Peak shape is further optimized using trifunctional C18 
bonding chemistry and a proprietary end-capping procedure[114].  
High efficiency separations employing 1.7 µm solid phase particles routinely produce 
peaks with a half-height width of less than 1 second which poses significant challenges for the 
detection system[110]. One major concern when operating with very narrow peaks is the ability 
of the mass spectrometer to obtain a sufficient number of data points across a peak to perform 
peak integration and data-dependant MS/MS analysis[115]. To accurately and reproducibly 
quantify analyte peaks with half-height widths of less than one second, detection systems capable 
of rapid data acquisition are required to ensure that sampling rates are high enough to capture 
sufficient data points across such narrow peaks.  
2.5 Mass Spectrometry (MS) 
Mass spectrometry describes the analytical technique in which components of a sample 
or mixture are converted into rapidly moving gaseous ions and subsequently separated and 
identified based on their mass-to-charge ratios. Mass spectrometry provides both qualitative 
(structural) and quantitative (molecular mass or concentration) information about analyte 
molecules following their conversion into gaseous ions[116]. Mass spectrometry is typically 
preceded by a chromatographic separation such as gas chromatography (GC) or liquid 
chromatography (LC) to resolve the molecules of interest from possible matrix interferences. 
Following elution from the chromatographic column, molecules of interest are introduced into 
the ionization source of the mass spectrometer.  
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Ionization can be achieved using a variety of mechanisms which are referred to as either 
“hard” or “soft” ionization techniques as described my McLafferty et al[117]. Hard ionization 
techniques produce ions which possess appreciable internal energies and tend to undergo 
fragmentation, whereas soft ionization techniques produce ions with low internal energy which 
reduces the propensity for fragmentation. Efficient ionization produces either positive or 
negative ions of interest which then travel through the mass analyzer where they are separated 
and/or filtered according to their mass-to-charge (m/z) ratio. Following mass analysis, stable ions 
make contact with the detector where a signal is generated describing the relative abundance of 
each signal according to the mass-to-charge ratio[116].  
Mass spectrometry is recommended as the confirmatory technique in forensic 
toxicological analysis because of its ability to generate a unique mass spectrum for most 
compounds which can be used to characterize the sample[118]. Strong recommendations for the 
use of mass spectrometry exist because of its ability to both determine molecular weight and 
elucidate structural information[119].  
Although direct mass spectrometric analysis is feasible through injection without prior 
chromatographic separation, traditional toxicological analyses have utilized mass spectrometers 
coupled to gas chromatographs. Chromatographic separations are often required prior to mass 
spectrometric analysis due to the complex biological matrices typically encountered in the 
forensic toxicology laboratory. Due to the ease at which gas chromatographic systems are 
interfaced with mass spectrometers, GC/MS analysis has become the most common technique 
for toxicological screening and confirmation in the forensic and clinical industries.  
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Electron ionization (EI) is a hard ionization technique commonly employed in GC/MS 
experiments. EI induces significant fragmentation of the analyte giving rise to characteristic 
fragments which are subsequently used for structural information. The masses of these fragments 
are characteristic of the original analyte molecule and the way in which it fragmented under EI 
conditions. Confirmation analysis by GC/MS has traditionally offered superior sensitivity, 
selectivity, speed and precision and remains the method of choice for the detection and 
quantification of drugs and poisons volatile under GC/MS conditions[120]. GC/MS is still 
widely employed in many toxicology laboratories for a number of reason including; (1) 
instrumentation is readily available and reasonably inexpensive, (2) laboratory staff have 
extensive working knowledge of both the hardware and software, (3) electron impact ionization 
(EI) provides structural information through ‘hard’ ionization, (4) extensive searchable mass 
spectral libraries exist to assist with identification of unknowns, and (5) GC/MS interfaces are 
relatively simple and easy to maintain[121].  
While gas chromatographs represent an almost ideal inlet device for a mass spectrometer, 
the chromatographic separation itself is not suited to all molecules and hence limits both the 
capabilities and applications of GC/MS in the toxicology laboratory. In order for a compound to 
be amendable to GC analysis it must possess sufficient volatility so that its molecules exist in the 
gas or vapor phase at temperatures at or below 400°C. Gaseous analyte molecules need also be 
thermally stable to avoid sample degradation in the injection port of the gas chromatograph. 
Many drugs of forensic importance such as the benzodiazepines, tricyclic antidepressants, and 
acetaminophen are not naturally amendable to GC as a result of their high polarity, thermal 
lability or low volatility[122]. As a result LC has acquired a role of growing importance due to 
its separation capabilities for such compounds[123].  
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Early in development, conventional detection systems for LC did not include mass 
spectrometry. This was because solutes eluting from an LC column are dissolved in a liquid 
mobile phase at atmospheric pressure, and mass spectrometers are configured to detect gas phase 
ions under vacuum. Due to the incompatibility of LC with MS detection, unequivocal 
identification of analytes was not always possible due to the possibility of co-elution and false-
positives associated with ultra violet (UV) detection. While the potential capabilities and 
advantages of coupling LC with mass spectrometry (LC/MS) were well recognized, design and 
development of sophisticated interfaces for devices having different strategies proved both time 
consuming and expensive. 
2.6 The Rise of Liquid Chromatography – Mass Spectrometry (LC/MS) 
Research and long-term development over the last 35 years has produced seven major 
interfacing techniques that have made LC/MS experiments both possible and suitable for the 
field of analytical and forensic toxicology[124]. In 1969 Tal’roze and coworkers employed a 
capillary inlet interface in one of the earliest reported attempts at developing an LC/MS 
experiment[125]. Since the early work of Tal’roze et al., various interfaces have been designed 
to achieve both chromatographic solvent evaporation and analyte ionization. Elimination of the 
chromatographic solvent prior to MS detection, flow rate incompatibilities, the inability of mass 
spectrometers to handle non-volatile buffers, and achieving efficient and reproducible ionization 
of non-volatile and/or thermally labile analytes all arose as problematic complications during the 
development of LC/MS interfaces. Several interfaces, each providing a variety of technological 
solutions to the problems listed above, have transformed LC/MS into a robust, widely applicable 
and wide-spread analytical technique[126]. 
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2.7 LC/MS Interfaces 
Recent reviews have indicated that of the 25 different LC/MS interfaces that have been 
described in the literature over the past 20 years, only 5 are actively used today and even fewer 
are the subject of any further developmental research efforts[127, 128]. Interfaces most 
commonly employed today include thermospray (TS), particle beam (PB), fast atom 
bombardment (FAB), atmospheric pressure chemical ionization (APCI), and electrospray 
ionization (ESI).  
2.7.1 Thermospray Interface (TP) 
The original thermospray interface introduced by Vestal and co-workers in 1983 used a 
heated vaporizer tube to generate a jet of vapor and small droplets from the LC column 
effluent[129, 130]. The pressurized solution flows through the heated capillary at flow rates 
approaching 2 mL/min where it undergoes almost complete volatilization. It is then nebulized 
into an expansion chamber where it is ionized at low pressure by the solvent buffer (solvent-
mediated chemical ionization), a filament, or by a discharge electrode[124].  
Following ionization and complete desolvation, analyte ions are transferred to the mass 
spectrometer by means of a repeller electrode which can have varying voltages applied to it to 
enhance fragmentation of the analyte. Application of a higher voltage to the repeller electrode 
increases the acceleration of the analyte ions so that subsequent collisions with residual solvent 
molecules will result in fragmentation.  
Mass spectra resulting from thermospray ionization usually yield little structural 
information and prove less useful for the identification of unknown compounds. Because of this, 
TS ionization is generally employed for target compound analysis[130]. A review in 1997 
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highlighted the widespread use of the thermospray interface in the early 1990s, in particular, for 
the sensitive detection of steroids, drugs of abuse, thiourea pesticides, mycotoxins, indolic 
compounds and tricyclic antidepressants[124]. The introduction of more sensitive and robust 
approaches to mass spectrometric analyses based on atmospheric-pressure ionization techniques 
have largely replaced thermospray applications[131]. 
2.7.2 Particle Beam Interface (PB) 
The original particle beam (PB) interface was introduced as the ‘mono-disperse aerosol 
generating interface for chromatography’ (MAGIC-LC-MS) in 1984 by Willoughby and 
Browner[132]. In PB ionization experiments, the chromatography effluent is nebulized either 
pneumatically or by thermospray nebulization at atmospheric pressure into a slightly heated 
desolvation chamber. The desolvation chamber is connected to a momentum separator which is 
the principle component of the PB interface. Following desolvation, analytes are transferred into 
the low-pressure ion source through a two-stage jet separator where the high mass analytes are 
preferentially transferred to the MS ion source while the low mass solvent molecules are 
essentially pumped away[126]. Subsequent ionization occurs via EI, CI, or fast atom 
bombardment (FAB). The PB interface offers the advantage of compatible coupling to any mass 
spectrometer with minor (if any) modification. Such compatibility means that the PB interface 
enables the coupling of a wide range of LC separations to conventional CI or EI MS procedures.  
Offsetting the advantage of accommodating EI for structural information are the 
disadvantages of low sensitivity, non-linear responses due to matrix effects, and possible 
discrimination of low mass, volatile samples in the jet-separating region [124, 130, 132]. 
Although the PB interface has been sparsely used for the confirmation of ivermectin in bovine 
milk and liver[133] and human metabolites of nicotine in serum and serum[134], its 
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susceptibility to matrix effects significantly limits the useful linear dynamic range of the 
technique[131]. 
2.7.3 Fast Atom Bombardment Interface (FAB) 
In a continuous flow or dynamic fast-atom bombardment (CF-FAB) interface, a small 
liquid stream (5-15µL/min) is mixed with a FAB matrix solvent such as glycerol, sulfolane, 
diethanolamine, or triethanolamine and introduced into the low-pressure ion source of the mass 
spectrometer through an open-ended or frit-terminated (frit-FAB) capillary[124]. Ions are 
generated by bombardment of the resulting liquid film with accelerated atoms of an inert gas 
such as argon or neon. Generated ions are extracted by an electrode and subsequently transferred 
to the mass analyzer.  
FAB is a relatively soft ionization technique primarily producing intact molecular ions. 
Dynamic FAB alleviates many of the problems associated with static FAB such as differing 
responses for hydrophobic and hydrophilic analytes and low detection limits due to background 
signal from matrix related ions[126]. Secondary ions mass spectrometry (SIMS) experiments can 
also be performed using the same type of interface when using ions rather than atoms for 
bombardment ionization[124]. Although easy to implement, FAB interfaces are finding limited 
use in modern literature, primarily due to the introduction of atmospheric pressure ionization 
(API) techniques. 
2.7.4 Atmospheric Pressure Ionization (API) Techniques 
Atmospheric pressure ionization techniques have quickly become the most widely 
employed LC/MS interfaces for the analysis of a variety of analytes in forensic and clinical 
toxicology since their introduction in the mid 1980s. The two most common API techniques 
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include atmospheric pressure chemical ionization (APCI) and electrospray ionization (ESI). API 
interfaces consist of five principle components (Figure 2): (1) the liquid introduction device or 
spray probe, (2) the atmospheric-pressure ion source region, where ions are generated by means 
of electrospray ionization (ESI), or atmospheric-pressure chemical ionization (APCI), (3) an ion 
sampling aperture, (4) an atmospheric-pressure to vacuum interface, and (5) an ion optical 
system which is responsible for transferring the generated ions into the mass analyzer[135, 136].  
Figure 2: Schematic of an electrospray interface (ESI) (Adapted from Slobodnik 1995). 
Specialized design of the last two components is crucial as they determine whether or not 
the analyst achieves the high ionization efficiencies that are possible with such techniques. Ion 
losses during transfer from the atmospheric ionization region to the high vacuum region of the 
mass spectrometer are inevitable, however, proper design of the vacuum interface and ion optics 
will act to minimize these losses and ensure optimal sensitivity[135].  
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Both ESI and APCI operate by first generating a fine, continuous spray from the liquid 
chromatographic effluent. Nebulization into the atmospheric-pressure ion source region is 
achieved pneumatically (APCI), by the action potential of strong electrical field (ESI), or by a 
combination of the two (pneumatically assisted ESI)[135]. Following generation of the aerosol, 
gas phase ions are formed by one of several mechanisms explained in more detail below (see 
sections 2.7.5 and 2.7.6), and these ions, along with solvent vapor and nitrogen bath gas are 
sampled into a first pumping stage by an ion sampling device. As the mixture of analyte ions, 
solvent vapors and gases supersonically expand into this first low pressure region, the ions of 
interest along with other high molecular mass molecules populate the core of this expansion. By 
employing an appropriate skimmer to sample these core components, analyte ions are transferred 
into a second pumping stage which is equipped with an ion focusing device and transfer optics 
which subsequently transfer the ions of interest to the mass analyzer region of the mass 
spectrometer (pressure <10-3 Pa)[136].  
API techniques such as APCI and ESI offer several advantages over the earlier LC/MS 
interfaces, four of which were noted by Voyksner as being: (1) Techniques such as APCI and 
ESI can handle liquid flow-rates that are typically used in LC because the sampling orifice 
actually acts as the restrictor between the atmospheric-pressure region and the first pumping 
stage, (2) API techniques are suited to the analysis of highly polar, non-volatile, and thermally 
labile species typically separated in the liquid phase, (3) API-MS techniques exhibit high 
sensitivities due to the soft nature and high efficiency of the ionization mechanisms, (4) API-MS 
techniques are comparatively robust and relative easy to use[137]. LC/MS interfaces relying on 
the formation of ions at atmospheric-pressure also prevents the problem of vaporized solvent 
entering the vacuum system of the mass spectrometer[123].  
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APCI and ESI are both soft ionization techniques giving rise to ions which possess 
minimal internal energies and thus undergo little fragmentation[138]. Ionization of analytes 
using either APCI or ESI results in the formation of primarily singly-charged ions (“quasi 
molecular ions”) through the addition or subtraction of a proton giving rise to [M+H]+ and [M-
H]- ions respectively[139]. While the formation of singly charged molecular species using API 
techniques provides little structural information in comparison to hard ionization techniques such 
as EI, the ease of identification based on, or information pertaining to, the molecular weight of 
the analyte is maximized. 
2.7.5 Atmospheric Pressure Chemical Ionization (APCI) 
APCI describes the chemical ionization of compounds in an ion source operated at 
atmospheric-pressure conditions[140, 141]. A typical APCI source requires the following 
components for successful operation:  
• A capillary out of which the chromatographic effluent is sprayed by means of a 
concentric nebulizer gas. 
•  A heated vaporizer tube which desolvates the analyte molecules. 
• A corona discharge needle which ionizes the molecular mist exiting the vaporizer tube. 
• Ion focusing and entrance optics for ion transfer into an area of intermediate vacuum, 
followed by further focusing elements and skimmers which transport the ions into the 
high vacuum mass analyzer[142].  
Nebulization of the LC effluent into the atmospheric-pressure ion source is performed by 
a heated nebulizer with pneumatic assistance. Nebulizer temperatures of up to 500°C induce 
solvent evaporation and ions are generated through subsequent gas-phase ion-molecule reactions. 
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Reagent ions responsible for the ionization of analyte species are normally created by means of a 
corona discharge and the subsequent ionization mechanisms are the same as those encountered in 
traditional medium-pressure chemical ionization (CI)[126, 135]. Positive ion formation takes 
place following proton transfer, adduct formation or charge exchange reactions while negative 
ion formation is achieved by proton abstraction, anion attachment, or electron-capture 
reactions[126].  
APCI is widely employed for the analysis of low to moderately polar compounds. Unlike 
ESI, solvent evaporation in APCI experiments occurs prior to analyte ionization and the two 
processes are separate. Solvent evaporation during APCI experiments is supported by the 
application of high temperatures to the nebulizer while a discharge electrode subsequently acts to 
ionize solvent molecules, which, after several ion molecule interactions, transfer a charge to the 
analyte molecule resulting in ionization[124, 139]. APCI is slightly harder than ESI and can 
induce some degree fragmentation of the molecular species due primarily to the high 
temperatures employed for the purpose of solvent evaporation[139]. APCI allows for the 
sensitive determination of analytes possessing moderate polarity and molecular mass (Figure 3) 
and exhibits high sensitivity for large lipophilic molecules which are not amendable to ionization 
by other techniques[124, 142]. 
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Figure 3: Relationship between molecular mass and analyte polarity for analytes suited to 
GC/MS and different LC/MS interfaces (Adapted from Maurer 1998). 
 
2.7.6 Electrospray Ionization (ESI) 
Electrospray ionization (ESI) has quickly become one of the most important and widely 
employed ionization techniques for the on-line coupling of liquid phase separation 
methodologies with mass spectrometry (MS). Such coupling has paved the way for numerous 
electrospray ionization mass spectrometric (ESI-MS) methodologies which have revolutionized 
the capabilities of clinical and forensic laboratories to detect low levels of analytes in complex 
biological matrices. Coupling of electrospray ionization with modern mass analyzers provides 
the analyst with a sensitive, robust and reliable tool for the analysis of femto-mole quantities of 




The electrospray ionization process employs electrical energy to assist the transfer of 
ionic species from solution into the gas phase before they are subjected to mass spectrometric 
analysis (Figure 4). The process of transferring ionic species from a solution into gas phase ions 
can be described by a three step process:  
1. Nebulization of a sample solution into electrically charged droplets (Figure 4). 
2. Solvent evaporation (Figure 4). 
3. Ion ejection from the highly charged droplets (Figure 4)[116]. 
 
 
Figure 4: Schematic of electrospray ionization (ESI) showing the three steps of ionization: 1.) 
Nebulization of a sample solution into electrically charged droplets, 2.) Solvent evaporation, and 
3.) Ion ejection from the highly charged droplets (Adapted from Lam 2003). 
 
The initial formation and dispersion of a fine mist of charged droplets is achieved through 
electrospray nebulization. When a liquid is exposed to a high electrical field, a mist of highly 
charged droplets is formed in a process termed electrospray nebulization. Electrospray 
nebulization is achieved by pumping a continuous sample solution through a stainless steel or 
1.) 2.) 3.) 
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quartz silica capillary tube at a very low flow rate (0.1-10 µL/min). A high voltage (2-5 kV) is 
applied to the capillary relative to the wall of the surrounding chamber[116]. The high electrical 
field at the tip of the capillary tube acts to pull like charge toward the liquid front resulting in 
charge deposition on the surface of the emerging liquid. As charge accumulates at the liquid 
front, electrostatic repulsions at the exit of the electrospray tip also increase. When the 
electrostatic repulsion becomes stronger than the surface tension, a highly charged droplet with 
the same polarity as the capillary voltage is generated[116, 143]. The point at which droplets 
emerge from the liquid solution is referred to as the Rayleigh limit and is defined as the point at 
which coulombic repulsion of the surface charge is equal to the surface tension of the 
solution[144].  
Electrically charged droplets generated at the tip of the capillary tube through 
electrospray nebulization then pass through the surrounding gas, down a potential gradient, to the 
counter-electrode. Positively charged droplets are generated when the capillary is held at a more 
positive potential than the counter-electrode causing positive charge to accumulate at the 
capillary tip. A reversal of the electric field will result in the formation of negatively charged 
droplets travelling down a potential gradient to a counter-electrode being held at a more positive 
potential. The formation of micrometer-sized droplets depends on the liquid’s flow rate, surface 
tension and electrolyte concentration[143]. A significant increase in any one of the three 
aforementioned variables can greatly decrease the ability of the electric field to generate the 
desired aerosol required for ion transfer to the mass spectrometer. Small increases in a liquid’s 
flow rate, surface tension or electrolyte concentration may be overcome by increasing the 
electrical field at the tip of the capillary however care must be taken to ensure that the increase in 
electric field energy does not give rise to an electrical discharge[143]. 
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The second step in the process of transferring condensed phase ion into gas phase ions 
suitable for mass spectrometric analysis involves solvent evaporation. Electrospray nebulization 
produces electrically charged droplets when charge repulsion exceeds the cohesive force that 
holds the liquid together. Electrically charged droplets then traverse down a potential gradient 
toward the entrance to the mass spectrometer, and generate analyte ions by one of several 
proposed mechanisms.  
The coulomb fission mechanism proposes that the increased charge density due to solvent 
evaporation causes large droplets to undergo size reduction into successively smaller droplets 
which eventually consist of a single analyte ion[145]. Solvent evaporation is aided by elevated 
source temperatures and/or the introduction of a stream of nitrogen drying gas. The reduction in 
droplet size through solvent evaporation results in an increase in charge density at the surface of 
the droplet. Further deformation of the droplet occurs as a result of the shear forces experienced 
by the droplet during its flight through a dense desolvation gas toward the counter-
electrode[143]. As the droplets evaporate, the increasing coulomb forces exceed the surface 
tension causing the droplet to undergo fission (Figure 4). Successive fissions ultimately give rise 
to droplets containing a single analyte molecule possessing and retaining the droplet charge as 
the remaining solvent evaporates[146]. A second mechanism for the formation of single analyte 
ions assumes that the increase in charge density resulting from solvent evaporation eventually 
results in coulombic repulsions that exceed the liquid’s surface tension and as a result, ions are 
released from the droplet surfaces[147]. This mechanism is termed ion evaporation and theorizes 
that microdroplets with an approximate radius of 10nm resulting from successive fissions, do not 
experience further disintegration to smaller droplets but rather emit ions from their surface in 
order to alleviate charge repulsion[116, 143].  
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While ionization of analytes during ESI experiments occurs predominantly through 
condensed phase equilibrium or charge transfer complexation in solution, gas phase interactions, 
occurring after the analyte has been released from solution also exist[148]. Gas phase 
interactions occur following droplet emission and prior to the analyte reaching the mass analyzer. 
As a result, such reactions can have a significant effect on MS response[149]. Gas phase 
interactions which result in analyte charging during ESI experiments occur through gas-phase 
proton-transfer reactions. Such a phenomenon exists primarily because the gas phase basicity, 
and therefore proton affinity, of certain molecules can be markedly different to their basicity in 
solution. Initial charging of molecules during ESI experiments occurs in the condensed phase 
through equilibrium and charge transfer according to the molecules solution-phase basicity. 
Following electrospray nebulization into the gas phase, molecules that were protonated in 
solution can yield their protons to solvents or analytes with greater gas-phase basicity[149]. Such 
gas-phase proton transfer reactions take place when there is an inversion in the order of basicity 
among a series of molecules proceeding from solution into the gas phase[150]. Analyte 
molecules which are sprayed and ejected as neutrals can become positively charged through gas-
phase interactions with solvent ions which exhibit a higher basicity in solution but possess 
inferior gas-phase basicity. As a result of this basicity inversion, the protonated solvent molecule 
yields its proton to the more basic gas-phase analyte resulting in gas-phase charging. Increased 
signal through gas-phase analyte charging can greatly increase sensitivity in ESI-MS 
experiments however analyte response may also be completely suppressed in situations where 
the electrospray solvent has a higher gas-phase proton affinity than the analyte[151]. It is 
therefore imperative to select an electrospray solvent which possesses a lower gas-phase proton 
affinity than the analyte of interest.  
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Of the above interface technologies, most research and further development efforts are 
focused around the atmospheric pressure ionization (API) techniques, specifically, atmospheric 
pressure chemical ionization (APCI) and electrospray ionization (ESI). 
2.8 LC/MS/MS and its Applications in Forensic Toxicology 
The vast majority of LC/MS instrumentation employs APCI or ESI due to the large 
number of compounds which are amendable to soft ionization techniques, regardless of their 
polarity or molecular weight (Figure 3). API techniques produce characteristic ions depending on 
the ion mode in which the spectra are obtained. In positive-ion mode the base peak is normally 
the protonated molecular ion [M+H]+ which is often accompanied by less abundant metal 
adducts such as [M+Na]+ and [M+K]+[152, 153]. When spectra is obtained in negative-ion 
mode, the deprotonated molecular species [M-H]- generally constitutes the base peak[152]. 
While soft ionization techniques such as APCI and ESI provide abundant ions of the molecular 
species, leading to increases in sensitivity, they yield very few, if any, fragments and therefore 
provide relatively little structural information and limited selectivity[154]. To order to increase 
the selectivity of experiments employing soft ionization techniques, tandem mass spectrometry 
(MS/MS) is applied to induce fragmentation of the molecular species and give rise to structurally 
significant product ions[155].  
Tandem mass spectrometry employs two stages of mass analysis to examine the 
fragmentation of analyte ions within a mixture of ions. The increased selectivity afforded by 
tandem mass spectrometry has been widely utilized in the fields of forensic and clinical 
toxicology where analyte identification can prove challenging due to the complex nature of 
biological matrices[154]. Tandem mass spectrometers provide an added dimension of mass 
spectral information by creating ionic species from a sample, mass selecting a precursor ion, 
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inducing fragmentation of that selected ion and obtaining the mass spectrum of the structurally 
significant fragments[156]. The goal of tandem mass spectrometry is to provide the analyst with 
additional structural information not normally yielded by soft ionization techniques, while 
simultaneously retaining the sensitivity afforded by the soft ionization. By employing two or 
more mass spectrometers with a collision cell positioned in between, tandem mass spectrometry 
ensures increases in selectivity by providing characteristic molecular fragments generated by 
collision-induced dissociation (CID)[157]. Tandem mass spectrometers allow for the selective 
determination of multiple analytes within a single run by monitoring multiple ions or 
fragmentation transitions characteristic to individual analytes. In addition, the baseline separation 
of analytes from matrix interferences, which is a must for HPLC employing UV or MS detection, 
is not required in MS/MS experiments because of its inherent selectivity[157].  
Tandem mass spectrometry is achieved using a variety of instruments which can be 
classified into two categories of tandem mass spectrometers. The first category is made up of 
instruments in which two mass spectrometers are assembled in tandem such tandem mass-
analyzing quadrupoles, tandem time-of-flight analyzers or a combination of the two (QTOF). 
The coupling of several different analyzers for the purpose of MS/MS experiments have been 
described in the literature. The sequential combination of mass analyzers is generally intersected 
by a collision cell which is designed to induce dissociation of the precursor ions through 
collisions with an inert gas such as argon. Product ions resulting for CID are then analyzed in the 
second quadrupole. Experiments performed using the sequential combinations of mass analyzers 
are referred to as tandem-in-space mass spectrometry. Tandem mass spectrometry experiments 
can also be performed using another category of instruments which are characterized by their 
ability to store ions. Mass analyzers which are capable of storing ions for subsequent analysis 
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include the ion cyclotron resonance (ICR) and the quadrupole ion trap mass[154]. Mass analysis 
is performed by creating precursor ions and storing them in a radio frequency (rf) trapping field. 
Following ion production, separation and storage, precursor ions can be excited and caused to 
fragment during a selected time period by the application of additional rf waveforms. 
Fragmentation of the precursor ions leads to the generation of characteristic product ions which 
can be observed in a mass spectrum by utilizing the highly efficient ion manipulation capabilities 
of such analyzers[154, 158]. This process may be repeated to obtain the mass spectrum of 
fragments over several generations without the need to transfer ions from one vacuum chamber 
to the next, rather, a single chamber utilizing a quadrupole rf field is used for all analyses[154, 
158]. Experiments performed using mass analyzers capable of ion storage are referred to as 
tandem-in-time mass spectrometry. Tandem mass spectrometry combined with the appropriate 
chemical separation technique such as liquid chromatography or gas chromatography provide 
analysts with impressive selectivity and sensitivity by eliminating a large majority of chemical 
noise, resulting in superior selectivity and limits of detection relative to single mass spectrometry 
experiments[158]. The majority of tandem mass spectrometric experiments performed in recent 
times have employed a “tandem-in-space” approach and the most widely used tandem mass 




2.9 Triple Quadrupole Mass Spectrometer 
2.9.1 Introduction 
The triple quadrupole assembly was first introduced by Yost and Enke in 1978 for the 
purpose of mixture analysis and structural elucidation[156]. A quadrupole is a mass analyzer 
consisting of four co-linear rods, set parallel to each other (Figure 5).  
 
 
Figure 5: Schematic of a quadrupole mass analyzer. 
 
Each opposing pair of rods is connected electrically and an RF voltage is applied between the 
two rod pairs. A DC voltage is then superimposed onto the RF voltage and it is the ratio of these 
two voltages that enables the quadrupole to perform mass analysis. Depending on the exact 
potential applied to the rods, only ions with a certain m/z ratio will pass through the quadrupole 
and reach the detector because the applied voltages affect the trajectories of ions travelling down 
the flight path which is centered between the two sets of rods. Ions with unstable trajectories in 
the oscillating electric fields will collide with the rods and exit the system through vacuum. For a 
given voltage, only ions with a certain m/z ratio will pass through the quadrupole and reach the 
detector while all other ions are essentially filtered out. Quadrupole mass analyzers were 
employed in the first desktop LC/MS systems and are still the most commonly employed and 
least expensive mass analyzers used in LC/MS instruments[159]. 
From ion source To detector
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The stability and motion of ions in a quadrupole is significantly different from those 
observed in field-free regions and in magnetic and electrostatic sectors[160]. Ion trajectories in 
dynamic instruments such as quadrupole devices are influenced by time-dependant forces which 
complicate their mathematical prediction relative to sector instruments. The motion of ions in a 
quadrupole field can be mathematically described by solutions to the second-order linear 
differential Mathieu equation (Equation 10).  
((d2u)/(dζ2)) + (au – 2qucos2ζ)u = 0       Equation 10  
Mathieu was able to describe solutions in terms of regions of stability and regions of instability 
while investigating the mathematics of vibrating stretched animal skins[160]. The Mathieu 
equation can be applied to describe the regions of stability and instability during ion trajectory in 
a quadrupole device. The Mathieu mass stability diagram shown in Figure 6 is derived from the 
Mathieu equation and illustrates regions of stable and unstable trajectory for two ion masses (A 




Figure 6: Mathieu stability diagram of two masses (A and B) in a quadrupole mass filter. Voltage 
coordinates corresponding to points under the stability curve represent stable trajectories while 
all other voltage conditions result in unstable ion trajectory in the quadrupole device. 
 
Any of the RF/DC conditions under the stability curve represent conditions of stable 
trajectory during which that mass will pass through the quadrupole to the detector. RF/DC 
conditions appearing only under the left hand curve will allow only mass A to pass through the 
quadrupole while mass B will experience unstable trajectory and be removed from the 
quadrupole through vacuum. Similarly, any of the RF/DC condition appearing only under the 
right hand curve will only allow mass B to pass through the quadrupole. Figure 6 shows three 
dotted lines which represent typical quadrupole scan lines which pass through the stable regions 
of each curve under different RF/DC conditions. If the slope of the RF/DC scan is steep, similar 
to the top line in Figure 6 the spectral peaks will be narrow and well separated due to the smaller 
regions of stability encountered by those scan conditions. If the slope of the RF/DC scan is 
shallow, as represented by the middle line in Figure 6, spectral peaks will be wider and poorly 
Area of instability







separated leading to less resolving power. If the slope of the RF/DC scan is too shallow, as 
represented by the bottom line in Figure 6, masses A and B will pass through the quadrupole 
without being separated due to significant overlap in regions of stability[161]. 
Understanding the principles of the Mathieu equation and corresponding stability plots 
enables the analyst to monitor the presence and abundance of a particular mass or scan the mass 
range by varying the rf and dc voltages applied across the rods and obtaining the corresponding 
mass spectrum. Only the first (Q1) and third (Q3) quadrupoles are operated using a combination 
of rf and dc voltages necessary for mass analysis, while the second quadrupole (Q2) is operated 
with a fixed rf voltage only and therefore allows ions of all masses to pass through it. Q1 and Q3 
both have the ability to perform mass analysis while Q2 is employed as a collision cell with ion 
focusing properties in which precursor ions, having already passed through Q1, undergo collision 
induced dissociation (CID) into characteristic product ions which can then be scanned or 
transmitted using Q3 (Figure 7)[154]. Collision induced dissociation is achieved by selecting a 
parent mass to pass through Q1 and into the quadrupole collision cell where it collides with 
atoms of an inert gas, usually argon, and acquires energy which leads to its subsequent 
decomposition into characteristic product or daughter ions[118]. CID is widely employed to 
obtain structurally characteristic fragmentation patterns which are used for the unequivocal 
identification of analytes in complex matrices[162]. The reproducibility of CID is dependent 
upon the chosen collision gas, collision energies, and collision gas flow. While specific 
parameters may be optimal and constant on one instrument, significant variation is common 
between instruments meaning that CID product ions may also be instrument and laboratory 
dependant. Variations in CID parameters, and therefore product ions, between laboratories 
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complicate the development of reference spectral libraries. For this reason LC-MS/MS does not 
currently possess the same discriminative power as GC/MS employing EI. 
 
Figure 7: Schematic representation of a triple quadrupole mass spectrometer. 
2.9.2 MS Operating Modes 
Mass analysis can be performed utilizing one or both of the mass analyzers when 
employing triple quadrupole instruments as they have the ability to operate in the single mass 
spectrometry (MS) mode or tandem mass spectrometry (MS/MS) mode. Single mass 
spectrometry experiments are performed using one of three main MS scan modes (Table 3). The 
most widely employed MS mode is the MS1 mode in which the first quadrupole (MS1) is 
employed as a mass filter while the collision cell and MS2 allow all masses exiting MS1 to pass 
through to the detector. MS1 mode is the most sensitive method for performing MS analysis and 
it is directly analogous to experiments employing a single-quadrupole mass spectrometer for the 
purposes of scanning a mass range[163]. The MS2 mode of operation is also employed for MS 
experiments however it provides optimum performance with scan speeds greater than 2000 
Da/s[163]. MS2 is achieved by allowing ions of all masses to pass through MS1 and Q2 while 
employing the fast MS scanning capabilities of MS2. The SIR (selected ion recording) mode of 
operation is employed as a quantitative tool for MS analysis when no suitable or reproducible 
fragmentation pattern of the parent molecule can be identified to allow for a more selective 
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MS/MS analysis[163]. SIR (or SIM) is directly analogous to single quadrupole mass 
spectrometry experiments in which a single ion of interest is pre-selected to oscillate through the 
quadrupole.  
Table 3: MS operating modes using the triple quadrupole mass spectrometer. 
Operating mode MS1 Collision cell MS2 
MS1 Resolving (scanning) Pass all masses 
MS2 Pass all masses Resolving (scanning) 
SIR Resolving (static) Pass all masses 
 
2.9.3 MS/MS Operating Modes 
By operating in tandem mass spectrometry (MS/MS) mode by utilizing the mass analysis 
capabilities of Q1 and Q3, an additional dimension of mass spectral information is provided. The 
combination of two mass analyzers provides the analyst with the option to acquire information 
using additional operating modes not amendable to traditional single-quadrupole MS analysis. 
Because both analyzers can be operated in the scan or selected-ion mode (SIR), the number of 
possible combinations and therefore operating modes is extended to four (Table 4)[120]. 
Table 4: MS/MS operating modes of the triple quadrupole mass spectrometer. 
Operating mode MS1 Collision cell MS2 
Product Static Pass all masses Scanning 
Precursor Scanning Pass all masses Static 
MRM Static Pass all masses Static 
Constant neutral loss Scanning Pass all masses Scanning 
 
When operating in product (daughter) ion scan mode, the first quadrupole is static and allows 
only ions with a specific m/z (precursor ions) to pass through into the collision cell. The collision 
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cell operates as normal by inducing fragmentation of the precursor ions through energetic 
collisions with atoms of an inert gas such as argon. Fragmentation produces characteristic 
product ions which are then scanned by the third quadrupole which is set to scan over an 
appropriate mass range. A product ion spectrum (formerly referred to as a daughter ion 
spectrum) is obtained when operating in product ion scanning mode. (Figure 8)[163]. Product 
ion scanning is most commonly employed in method development to identify fragmentation 
patterns of a specific analyte. Optimization of CID conditions is achieved using product scanning 
by identifying collision parameters which maximize the yield of specific product ions passing 
through Q3 and reaching the detector. Product scanning is also employed for structural 
elucidation as product ions are characteristic of precursor ions. Product ion scanning is widely 
employed for the unequivocal identification of drugs and their metabolites in complex biological 
matrices. Chemical separation of the analyte from the complex matrix is achieved by the 
chromatographic separation and the first quadrupole, while fragmentation of the analyte in the 
second quadrupole provides structural information[120, 163]. A product ion spectrum displays 
the ions produced by fragmentation of a known parent ion[118]. 
 




Static (at precursor mass) Collision cell  





Precursor ion scanning is achieved by scanning the first quadrupole over a chosen mass range 
while the third quadrupole is set to pass only ions with a particular m/z (product ions) (Figure 9). 
Precursor scanning allows all ions to pass through Q1 and undergo CID in the second quadrupole 
however only desired product ions will be allowed to pass through the third quadrupole. By 
constantly scanning the first quadrupole, precursor ions which fragment into the desired product 
ions will be identified. Ions which pass through the first quadrupole will only be detected if they 
produce the pre-selected product ions through fragmentation in the collision cell[154]. Precursor 
scanning is typically employed to corroborate information obtained from product scans during 
structural elucidation experiments. Precursor scanning is also employed to identify possible 
precursors of a common product ion[163].  
 
Figure 9: Schematic representation of precursor ion scanning mode. 
 
Multiple reaction, or selected reaction monitoring (MRM or SRM) mode is a highly selective 
tandem mass spectrometry equivalent of SIR. MRM experiments are performed by setting Q1 
static to only transmit ions with specific m/z corresponding to the precursor ion of interest. 
Following fragmentation in the collision cell, only characteristic product ions of the precursor are 
transmitted through Q3 which is also held static (Figure 10). MRM experiments can only be 
performed when fragmentation patterns for the analyte have been determined. Once 
Ionization chamber 
MS1 
Scanning Collision cell 
(Pass all masses) 
MS2 
Static (product ion) 
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characteristic product ions have been identified and CID parameters have been optimized, Q3 
can be programmed to allow only product ions with certain m/z values through to the detector. 
MRM mode is widely used for quantitative analysis is MS/MS experiments. Dwell times can be 
maximized because both Q1 and Q3 are held static to only allow through ions with pre-selected 
m/z values (precursor and product ions respectively), meaning that enhanced sensitivity is 
achieved compared to single mass spectrometry experiments performed in the scanning-
mode[163]. MRM is most commonly employed to quantify target analytes in complex matrices 
such as drugs and /or metabolites in biological samples. Because individual transitions are 
monitored in both SIR and MRM the product of such scans is not a mass spectrum, rather a 
chromatogram[163]. While the number of MRM transitions required for an unequivocal 
identification is still largely debated, most laboratories monitor two transitions and require 
product ions to be present at a predetermined ratio. Ion ratios are generally determined using 
quality control standards which are analyzed prior to patient samples. Increasing the number of 
MRM transitions enhances selectivity at the cost of sensitivity due to decreased dwell times.  
 
Figure 10: Schematic representation of multiple reaction monitoring (MRM) mode. 
 
Neutral loss tandem mass spectrometry experiments identify the loss of a specific neutral 
fragment (eg. expulsion of H2O) or functional group from an unspecified precursor (Figure 
Ionization chamber 
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(Static at precursor mass) Collision cell 
(Pass all masses) 
MS2 
Static (at product mass) 
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11)[163]. Neutral loss scanning requires that both Q1 and Q3 are scanned simultaneously with a 
constant m/z difference between them corresponding to the mass of the lost fragment or 
functional group[154]. When the scanning of Q1 and Q3 is synchronized, Q3 determines 
whether precursor ions transmitted through Q1 have lost a fragment corresponding to the mass 
difference between the two scanning spectrometers. If Q3 detects a fragment loss corresponding 
to the mass of the neutral fragment of interest, the loss registers at the detector and the mass 
spectrum displays all precursor ions that experienced a mass loss corresponding to the fragment 
of interest[164]. Neutral loss scan mode is most commonly employed to screen for a certain class 
of compounds by identifying all ions which undergo the loss of a given neutral fragment through 
fragmentation[154, 164]. Screening for a certain class of compounds which are known to follow 
a characteristic fragmentation pathway, involving the loss of a certain neutral fragment or 
functional group, could be achieved by employing a neutral loss scan. Neutral loss scanning is 
commonly employed in early drug discovery for the identification of drug classes. An example is 
the identification of glycerol phosphatidylcholine phospholipids (GCP) using a constant-neutral-
loss scan of m/z 59. Under certain CID conditions the dominant fragmentation of GCP’s is the 
loss of trimethylamine (m/z 59) from the polar head group. Detection of a neutral loss of mass 59 
Da at Q3 would indicate the presence of a GCP and allow for differentiation of this class from 




Figure 11: Schematic representation of neutral loss scanning mode. 
 
2.10 Mass Spectral Criteria for a Positive Identification 
Prior to the introduction of atmospheric pressure ionization techniques such as ESI, and 
APCI, a large majority of toxicological analyses were performed using GC/MS employing EI. 
Electron ionization (EI) yields fragment ions which are very characteristic of, and therefore 
provide significant information pertaining to, molecular structure. This is due primarily to the 
ability of EI to produce odd electron molecular ions. Dissociation of odd electron molecular ions 
produces fragment ions which are significantly more characteristic of molecular structure than 
are even electron molecular ions[117]. The extensive fragmentation of odd electron molecular 
ions into structurally significant fragment ions under EI conditions provides the analyst with an 
EI mass spectrum possessing an unusually high content of structural information. This additional 
structural information afforded by EI mass spectra has allowed for the development of EI 
reference spectral libraries. Identification of unknown compounds is achieved by ‘library 
matching’ which involves matching the EI spectrum of an unknown compound with one or 
several contained within the library database. Library matches are made by comparing molecular 
ions, relative abundances of fragment ions, and isotope patterns of the unknown compound with 
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installed into instrument software to allow for automatic library matching following data 
acquisition of an unknown compound. For this reason, EI remains the method of choice for the 
routine, efficient, identification of unknown compounds at trace levels[166].  
Identification of unknown compounds using API techniques is achieved using a different 
approach due to the relatively small amount of structural information afforded by soft ionization. 
While the protonated molecular ions produced during API experiments assist in molecular 
weight determinations, little information is provided to assist with structural elucidation. As a 
result, ESI or APCI spectral libraries are not practical and do not currently exist to aid with 
unknown identification. Due to the lack of structural information provided by soft ionization, 
API techniques are not commonly employed for broad based, general unknown screening. 
General unknown screening in complex biological matrices employing API techniques would 
prove impractical as identifications would be based solely on the presence or absence of 
protonated molecular ions. For this reason, GC/MS employing EI remains the most commonly 
employed technique for broad based drug screening. Identifications are based on full EI spectra 
containing characteristic information that can be automatically matched with reference spectra. 
While API techniques do not naturally lend themselves to general unknown screening 
applications, several tandem mass spectrometric screening techniques employing soft ionization 
have been reported in the literature [167-170]. The identification of analytes using API-
LC/MS/MS is normally achieved using retention times and by monitoring the presence of 2-3 
multiple reaction monitoring (MRM) ion channels. Unlike GC/MS screening in which 
identifications are made based on pre-existing spectral libraries, API-MS/MS methods must be 
developed through the analysis of standards. A reference standard of each analyte must first be 
infused into the mass spectrometer to obtain ionization, and CID fragmentation information. 
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Following optimization of the mass spectral conditions, standards must be injected onto the LC 
to determine individual retention times. The screening method is then built by designating each 
analyte a characteristic retention time and a minimum of one characteristic MRM transition 
which is monitored during the analysis of unknowns. Screening methods based on monitoring 
MRM transitions present additional problems as the number of analytes increase. Monitoring the 
presence of analytes based on MRM transitions requires the mass spectrometer to continuously 
scan the appropriate mass range. As the number of analytes increase, dwell times and therefore 
sensitivity decreases. Additional screening selectivity may be achieved by monitoring more than 
one MRM transitions for each analyte, however, the addition of more MRM transitions to the 
MS/MS method further limits dwell times and decreases overall method sensitivity. Care must be 
taken when optimizing dwell times to ensure that sufficient data points are obtained across each 
chromatographic peak. Many forensic samples contain very low concentrations of analytes and 
attempts to increase screening sensitivity by increasing dwell times may result in an inability to 
accurately characterize chromatographic peaks as a result of insufficient data points.  
Due to the nature of data acquisition, API-MS/MS techniques are better suited to, and 
more commonly employed for confirmation analysis. Confirmation methods employing API-
MS/MS are generally employed to confirm the presence of, and quantitate a specific drug. These 
confirmation methods may be designed to detect and quantitate a single analyte or several 
members of a certain family of drugs, such as the opiates. Specific LC-MS/MS methods are 
again developed through the analysis of standards and positive identification criteria normally 
include retention times, and the presence of 2-3 MRM transitions in the correct abundance. 
During the analysis of reference standards, the most abundant MRM transition for each analyte is 
routinely employed at the quantifying ion, while the second most abundant transition is 
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employed for qualitative identification purposes. Confirmation methods are rarely designed to 
detect and quantify more than a few drugs at any one time meaning that dwell times, and 
therefore sensitivity can be maximized. Confirmation methods employing API-MS/MS combine 
the increased sensitivity afforded by soft ionization with the inherent selectivity of tandem mass 
spectrometry. 
2.11 Mass Range and Resolution 
The mass range of any mass spectrometer refers to the range of m/z values that can be 
characterized with sufficient resolution to characterize adjacent peaks. Mass resolution refers to 
the ability of the mass spectrometer to distinguish between two peaks of differing m/z values 
within a single mass spectrum. A numerical expression of resolution can be obtained from the 
ratio m/∆m, where ‘m’ is the nominal m/z value of one of the compounds and ‘∆m’ is the 
difference in m/z values between the two peaks. If two peaks at a nominal m/z of 100 are 
observed on separate channels of an oscilloscope sweep and offset by 0.100 mass units then the 
resolving power of the mass spectrometer would be 1,000 (100/0.1)[118]. Measuring peak 
separation can be done using the peak width definition method or the valley width definition 
method. According to the peak width definition, the value of ∆m is the width of the peak 
measured at a designated peak height level and m is again the m/z value of the peak. 
The valley width definition method evaluates resolution by calculating the degree of 
overlap between two peaks. This method defines ∆m as the closest possible spacing of two peaks 
of equal intensity where the height of the valley between them is less than a certain specified 
fraction of the peak height. When calculated using this method, resolution is generally reported 
as a certain resolving power with a percentage valley definition. If we take the previous example 
of a mass spectrometer where m/∆m is equal to 1,000 and we find that the height of the valley 
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between the two peaks is 10% of the peak height, the mass spectrometer has a resolving power of 
1,000 with a 10% valley definition[118].  
The ability of a quadrupole device to resolve different masses depends on several factors 
including the shape and diameter of the rods, the applied RF/DC voltages and the kinetic energy 
of ions entering and exiting the quadrupole[161]. Figure 6 in section 2.9.1 shows a Mathieu 
stability diagram of two masses entering a quadrupole at the same time. The three dotted lines 
passing through the plot represent RF/DC scan rates and while all three lines pass through 
regions of stable trajectory for both masses, resulting signals and ion abundances will be 
significantly different for each scan. The top line represents a high resolution scan as resulting 
spectral peaks will be narrow and well separated. If the mass range is scanned according to the 
middle line, peaks will be much wider and poorly separated resulting in decreased resolving 
power. Finally, if the mass range is scanned according to the bottom line, the spectral peaks will 
overlap and pass through the quadrupole without being separated. This results in inadequate 
resolution due to significant overlap of the spectral peaks[161].  
It can also be seen in Figure 6 that the slope of the RF/DC scan rate can have a significant 
effect on sensitivity. The sensitivity of a certain scan rate for an ion of interest depends on how 
many of the variable RF/DC conditions fall within the regions of stability for that ion. If we 
again use Figure 6 as an example, it can be seen that while the top scan line represents a high 
resolution scan, the total number of ions that reach the detector will be quite low due to the 
minimal number of RF/DC combinations corresponding to stable trajectory. Conversely, the 
RF/DC scan slope represented by the bottom line will provide greater sensitivity as more area of 
the stable trajectory curve is covered by the scan, however, spectral peaks will be wide and 
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poorly separated. Because of this phenomenon, increased resolution is always accompanied by a 
sacrifice in sensitivity when using quadrupole mass filters.  
2.12 Waters TQD 
The Waters TQ Detector is a tandem quadrupole, atmospheric pressure ionization (API) 
mass spectrometer designed specifically for tandem mass spectrometric analyses following ultra 
performance liquid chromatographic (UPLC) separations[163]. The TQ Detector has been 
designed for compatibility with the ACQUITY UPLC™ system and can be employed for both 
qualitative and quantitative analyses. The Waters TQD utilizes technological advances made in 
ion source configuration, T-Wave™ collision cell technology and data acquisition speed to take 
full advantage of the UPLC separation. The TQ detector utilizes a Z-Spray dual orthogonal ion 
source which acts to protect critical source and analyzer elements from the harmful effects of 
contamination by non-ionic species in complex biological matrices such as meconium (Figure 
12)[171].  
 




Dual orthogonal sampling achieved with the Z-spray technique utilizes the same principles as 
conventional electrospray sources except that the trajectory of ions entering the analyzer is not a 
straight line, rather an approximate Z-shape[172](Figure 12). This trajectory deflects many 
neutral molecules which can build up on the orifice of skimmers in conventional sources. The 
final skimmer in the Z-spray ion source is set off to one side eliminating much of this material 
build up[172]. Protection of the source from matrix contamination through dual orthogonal 
sampling provides inherent sensitivity by not only decreasing background noise but also 
allowing for an increase in cone orifice size. Decreased background noise is achieved by the 
more effective removal of non-ionized contaminants by the dual orthogonal sampling technique. 
Due to the more effective removal of matrix contaminants, the sampling size of the cone orifice 
can be increased to allow more analyte ions to pass through to the mass spectrometer. By 
decreasing the background noise and increasing the number of analyte ions reaching the mass 
spectrometer, the Z-Spray dual orthogonal ion source ensures inherent sensitivity. The detection 
system has also been redesigned to accommodate the narrow (2-3 seconds) peaks typical of 
UPLC separations. Accurate quantitation of such narrow peaks demands fast acquisition speeds 
to ensure that sufficient data points are obtained across each chromatographic peak. Failure to 
couple the UPLC with a detection system capable of rapid acquisition would result in the 
inability to accurately characterize chromatographic peaks. Table 5 outlines select system 





Table 5: Select system specifications of the Waters triple quadrupole detector (TQD). 
System specification Details 
Acquisition modes Full scan; Selected ion recording (SIR); Product ion scan; 
Precursor ion scan; Constant neutral loss/gain; Multiple reaction 
monitoring (MRM)
Mass range 2 to 2000 m/z 
Scan speed Up to 10,000 Da/s 
MRM acquisition cycle time Minimum dwell time of 5 ms per channel 
Mass resolution Valley between 2034.63 Da and 2035.63 Da peaks is <12% of 
the average height of the two peaks 
 
2.13 Application of Tandem Mass Spectrometry in Forensic Toxicology 
The fields of forensic and clinical toxicology require confirmatory testing techniques 
which are capable of providing the most reliable and accurate information possible. The 
importance of superior selectivity, sensitivity, precision, robustness and speed may be more 
pronounced in the fields of forensic and clinical toxicology than any other. Analytical 
methodologies employed for the purposes of identifying and quantifying analytes in these fields 
need offer the highest selectivity and sensitivity as analyses commonly involve the determination 
of trace level xenobiotics in complex biological matrices rich in interferences.  
The hyphenation of gas chromatography with mass spectrometry (GC/MS) has been 
widely employed in forensic and clinical laboratories worldwide since its introduction in the 
mid-twentieth century. The separation power, speed and cost effectiveness of gas 
chromatography, combined with the sensitivity and selectivity of mass spectrometry alleviated 
many of the problems associated with the detection of xenobiotics in complex samples of 
biological origin. GC/MS has long been the most widely employed technique for the selective 
determination and accurate quantification of drugs and their metabolites in biological 
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samples[120]. Review of the scientific literature indicates a significant shift in the popularity and 
employment of confirmation techniques from largely GC/MS based methodologies to LC-MS 
and LC-MS/MS assays.  
Early studies into the applications of tandem mass spectrometry were published by 
pioneering research groups such as Cooks and colleagues at Purdue University[173], Hunt and 
colleagues at the University of Virginia[174], and Enke et al at Michigan State University[175], 
however much of the earlier work utilized the selectivity and sensitivity of MS/MS without prior 
chromatographic separation. Reports of liquid chromatography-tandem mass spectrometry 
methodologies for the selective and sensitive determination of drugs in biological matrices 
consistently began to appear in the literature in the mid 1990s as a direct result of advances made 
in the design and commercial availability of sophisticated LC-MS interfaces.  
Verweij and colleagues described a quantitative LC-MS/MS methodology for the 
determination of some analgesics and tranquilizers of the methadone, butyrophenone, or 
diphenylbutylpiperidine groups in whole blood. The authors employed a SRM mass 
spectrometric technique to monitor daughter ions produced by CID following thermospray (TS) 
ionization[176]. The same authors described a LC-MS/MS technique employing thermospray 
ionization for the quantitative analysis of several drugs with hypnotic, sedative and tranquillizing 
properties in whole blood in the following year. Quantitation was performed using a triple 
quadrupole mass spectrometer operating in the SRM mode following HPLC separation. The 
authors report detection limits in the range of 0.05 – 0.5 ng/mL for most analytes[177].  
The potential of the atmospheric pressure ionization techniques was realized from the 
beginning and the mid 1990s saw a large increase in the number of published applications while 
alternative ionization techniques such as thermospray, fast atom bombardment, and particle 
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beam ionization began to disappear from the literature[131].Cai and Henion employed a triple 
quadrupole mass spectrometer interfaced with an electrospray ionization source for the trace 
analysis of LSD and analogues in human urine following on-line immunoaffinity extraction. 
Coupling of the on-line extraction to the tandem mass spectrometric analysis provided the Cai 
and Henion with detection limits as low as 2.5 ppt which represented a 20 fold increase in 
sensitivity relative to their previous solid phase extraction technique[178]. Cai and Henion also 
describe a technique for the elucidation of LSD metabolism pathways in vitro by employing the 
precursor and neutral loss scanning modes of the triple quadrupole mass spectrometer (see 
section 2.9.4) following separation by LC and capillary electrophoresis. Although the precursor 
and neutral loss scanning modes employed here are seldom used for the quantitation of target 
drugs, Cai and Henion were able to positively identify two new in vitro metabolites of the 
hallucinogen whose structures were unequivocally established through comparisons with 
reference standards[179]. Constanzer and colleagues employed a triple quadrupole mass 
spectrometer interacted with positive ion APCI for the determination of cyclobenzaprine in 
human plasma and urine. The sensitivity of the LC-MS/MS method was compared to a 
previously established GC/MS method and a HPLC separation employing UV detection. The 
authors concluded that the LC-MS/MS technique allowed for a ten-fold increase in sensitivity 
relative to the GC method and a five-fold increase in sensitivity relative to the HPLC-UV 
methodology[180]. Kleinschnitz and co-workers also employed APCI interfaced with a triple 
quadrupole mass spectrometer for the analysis of 1,4-benzodiazepines in serum and urine 
allowing detection quantification limits of 2 ng/mL[181].  
In the years following these early studies, reported applications of LC-MS/MS, in 
particular, liquid chromatography coupled to triple quadrupole instruments, for the determination 
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of drugs or toxins in sample of biological origin increased exponentially. The current role of LC-
MS/MS in forensic and clinical toxicology has been the focus of several reviews [120, 131, 182]. 
Several LC-MS/MS techniques with forensic significance are reviewed here, focusing primarily 
on the detection and/or quantification of drugs of abuse in biological samples.  
Hegstad and co-workers validated a triple quadrupole mass spectrometry method 
employing positive ion mode ESI for the purpose of screening nicotine, cotinine, morphine, 6-
monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymeth-
amphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-
aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, 
meprobamate, buprenorphine, and methadone in hair samples. Following validation, the ESI-
MS/MS method was implemented for the analysis of authentic samples[183]. Concheiro et al 
recently employed positive mode electrospray chemical ionization (ESCI) interfaced with a triple 
quadrupole mass spectrometer for the determination of morphine, codeine, 6-
monoacetylmorphine, methadone, amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxy-N-
ethylamphetamine, benzoylecgonine, cocaine, delta-9-tetrahydrocannabinol, zolpidem, 
zopiclone, alprazolam, clonazepam, oxazepam, nordiazepam, lorazepam, flunitrazepam, 
diazepam, diphenhydramine and amitriptyline in preserved oral fluid specimens. Detection limits 
of 0.5µg/L were achieved using the tandem-in-space mass spectrometry method[184]. Gaulier et 
al reported a tandem mass spectrometry method for the sensitive determination of acepromazine 
for the purpose of identifying drug facilitated sexual assault (DFSA) crimes. The authors 
employed a TSQ tandem mass spectrometer equipped with an orthogonal electrospray ionization 
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source and determined the presence of acepromazine in a sample of the victims hair at a 
concentration of 31 pg/mg[185].  
Ojanpera and co-workers reported a sensitive tandem mass spectrometry technique for 
the detection of the highly potent opioid designer drug 3-methylfentanyl (TMF) in post-mortem 
specimens. Analysis was performed using a QTrap LC-MS/MS operated in triple quadrupole 
mode allowing for the unequivocal identification of the drug at lethal levels in 117 cases over a 
two year period[186]. Roman et al investigated the potential of tandem mass spectrometry 
following liquid chromatographic separation for the detection of seven antipsychotic drugs 
commonly dosed at low levels. Analysis was performed on a triple quadrupole instrument 
equipped with an electrospray interface and the authors conclude that the enhanced sensitivity 
and selectivity afforded by LC-MS/MS is fast becoming essential for the determination of such 
drugs to properly assess their role in post-mortem cases[187].  
Liu et al describe a method employing the fast scanning capabilities of a triple 
quadrupole mass spectrometer operating in the MRM mode for the purpose of screening 22 
poisonous alkaloids in human blood. Positive ion ESI followed by MS/MS analysis enabled the 
authors to selectively identify 22 compounds in human blood based on two fragmentation 
transitions for each analyte. The authors achieved detection limits in the range of 0.1ng/mL to 
20ng/mL[188]. Concheiro and co-workers utilized a triple quadrupole mass spectrometer 
equipped with a Z-spray ion source for the simultaneous determination of ecgonine methyl ester, 
benzoylecgonine, morphine, codeine, 6-acetylmorphine, amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 
methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and d-lysergic acid 
diethylamide (LSD) in human urine and highlighted the importance of ion ratios in the 
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identification criteria. The authors suggest that additional research efforts should be focused on 
determining satisfactory variations in ion ratios following fragmentation by the softer LC-
MS/MS ionization techniques[189].  
Castaing and co-workers capitalized on the sensitivity, selectivity and multi-analyte 
detection capabilities of a triple quadrupole mass spectrometer equipped with an ESI source to 
simultaneously screen and quantify selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, 
paroxetine, sertraline, fluvoxamine, and citalopram), serotonin noradrenergic reuptake inhibitors 
(SNaRIs) (milnacipram and venlafaxine), mirtazapine and five of their active metabolites in 
whole blood. The authors describe the first method in the literature for the simultaneous 
screening and quantification of all aforementioned drugs using LC-MS/MS and highlight that the 
more traditional analytical techniques lack the capability to detect and quantify drugs from the 
SSRI, SNaRI and related classes simultaneously[190].  
Castro and co-workers successfully combined a solid phase extraction and LC separation 
into a single system to allow for the direct injection of plasma samples for the simultaneous 
determination of 14 antidepressants and their metabolites by positive ion ESI and tandem mass 
spectrometry. The authors’ state that the minimal sample preparation required for LC-MS/MS 
analysis, its high selectivity and sensitivity in combination with good precision and accuracy 
over a wide dynamic range, allow for the development of much more efficient and rapid 
analytical methodologies. In particular the authors state that the application of LC-MS/MS for 
the separation and detection of multiple antidepressants in a single sample eliminates the need 
for lengthy sample preparation steps such as fluorescence derivatization which is required for the 
more traditional HPLC with fluorescence detection approach[191].  
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The enhanced sensitivity of tandem mass spectrometry was employed by Quintela et al 
for the detection of low concentrations of 21 benzodiazepine, metabolites and analogues in urine 
using a triple quadrupole mass spectrometer equipped with an ESI interface. Successful detection 
was achieved by monitoring two fragmentation transitions for each analyte in the MRM mode. 
The authors conclude that the increased sensitivity afforded by tandem mass spectrometry assists 
in the detection of low concentrations of benzodiazepines used in drug facilitated sexual assault 
crimes[192].  
Almost 15 years on from the first reported applications of API techniques for the 
ionization of analytes prior to tandem mass spectrometric analysis, ESI and APCI find 
widespread use in routine toxicological analysis worldwide[120, 131, 182]. Just as API 
techniques have become common practice in toxicological analysis, triple quadrupole mass 
spectrometers have been the focus of the vast majority of studies involving the detection and 
quantitation of xenobiotics in toxicological specimens. Tandem mass spectrometry employing 
hybrid mass analyzers for the purpose of qualitative and/or quantitative determination of 
xenobiotics in toxicological specimens became the focus of many research groups in the early 
twenty first century.  
Ballard and co-authors described a novel analytical strategy for the analysis of quaternary 
ammonium neuromuscular blocking agents in a wide variety of biological specimens using a 
tandem quadrupole orthogonal acceleration time of flight (Q-TOF) instrument. The authors 
exploit the qualitative power of the modern quadrupole/time-of-flight (Q-TOF) mass 
spectrometer by using the full scan product-ion spectra to unequivocally identify several 
neuromuscular blocking agents at levels as low as 2-10 ng/g in various biological matrices. 
Concluding remarks highlight the superiority of the modern Q-TOF instrument relative to the 
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commonly employed tandem quadrupole for forensic analyses in which qualitative findings are 
of the utmost importance[193].  
Frison et al recently employed an ion trap mass spectrometer equipped with an 
electrospray ionization source (ESI) for the sensitive determination of citalopram and its (S) 
enantiomer, escitalopram, along with their demethylated metabolites in neonatal hair samples. 
The authors reported a quantification limit of 25pg/mg for all analytes using the tandem-in-time 
mass spectrometry approach[194].  
Deviation from conventional tandem quadrupole mass spectrometers for forensic 
screening and confirmation was also demonstrated by Sauvage and co-workers who developed a 
comprehensive screening method for 1250 exogenous compounds in human blood and urine 
using a triple quadrupole linear ion trap mass spectrometer. The authors developed a general 
unknown screening procedure based on linear ion trap MS/MS using advanced computer 
programming capabilities for the analysis of clinical and forensic samples. By storing product 
ions in the linear ion trap following CID, the authors demonstrated superior identification 
capabilities in a direct comparison with GC/MS and HPLC-DAD[167]. Favretto et al employed 
an ion trap mass spectrometer for the sensitive determination of buprenorphine and 
norbuprenorphine in urine, blood and hair samples and comparatively investigated the use of an 
ion trap for the purposes of collision induced dissociation rather than the in-source fragmentation 
techniques previously reported in the literature. The authors report a much higher CID efficiency 
through the use of an ion trap which appears to generate not only more product ions but also a 
higher abundance of each. Collective data suggests that ion trap MS/MS experiments for the 
determination of buprenorphine and its active metabolite are not only superior to the previously 
reported LC/MS experiments employing in-source collisions and a single quadrupole, but also 
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offer enhanced sensitivity relative to triple quadrupole mass spectrometers employing a CID cell. 
Variations in sensitivity between the two instruments were attributed to the high collision 
energies required to produce any appreciable fragmentation in the triple quadrupole CID, 
combined with the losses in sensitivity associated with ion transfer through tandem-in-space 
instruments[195].  
In 2005, Herrin and co-workers utilized the large database of multiple reaction 
monitoring transition ions for drugs amendable to LC/MS/MS to create a tandem mass 
spectrometry technique for the screening of drugs in post mortem specimens. Herrin et al 
employed a QTrap LC-MS/MS for the purpose of unequivocally identifying over 100 drugs, 
many of which are not amendable to enzyme immunoassay (EIA) screening techniques. 
Qualitative determinations were made based on the detection of MRM transition ions and the 
enhanced product ion (EPI) scans produced by the linear ion trap. Enhanced product ion scans 
are produced when Q3 is employed as a linear ion trap while simultaneously performing the role 
of Q3 for the MRM experiments. Identifications based on the detection of one MRM transition 
ion and a matching EPI scan enabled the authors to unequivocally identify over 100 drugs in 
post-mortem specimens using dwell times in the range of 1-25 ms[168].  
Prior to the studies of Herrin et al, several groups published methodologies describing the 
application of quadrupole-linear ion-trap mass spectrometry for the broad based screening of 
forensically significant drugs in post-mortem specimens[167, 169, 196, 197]. The number of 
published methodologies describing the use of liquid chromatography coupled to tandem mass 
spectrometry for the forensic analysis of drug or other xenobiotics continues to increase each 
year as the instrumentation capable of performing LC-MS/MS analysis continues to become 
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Chapter 3: Analytical Method Validation 
3.1 Introduction 
Analytical methodologies play an integral role in many fields of the life sciences and as a 
result, produce data that is subsequently interpreted to provide pivotal information which is then 
used to make medical, legal, clinical, and environmental decisions. Correct interpretation and 
evaluation of analytical data is obviously a crucial component in the decision making process, 
however, preliminary procedures must also be implemented by analytical chemists to ensure that 
such methodologies are generating reliable analytical data at all times. Analytical data of high 
quality and integrity can only be produced by an analytical method which has demonstrated both 
suitability and reliability for its intended purpose. Careful method development followed by a 
thorough bioanalytical method validation is required for analytical methodologies whose 
intended use is to quantify the concentration of an analyte in a particular biological matrix for the 
purpose of forensic and/or clinical toxicology analysis[198].  
Bioanalytical method validation for analytical techniques intended for forensic 
toxicology analysis is of extreme importance as it objectively demonstrates the inherent quality 
of the analytical method for its intended purpose by fulfilling minimum performance and 
acceptance criteria[198]. Failure to validate a bioanalytical methodology for its intended purpose 
may unknowingly generate unreliable data which will not only be questioned in a court of law, 
but may result in unjustified legal consequences or the inappropriate treatment of patients[198]. 
Unreliable data generated during analytical studies to assess the pharmacological efficacy of a 
new drug or patient compliance in pain management toxicology can have detrimental effects on 
both the patient and the toxicology laboratory responsible for generating the data. All appropriate 
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steps must be taken to ensure that the data generated by bioanalytical methodologies in the 
forensic toxicology laboratory is both accurate and reliable.  
The first step in validating a bioanalytical method is to identify and define its intended 
purpose as this will largely determine which method parameters require validation. As there is no 
one single guideline on bioanalytical method validation, it is routinely customized by individual 
laboratories by the identification and validation of only select performance criteria which have 
been chosen based largely on the intended purpose of the test. Selection of relevant performance 
criteria is made easier by first identifying the intended purpose or application of the method. For 
example, certain validation parameters such as precision and accuracy are vital performance 
criteria which need be addressed during the validation of a quantitative bioanalytical method 
whereas validation of certain qualitative assays may not incorporate the assessment of such 
parameters. Bioanalytical method validation procedures show significant variation from 
laboratory to laboratory and although there is no single guideline describing the processes for full 
method validation, several guidance documents addressing the bioanalytical analysis of drugs 
and poisons in biological samples exist in the literature [119, 198-202]. In the present study, 
analytical methodologies were developed for the purpose of quantifying drugs of abuse in 
meconium. All analytical method validation protocols were designed and followed according to 
validation guidelines set out in documents such as the bioanalytical method validation guidance 
for industry document published by the US Food and Drug Administration in 2001, and the 
Forensic Toxicology laboratory guidelines published by the Society of Forensic Toxicologist 
(SOFT) and American Academy of Forensic Sciences (AAFS).  
Full bioanalytical validations should be completed when developing and implementing a 
method for the first time or if the method is intended for the detection of drugs and/or 
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metabolites in novel matrices. Guidance presented in these documents applies to the validation of 
bioanalytical procedures such as gas chromatography (GC), high-pressure liquid chromatography 
(LC), combined GC and LC mass spectrometric procedures such as LC-MS, LC-MS/MS, GC-
MS, and GC-MS/MS performed primarily for the quantitative determination of drugs and their 
metabolites in various biological matrices such as blood, serum, plasma, or urine.  
The present study describes the development of three UPLC-MS/MS methodologies for 
the quantitative determination of several drugs of abuse in human meconium. Implementation of 
this technique for the intended purpose has not occurred previously and because of this, all three 
UPLC-MS/MS methodologies were subjected to full analytical method validation procedures. 
Fundamental parameters for a full bioanalytical method validation include accuracy, 
precision, selectivity, sensitivity, reproducibility, and stability. Method validation was performed 
for each confirmation assay by determining and assessing (1) selectivity, (2) accuracy, (3) 
precision, recovery, (3) calibration curve, (4) Limit of detection, and (5) stability. Validation of 
each analytical method involved documenting the performance of each of these criteria during 
laboratory experiments designed specifically for that purpose. Each performance parameter was 
designated certain acceptance criteria which had to be satisfied in order to deem the method 
suitable and reliable for its intended purpose. Table 6 provides an overview of bioanalytical 







Table 6: Overview of bioanalytical method validation terms and definitions. 
Term Definition 
Selectivity The ability of an analytical method to differentiate and quantify the 
analyte of interest in the presence of other components in the sample 
 
Accuracy The closeness of mean test results obtained by the method to the true 
concentration of the analyte 
Precision The closeness of individual measures (degree of scatter) of an analyte 
concentration when the procedure is applied repeatedly to multiple 
aliquots of a single standard 
Recovery Recovery pertains to the extraction efficiency of an analytical method 
within the limits of variability 
Calibration curve Represent the relationship between instrument response and known 
concentrations of an analyte 
Stability Pertains to the stability of an analyte in a biological matrix during sample 
collection, and storage 
Limit of detection (LOD) The lowest concentration or amount of analyte in a sample that can be 
unequivocally identified but not necessarily quantified 
Lower limit of quantitation (LLOQ) The lowest concentration of an analyte in a sample that can be quantitated 
with suitable accuracy and precision 
 
3.2 Bioanalytical Validation Parameters 
3.2.1 Selectivity 
Selectivity is the ability of an analytical method to differentiate and quantify the analyte 
of interest in the presence of other components in the sample[199]. Selectivity is an extremely 
important validation parameter in forensic toxicology due to the complex nature of biological 
specimens such as blood, urine, tissue, and meconium. Complex matrices such as meconium are 
expected to be rich in interfering species of both endogenous and exogenous origin. This means 
that bioanalytical methods intended to quantify small amounts of analyte, must be capable of 
unequivocal identification and accurate quantification in the presence of additional sample 
88 
 
components such as xenobiotics, metabolites, impurities, degradants, and endogenous 
interferences[198].  
Chemical extractions are routinely employed in forensic toxicology to aid in the removal 
of interfering species from the biological matrix prior to instrumental analysis. While various 
chemical extractions (SPE, LLE, protein precipitations) have been shown to selectively extract 
common drugs of abuse while simultaneously removing matrix components, many of these 
techniques are validated only for blood or urine. Meconium presents a significantly different 
matrix of biological origin and the application of pre-existing extraction techniques may not 
necessarily provide extracts of the same purity.  
Selectivity studies for alternate matrices such meconium, are important for determining 
whether or not the chosen chemical extraction is suitable and sufficient. To determine the extent 
of sample cleanup, and therefore the suitability of the extraction technique, multiple (n=5) blank 
matrices should be subject to chemical extraction and analyzed for the analyte(s) of interest. Any 
analyte response generated by endogenous compounds in the blank matrix should correspond to 
an analyte concentration below the LLOQ. Five blank biological matrices should be subject to 
chemical extraction and analyzed for the analyte of interest to ensure that any analyte response 
generated by endogenous compounds could not result in a confirmed positive result. 
Selectivity of the instrumental detection system is also paramount to ensure that the 
analyte(s) of interest are accurately identified in the presence of chemically similar exogenous 
interferences. Chemical extractions are often sufficient for the removal of endogenous 
compounds which are chemically and physically distinct from the analyte(s) of interest, however, 
xenobiotics with similar physicochemical properties will likely not be removed during chemical 
extraction. For this reason, detection systems must be capable of accurate and unequivocal 
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analyte identification in the presence of chemically similar compounds. Mass spectral 
characteristics of chemically similar compounds commonly encountered in forensic specimens 
should be studied to ensure that they are distinguishable from the analyte of interest. In order to 
evaluate the selectivity of the methodology, several blank matrices should be spiked with the 
analyte of interest at a concentration corresponding to the LLOQ and also with various 
exogenous interferences. Samples should be analyzed to ensure that the methodology is capable 
of accurately identifying and quantifying the analyte of interest in the presence of chemically 
similar compounds.  
3.2.2 Accuracy 
The accuracy of an analytical methodology describes the closeness of mean test results 
obtained by the method to the true concentration of the analyte[199]. The accuracy of an 
analytical methodology should be determined by preparing and analyzing five replicate standards 
in the matrix under investigation at three concentrations spanning the calibration range of the 
method. Five standards containing a known amount of the analyte should be prepared at 
concentrations representing the upper limit of quantitation (ULOQ), the LOQ, and a 
concentration point midway between the two. Replicate analysis of the standards should produce 
mean values within 15% of the expected nominal value, except at the LLOQ where the mean 
value should be within 20% of the expected nominal value. The degree of deviation of mean 
values from the true values serves as the measure of method accuracy[199]. 
3.2.3 Precision 
The precision of an analytical method describes the closeness of individual measures 
(degree of scatter) of an analyte concentration when the procedure is applied repeatedly to 
multiple aliquots of a single standard[199]. The precision of an analytical methodology should be 
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determined by preparing and analyzing five replicate standards in the matrix under investigation 
at three concentrations spanning the calibration range of the method. Precision of the analytical 
method should not exceed 15% of the coefficient of variation (CV) except at the LLOQ where is 
should not exceed 20% of the CV. Precision studies can be further subdivided into intra-batch 
precision and inter-batch precision. Intra-batch precision evaluates the method precision during a 
single analytical run or single batch. Inter-batch precision evaluates the method precision over 
multiple batches and provides an indication of method repeatability with time. Inter-batch 
precision experiments may be as simple as analyzing replicates under identical conditions over 
several days or may involve using different analysts, instruments, reagents, or laboratories to 
determine the robustness of the methodology. Mathematically determining the precision of 
replicate analysis at any one concentration involves calculating the standard deviation of the 
replicate concentrations and dividing by their mean. 
3.2.4 Recovery 
Recovery of an analytical methodology should be evaluated to determine the extraction 
efficiencies for each analyte from the matrix of interest. Recovery pertains to the extraction 
efficiency of an analytical method within the limits of variability. Recovery is not among the 
validation parameters regarded as essential for quantitative assays unless the sensitivity of the 
assay is poor[198].  
Analyte recovery pertains to the detector response obtained from a known amount of 
analyte added to and then extracted from a biological matrix, compared to the detector response 
obtained for the same concentration analyzed as a pure authentic standard[199]. While the 
recovery of an analyte and its respective internal standard need not be 100%, the extent of 
recovery should be reproducible at concentrations spanning the calibration range. 
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3.2.5 Calibration Curves 
Calibration curves consist of a number of standards prepared at known concentrations in 
the same matrix as the unknown specimens. Following accurate preparation, calibration 
standards are analyzed to determine how the instrumental response changes with analyte 
concentration. Once this relationship has been established, unknown samples can be analyzed 
and quantified by measuring the analyte response and interpolating to find the concentration of 
the analyte. Calibration curves are the most commonly employed internal standard method for 
forensic toxicological analysis. Preparation of calibration curve standards in appropriate matrices 
for the purpose of quantifying unknown analytes is typical across toxicology laboratories. 
Calibration curves should be generated and assessed for each analyte encompassed in the 
analytical method. A sufficient number of calibrator concentrations should be employed to cover 
the entire calibration range and should be evenly spaced to accurately and adequately define the 
relationship between analyte concentration and detector response[119, 198, 199].  
Calibration standards used to construct calibration curves should be constructed from 
blank biological matrices which have been spiked with a known amount of analyte and internal 
standard. Detector responses are generally calculated as the area ratio of analyte versus internal 
standard for bioanalytical methods[198].  
3.2.6 Stability Studies 
Analyte stability in a biological matrix is a function of the storage conditions, the 
physicochemical properties of the drug itself, and the matrix in which the drug is present[199]. 
Stability studies should be performed to assess the stability of each analyte in the matrix of 
interest and in the storage container to be used. Stability studies are specific to the matrix, 
storage container, storage conditions, and the analyte investigated during validation studies and 
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results should not be extrapolated or applied to other matrices or conditions. Stability studies 
should be designed to evaluate the stability of each analyte during collection, pre-testing storage, 
analysis procedures, and post-testing storage. Studies should also be designed to investigate 
analyte stability during and after several freeze and thaw cycles. Stability of the analyte 
following several freeze-thaw cycles is important to establish as samples are routinely subject to 
such conditions during retesting. Investigations into analyte stability should be performed by 
spiking the appropriate blank matrix with each analyte at concentrations within the expected 
range. Samples prepared at a high and low concentration relative to the calibration curve are 
most appropriate. Spiked samples should then be subject to various conditions representative of 
sample collection, storage and preparation. Samples should also be subject to several freeze-thaw 
cycles and analyzed following each cycle to ensure stability over the time course. Mean values 
obtained after subsequent freeze-thaw cycles should be within 20% of the expected nominal 
values if the analytes are indeed stable in the matrix of interest. The stability of analytes and 
internal standards during and prior to analysis, but following extraction may also be investigated. 
These studies are important for high throughput production laboratories as samples are often 
batched and loaded into sample organizers for subsequent analysis. If multiple batches are to be 
analyzed over a significant period of time, prepared extracts may experience significant 
residence time in the autosampler. Stability of the analyte in such an environment should be 
established in such cases.  
3.2.7  Limit of Detection (LOD) and Lower Limit of Quantitation (LLOQ) Studies 
The limit of detection (LOD) for an analytical methodology is defined as the lowest 
concentration or amount of analyte in a sample that can be unequivocally identified but not 
necessarily quantified. It corresponds to the lowest concentration of analyte that the analytical 
93 
 
methodology can reliably differentiate from background noise[201]. The LOD can be determined 
either by a statistical approach based on measuring replicate blank (negative matrix) samples or 
by an empirical approach which consists analyzing progressively more dilute concentrations of 
analyte until reliable identification can no longer be made[203]. Statistical determination of the 
LOD is achieved by analyzing a series of blank samples (appropriate matrix with no analyte) and 
obtaining the mean blank value (µ) and the standard deviation (σ) of those values. The LOD is 
then determined using Equation 11. 
 
LOD = µ + 3σ          Equation 11 
 
The statistical approach assumes that the standard deviation of the blank is roughly equivalent to 
the standard deviation of the concentration that actually corresponds to the LOD[203]. Similar to 
the statistical approach is the method for determining the LOD based on the signal to noise (S/N) 
ratio. The signal to noise is defined as the height of the analyte peak (signal) and the amplitude 
between the highest and lowest point of the baseline (noise)[198]. The LOD is normally accepted 
as the concentration at which the S/N ratio is equal to, or greater than 3 for triplicate analyses. 
 The empirical or experimental approach to determining the LOD involves analyzing serially 
dilute samples of analyte until the LOD is determined. The LOD corresponds to the lowest 
concentration of sample at which the identification of the analyte still satisfies predetermined 
acceptance criteria[203]. Concentrations below the LOD do not satisfy such criteria and 
identification of the analyte would not be justified. The limit of detection was determined 
empirically for all confirmation methodologies by analyzing serially dilute samples until the 
methodology was unable to reliably identify the analyte as a result of shifts in retention times or 
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inaccurate ion ratios. Acceptance criteria for retention times were within 2% of calibrators and 
ion ratios were required to be within 20% of calibrators to positively identify the analyte. 
Evaluation and determination of the LOD for instrumental methods designed for forensic 
analysis may not always be necessary. While it is good practice to understand instrument 
limitations, forensic laboratories rarely report positive results at concentrations corresponding to 
the LOD. This is because most chromatographic methodologies employed in the toxicology 
laboratory are confirmatory assays aimed at quantitating an unknown analyte. As quantitation at 
the LOD is not feasible, many laboratories do not consider it a vital validation parameter. A more 
important validation parameter in the forensic toxicology industry is the lower limit of 
quantitation. 
The lower limit of quantitation (LLOQ) is defined as the lowest concentration of an 
analyte in a sample which can be accurately and precisely quantitated[199]. The LLOQ is an 
important parameter in toxicology as all chromatographic assays are designed to accurately 
quantitate an unknown analyte. As accurate quantitation below the LLOQ is not feasible, any 
sample that contains an analyte below the established LLOQ is generally considered negative in 
the toxicology laboratory. There are several approaches to determining the LLOQ and the most 
appropriate depends largely on the intended purpose of the analytical methodology. The LLOQ 
can be determined statistically using the same technique as the LOD method and substituting µ 
and σ into Equation 12. 
 




Similar to this approach is the method of determining the LLOQ based on the signal to noise 
(S/N) ratio. The signal to noise is defined as the height of the analyte peak (signal) and the 
amplitude between the highest and lowest point of the baseline (noise)[198]. The LLOQ 
normally corresponds to the concentration at which the S/N ratio is equal or greater than 10. 
Laboratory guidelines published by SOFT/AAFS state that for chromatographic assays, the 
LLOQ may be defined as the concentration of the lowest calibration standard. The LLOQ is the 
concentration at which the analytical methodology can still quantify the analyte with acceptable 




















Chapter 4: Introduction and Overview to the Development and Validation of 
UPLC-MS/MS Methodologies for the Quantitative Determination of Cocaine, 
Amphetamine, and Opiate Derivatives in Human Meconium.  
4.1 Introduction 
Cocaine, amphetamines, and opiates continue to find widespread abuse among users 
worldwide. Due to the detrimental effects of prenatal drug exposure, there is a growing need for 
methodologies capable of assisting with the identification of maternal drug use. Traditional 
methods for identifying maternal drug use have relied on the analysis of maternal and/or infant 
blood and urine. Due to the relatively short retention time of drugs in blood and urine, these 
analyses aid only in the identification of recent maternal drug use. Development of sensitive and 
selective methodologies capable of detecting drugs of abuse in human meconium will aid in 
identifying prenatal drug exposure occurring during the second and third trimesters which has 
previously gone undetected. Implementation of such methodologies will ensure that the correct 
intervention and treatment is made available to both the mother and the newborn. 
Development and full analytical method validation of three UPLC-MS/MS 
methodologies for the quantitative determination of cocaine, amphetamine, and opiate 
derivatives in human meconium is described. Methodologies were developed for the purpose of 
selectively determining and accurately quantifying cocaine, benzoylecgonine, amphetamine, 
methamphetamine, codeine, morphine, hydromorphone, and 6-monoacetylated morphine in 
meconium specimens. All experiments were performed using the Waters TQD triple quadrupole 
mass spectrometer equipped with an electrospray ionization (ESI) source operating in the 
positive ion mode. Chromatographic separations prior to mass spectrometric detection were 
achieved using the Waters ACQUITY UPLC™ chromatograph. Methodologies were validated 
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according to full analytical method validation guidelines published in the ‘Bioanalytical Method 
Validation Guidance for Industry’ document published by the US Food and Drug Administration 
in 2001, and the ‘Forensic Toxicology Laboratory Guidelines’ published by the Society of 
Forensic Toxicologist (SOFT) and American Academy of Forensic Sciences (AAFS)[119, 199]. 
Tables 7 provides an overview of the three analytical methodologies including the number of 
analytes detected by each methodology, sample preparation method, and figures of merit such as 
the calibration range, the limit of detection (LOD), and the lower limit of quantitation (LLOQ). 
Table 7: Overview of three UPLC-MS/MS methodologies developed and validated for the 
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1. Cocaine 1.Protein precipitation 
2. SPE 
10 – 250 ng/mL 1 ng/mL 10 ng/mL 
2. Benzoylecgonine 1.Protein precipitation 
2. SPE 






1. Morphine Supported-liquid 
extraction (SLE) 
10 – 500 ng/mL 2.5 ng/mL 10 ng/mL 
2. Codeine Supported liquid 
extraction (SLE) 
10 – 500 ng/mL 2.5 ng/mL 10 ng/mL 
3. Hydromorphone Supported liquid 
extraction (SLE) 
10 – 500 ng/mL 2.5 ng/mL 10 ng/mL 
4. 6-monoacetylmorphine Supported liquid 
extraction (SLE) 





1. Amphetamine Supported liquid 
extraction (SLE) 
5 – 500 ng/mL 1 ng/mL 5 ng/mL 
2. Methamphetamine Supported liquid 
extraction (SLE) 





Experimental sections 4.2.1 & 4.2.2 describe method development steps common to all 
three UPLC-MS/MS methodologies. These sections are designed to provide the reader with an 
overview of the steps taken and processes followed during preliminary method development. 
Pease refer to individual experimental sections in chapters 5, 6 and 7 for specific instrumental 
conditions and detailed experimental designs. Section 4.3 describes the details of method 
validation experiments for each of the three UPLC-MS/MS methodologies. Please refer to 
chapter 3 for definitions of validation parameters and generalized experimental approaches. 
Please refer to the individual results and discussion sections in chapters 5, 6, and 7 for discussion 
and interpretation of individual validation experiments. 
4.2.1 Development and Optimization of MS/MS Parameters 
Mass spectrometric detection was performed using a Waters TQD triple quadrupole mass 
spectrometer (Waters Corp., Milford, MA, USA) equipped with an electrospray ionization (ESI) 
source operating in positive ion mode. Method development was initiated by identifying 
appropriate quantifier and qualifier mass transitions for each analyte. Concentrated (10 µg/mL) 
solutions each analyte were directly infused into the mass spectrometer ionization source at a 
flow rate of 20 µL/min. The flow paths of the concentrated analyte solutions were modified with 
a T-mixer to allow mixing of the solution with mobile phase (Figure 14). This allowed for the 
simultaneous infusion of analyte solution and initial mobile phase into the mass spectrometer. 
Simultaneous infusion of the sample with the initial mobile phase ensured that any subsequently 
optimized tune page parameters were compatible with the initial mobile phase. Optimizing the 
tune page parameters under these conditions also ensured that analytes were being introduced 
99 
 
into the ESI source in an environment that was representative of an authentic sample. This 
ensured the most accurate optimization of ionization parameters specific to both the sample and 
the mobile phase.  
 
 
Figure 14: Schematic representation of the ‘T-mixing’ mode which allows for the simultaneous 
infusion of analyte solution from reservoir A and mobile phase eluting from the UPLC column. 
 
 
Concentrated (10 µg/mL) solutions of each analyte were concomitantly infused with the initial 
mobile phase composition at a flow rate of 0.6 mL/min. During infusion of each analyte, the 
collision gas was turned off to allow the protonated molecular ion of each compound to reach the 
detector and produce a recordable signal. Following identification of the molecular ion signal, an 
auto tune was completed for each analyte which involved adjusting the capillary voltages, cone 
voltages, and collision energies to maximize the signal for both the precursor ions and the 
product ions generated in the collision cell. Auto tuning of the protonated molecular ion of each 
compound yielded information necessary to collect data in the MRM mode. The mass transition 
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from the protonated molecular ion [M+H]+ to the most abundant product ion was designated the 
quantifying ion transition while the second most abundant mass transition was designated as the 
qualifying ion transition for each analyte. The most abundant product ion for each deuterated 
internal standard was also monitored and used to calculate the response ratio between internal 
standards and analytes for all experiments. Following auto tuning of each analyte and internal 
standard, the optimized parameters were used to construct the MS/MS method which was then 
used to acquire data in the MRM mode.  
4.2.2 Development of UPLC Separation Conditions 
Following development of the MS/MS detection method, analytes were individually 
injected onto the UPLC to optimize chromatographic separation conditions. Analytes were 
individually injected onto the column to obtain and record characteristic retention times and to 
optimize chromatographic conditions. Chromatographic conditions were optimized to ensure that 
all peak shapes were Gaussian in nature and baseline resolution was achieved, allowing for 
accurate and reliable identification. All liquid chromatographic separations were performed on a 
Waters ACQUITYTM ultra performance liquid chromatograph (UPLC™) (Waters Corp., 
Milford, MA, USA). Separations were achieved on one of several ACQUITY UPLC™ columns 
(see individual experimental sections for column dimensions). All mobile phases consisted of 
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1% 
formic acid (solvent B). Analytes elution was achieved using step-wise binary elution gradients 
and all flow was directed into the ESI source of the mass spectrometer. 
4.2.3 Considerations for UPLC-MS/MS Method Development 
Analytical separation and detection of xenobiotics in complex biological matrices can 
prove difficult when employing detection systems that lack the selectivity of mass spectrometry. 
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Traditional techniques such as HPLC equipped with UV detection require baseline separation of 
analytes from any endogenous interferences, xenobiotics, or sample contaminants with similar 
UV absorbance. UV detection systems measure the UV absorbance of column eluates at a 
particular wavelength or over a range of wavelengths. Compounds with similar chromatographic 
properties to the analyte of interest, which absorb UV radiation at the chosen wavelength may 
co-elute with the analyte making any subsequent attempts at integration and quantification 
inaccurate and unreliable. The problem of co-elution can be overcome by modifying sample 
extraction techniques, reconstitution solvents, mobile phase components, flow rates, 
chromatographic columns or detection wavelengths.  
Depending on the complexity of the biological extract, lengthy, complex 
chromatographic separations employing various mobile phase additives may be required to 
successfully resolve the analyte of interest from sample interferences. Mass spectrometry, in 
particular tandem mass spectrometry, offers the analyst enhances selectivity for the identification 
of low levels of analyte in complex biological matrices rich in interferences. According to the 
SOFT/AAFS forensic laboratory guidelines, the detection or initial identification of drugs or 
toxins should be confirmed whenever possible by a second testing technique based on a different 
chemical principle. Due to its superior sensitivity, mass spectrometry is the recommended 
confirmatory technique, where possible and practical[119].  
Confirmation assays in the forensic toxicology laboratory which employ mass 
spectrometry are generally performed in the single ion monitoring (SIM) mode for MS analysis 
and in the multiple reaction monitoring (MRM) mode MS/MS analysis. This is the general 
occurrence due to the sequence of testing procedures performed in the routine toxicological 
analysis of blood, urine, or alternate specimens. Confirmation techniques employing mass 
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spectrometry are generally developed and optimized to identify individual components of a drug 
class whose presence was indicated by the presumptive screen test.  
Due to the finite number of analytes monitored during a confirmation assay, data 
acquisition can be performed in either the SIM mode for single mass spectrometry experiments 
or MRM for tandem mass spectrometry techniques. SIM and MRM scanning during 
confirmation analysis provides the analyst with inherent selectivity for the analyte/s of interest 
and due to the reduction in background signal, sensitivity is also enhanced. Tandem mass 
spectrometry experiments employing the MRM mode do not produce mass spectrums, rather 
chromatograms as the data output is reflective of only one mass transition corresponding to the 
analyte of interest rather than a complete mass spectrum obtained by scanning a certain mass 
range. While chromatographic separations still play an integral role in LC-MS/MS assays, 
baseline chromatographic resolution is often not required when employing mass spectrometry as 
a detection technique because of its ability to monitor mass transitions specific to an individual 
analyte. When operating in MRM mode, mass spectrometers are constantly acquiring data for 
one or more mass transitions. Although co-elution may exist between transitions on the total ion 
chromatogram (TIC), data pertaining to each transition is being acquired individually and 
extraction of the individual trace allow for the accurate and reliable quantification of the analyte 
corresponding to that transition. Figure 15 shows the TIC for the chromatographic separation of 
eight tricyclic antidepressants on a Waters Acquity TQD. It can be seen from the TIC, which 
only contains five peaks, that the individual analytes are not chromatographically resolved. 
When operating in MRM mode however, triple quadrupole instruments are constantly acquiring 
data for individual ion traces. This information can be extracted from the TIC and used to 
quantify each analyte. Figure 16 shows the extracted ion traces for each analyte. While 
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chromatographic resolution was not achieved, all eight analytes can be accurately quantified 
using individual MRM ion traces (Figure 16). 
 
Figure 15: TIC for the chromatographic separation of eight tricyclic antidepressants on a Waters 
Acquity TQD. Analytes are not chromatographically resolved but can be quantified using their 
individual MRM ion traces. 
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Figure 16: Extracted in traces for each analyte. Individual ion traces are acquired in the MRM 
mode and eliminate the need for chromatographic resolution. 
  
There are however, circumstances in which baseline resolution is required for tandem 
mass spectrometric detection to enable accurate and reliable quantitative results. One such 
instance arises when the detection of two or more co-eluting compounds is performed by 
monitoring the abundance of product ions with identical masses. Chromatographic resolution is 
required in such cases to eliminate the detrimental effects of ‘cross-talk’ which is caused by the 
slow removal of ions from the collision cell. Cross-talk may occur when two co-eluting 
compounds with identical product ion masses are monitored by successive transition scans[196]. 
Cross-talk occurs when fragment ions from a certain mass transition scan event have not fully 
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cleared the collision cell before a second scan event takes place in which the same fragment ion 
is monitored. Residual fragment ions from the first scan event contributing to the analyte 
response for the second scan event lead to signal artifacts which impact the quantitation of the 
co-eluting analytes.  
The effects of cross talk can be minimized by introducing an inter-scan delay between the 
two transitions to ensure optimal clearance of the collision cell, however this increases the 
method ‘dead time’ and significantly affects the scan cycle time. Increasing the scan cycle time 
by introducing an inter-scan delay, decreases the number of data points obtained over a 
chromatographic peak which can also have a detrimental effect of quantitation accuracy[196]. In 
such cases, chromatographic resolution is the preferred option for alleviating the problems 
associated with ion cross-talk. Chromatographic resolution may not always be feasible for 
methods designed to detect a large number of analytes in a relatively short chromatographic 
run[196, 197] and in such cases, the effects of cross-talk on quantitation accuracy should be 
assessed during validation experiments. 
4.3 Experimental Design for Method Validation 
Preliminary method development experiments described in section 4.2 involved 
developing and optimizing a chromatographic separation which allowed for the accurate and 
reliable identification of each analyte and deuterated internal standard based on retention times. 
Experiments also involved developing and optimizing a mass spectral method capable of 
obtaining data in the multiple reaction monitoring (MRM) mode for each analyte and deuterated 
internal standard. Following the development and optimization of UPLC and MS/MS conditions 
using concentrated drug standards, each UPLC-MS/MS methodology was subject to a full 
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analytical method validation. Validation experiments were designed and carried out to determine 
the suitability of each method for its intended purpose. 
Scientific validation of the UPLC-MS/MS methodologies included performance studies 
assessing matrix equivalence, linearity, selectivity, accuracy, intra- and inter-run precision, 
recovery, stability and limit of detection (LOD). Method validation studies were performed over 
a ten day time period and methodologies were deemed suitable for the analysis of authentic 
samples if, and only if, validation studies had were completed and acceptance criteria were met 
for each validation parameter. Several validation experiments required the replicate analysis of 
standards prepared at concentrations spanning the concentration range for that specific analyte. 
With the exception of matrix equivalence experiments (see section 4.3.1) standards were 
prepared at the LLOQ, the ULOQ, and a concentration midway between the two. Table 8 lists 










Table 8: Concentrations of standards used in all validation experiments. Concentrations of 
standards spanned the calibration range of each method. 
Method Analyte Conc of Std. 1 
(LLOQ) 
Conc of Std. 2 
(midway point) 





Cocaine 10 ng/mL 50 ng/mL 250 ng/mL 





Morphine 10 ng/mL 50 ng/mL 500 ng/mL 
Codeine 10 ng/mL 50 ng/mL 500 ng/mL 
Hydromorphone 10 ng/mL 50 ng/mL 500 ng/mL 





Amphetamine 5 ng/mL 50 ng/mL 500 ng/mL 
Methamphetamine 5 ng/mL 50 ng/mL 500 ng/mL 
 
4.3.1 Equivalence Studies for Calibration Curves 
Certified drug free meconium cannot be purchased for the purpose of constructing 
calibration curves. In order to alleviate this problem, initial equivalence studies were performed 
to determine the suitability of using calibration curves constructed in blood for the quantitation 
of meconium specimens.  
Experiments were performed by quantitating five high quality control (HQC) standards 
and five low quality control (LQC) standards using a calibration curve constructed in blood and a 
calibration curve constructed in meconium which had previously screened negative at AIT 
Laboratories employing a cutoff of 50 ng/g. Equivalence studies were performed to ensure that 
calibration curves prepared in blood were able to accurately quantify quality control standards, 
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and therefore authentic samples, in meconium. Quantitative values obtained for QC standards 
using the calibration curve constructed in blood were required to be within 15% relative error 
(%RE) of the quantitative values obtained using the calibration curve constructed in meconium. 
If equivalence studies indicated that calibration curves constructed in blood were capable of 
accurately quantitating QC standards prepared in meconium, certified drug free whole blood 
would be employed for the remainder of validation for the purpose of constructing calibration 
curves. 
Preliminary equivalence studies were performed on the first day of validation to assess the 
suitability of calibration curves constructed in certified drug-free blood for the purpose of 
quantitating meconium specimens. High and low quality control specimens were prepared 
according the calibration range of each assay. The concentration of standards used in matrix 
equivalence studies varies slightly from those used in the remainder of validation experiments. 
Table 9 lists the concentration of all standards used for equivalence studies.  
Table 9: Concentrations of all LQC and HQC standards used in preliminary matrix equivalence 
studies. 
Analyte LQC used for equivalence studies HQC used for equivalence studies 
Cocaine 15 ng/mL 125 ng/mL 
Benzoylecgonine 15 ng/mL 125 ng/mL 
Morphine 10 ng/mL 500 ng/mL 
Codeine 10 ng/mL 500 ng/mL 
Hydromorphone 10 ng/mL 500 ng/mL 
6-monoacetylmorphine 10 ng/mL 500 ng/mL 
Amphetamine 10 ng/mL 500 ng/mL 
Methamphetamine 10 ng/mL 500 ng/mL 
 
Quantitative values obtained for QC standards using a calibration curve constructed in blood 
were required to be within 15% relative error (%RE) of the quantitative values obtained using a 
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calibration curve constructed in negative meconium. Relative error was calculated according to 
Equation 13.  
%RE = [(value from blood curve/value from meconium curve)-1] x 100%  Equation 13 
4.3.2 Selectivity 
The selectivity of each LC-MS/MS assay was assessed by analyzing five blank 
meconium samples which had previously screened negative at AIT Laboratories using a cutoff of 
50 ng/g. Negative meconium samples were analyzed as blanks because certified drug free 
meconium is not commercially available. Blank samples (n=5) were analyzed using each of the 
three confirmation methods employing appropriate internal standards, calibration curves and 
quality control standards to ensure that the method would be selective for the analytes of interest 
in the presence of any endogenous interferences. Methods were deemed selective if, and only if, 
the blank matrices did not generate an analyte response in excess of the LLOQ (see Table 8 for 
method LLOQs). Following the analysis of blank sample matrices for the presence of possible 
interferences, selectivity was established at the LLOQ for each analyte. In order to deem the 
methodology selective, negative meconium specimens were spiked with the analyte/s of interest 
at a concentration corresponding to the LLOQ. Specimens were then spiked with varying 
concentrations of potential interfering species to ensure that the method was selective for the 
analyte/s of interest in the presence of other endogenous matrix components. Samples were again 
analyzed by each of the confirmation methods using appropriate internal standards, calibration 
curves and quality control standards. Individual methodologies were deemed selective if, and 
only if, they were capable of quantifying the analyte/s of interest within +/-20% of the expected 




Accuracy of the analytical methodology was assessed by preparing and analyzing five 
replicate samples prepared in negative meconium at concentrations covering the calibration 
range of the method. Samples prepared at the LLOQ, and ULOQ and a concentration midway 
between the two were analyzed to assess the accuracy of the quantitation. The method was 
deemed accurate if, and only if, the values obtained for each specimen were within 15% of the 
expected nominal values, except at the LLOQ where values were expected to be within 20% of 
the expected nominal value. Table 8 lists the concentration of all standards used for accuracy 
experiments. 
4.3.4 Precision 
The precision of each confirmation assay was assessed by analyzing five replicates at 
three different analyte concentrations corresponding to the LLOQ, the ULOQ and a 
concentration point midway between the LLOQ and the ULOQ. Methodologies were deemed 
precise if, and only if, the relative standard deviation (RSD) did not exceed 15%, except for the 
LLOQ, where the RSD was required to be less than 20%. Intra batch precision was assessed by 
analyzing five replicates at three different concentrations within a single analytical run and inter 
batch precision was assessed by analyzing replicates over a four day/four batch period. Inter 
batch precision was assessed to determine the methods precision with time, and to provide an 
indication of method robustness. Intra batch precision was calculated by determining the 
standard deviation (σ) and the mean (µ) for each the five replicate analyses at each concentration. 
The absolute value of the coefficient of variation or the relative standard deviation (RSD) was 




R.S.D = (σ/µ) x 100%         Equation 14 
 
 Inter batch precision was calculated in the same manner using standard deviation (σ) and mean 
(µ) values calculated from values obtained over the four day period for each concentration. 
4.3.5 Recovery 
Recovery was evaluated to determine extraction efficiencies of each analyte from the 
meconium matrix. Recovery was determined by directly comparing the detector response (mean 
peak area) for extracted samples prepared and analyzed in triplicate at concentrations 
corresponding to the LLOQ, the ULOQ and a concentration midway between the two, with 
detector responses for unextracted samples at the same concentrations which represented 100% 
recovery[199]. Unextracted samples were prepared directly in mobile phase and injected. 
Recoveries were determined as a percentage (Equation 15) and although a high percent recovery 
was not necessary for validation, percent recoveries were required to be consistent and 
reproducible within triplicate samples and over the three concentrations studied. 
 
% Recovery = (response for extracted) / (response for unextracted) x 100% Equation 15 
4.3.6 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
Limit of detection studies were performed by analyzing serially dilute standards of each 
analyte until retention time shifts or inaccurate ion ratios prevented accurate and unequivocal 
identification. A series of blank meconium specimens were spiked with each analyte at serially 
dilute concentrations beginning with the LLOQ. Samples were analyzed by the appropriate 
confirmation method using internal standards, calibration curves and quality control standards. 
The LOD for each methodology was determined by evaluating analyte responses, retention time 
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accuracy, and ion ratio accuracy for each analyte at each concentration. The limit of detection 
was identified as the lowest concentration of analyte which could be accurately identified but not 
necessarily quantified. The increased sensitivity of the UPLC-MS/MS methodology meant that 
analyte responses were observed at concentrations lower than the LOD, however, retention time 
shifts and inaccurate ion ratios meant that unequivocal identifications could not be made. The 
limit of detection was identified as the lowest concentration of analyte which could be identified 
using established retention time windows and ion ratio abundances.  
In order for a methodology to be considered accurate and precise, quantifications at the 
LLOQ are generally required to exhibit precision within 20% of the coefficient of variation (CV) 
RSD and accuracy within +/- 20% of the expected nominal concentration [198]. The lowest point 
of each calibration curve was subject to these exact criteria for acceptance during all validation 
experiments and as a result, the LLOQ was subsequently defined as the concentration of the 
lowest calibration standard for each confirmation assay. 
4.3.7 Stability 
In order to assess the stability of each analyte in meconium, freshly made stock solutions 
of each analyte were prepared and used to spike blank meconium specimens which were then 
subject to several freeze and thaw cycles and subsequently analyzed. Blank meconium 
specimens which had previously screened negative at AIT Laboratories using a cutoff of 50 ng/g 
were spiked with analyte at concentrations corresponding to the LLOQ and the ULOQ (Table 8). 
Specimens were then frozen for 24 and subsequently thawed unassisted at room temperature. 
Once thawed, the specimens were again frozen under the same conditions for another 24 hours 
after which they were thawed again at room temperature. This cycle was completed a total of 
three times and specimens were analyzed upon thawing on the third freeze thaw cycle. Each 
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analyte was deemed stable during storage if, and only if, the quantitative values obtained were 
within 20% of the expected nominal concentration. 
4.3.8 Data Analysis 
Analytical data was analyzed using Masslynx version 4.1 software. Criteria for a positive 
result included accurate chromatographic retention time, presence of both the qualifying product 
ion and the quantifying product ion, and product ion ratios within acceptable limits[119, 199]. 
Chromatographic retention times are initially established for each analyte and deuterated internal 
standard during method validation through the analysis of reference standards. Retention times 
are updated following the analysis of calibration standards in each batch to account for minor 
drifts in daily retention times. Retention times for each analyte of interest were required to be 
within 5% of those determined with control samples. The ratio of the quantifying product ion 
peak area to the qualifying product ion peak area was required to be within +/- 20% of the ion 
ratio determined for calibrators. Quantitation was performed using a working standard 
calibration curve and comparing the ratio of quantifying ion peak area to internal standard peak 
area. Authentic samples were required to exhibit sufficient recovery of the internal standard. 
Internal standard response was required to be between 10% and 200% of the calibrator/control 
average. Calibration curves were required to comprise at least 50% of the original curve points 
and any specimens with quantitative values above greater than the upper calibrator were required 
to be rerun at an appropriate dilution. The analytical run is considered acceptable if the 





Chapter 5: Detection and Quantification of Cocaine and Benzoylecgonine in 
Meconium Using Solid Phase Extraction and UPLC-MS/MS 
5.1 Abstract 
A methodology for the selective determination and quantification of cocaine and its 
major metabolite benzoylecgonine in meconium using ultra performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) is described. Past studies indicate that up to 40% of 
neonates dying within two days of birth with no apparent cause of death have cocaine and/or 
benzoylecgonine in their blood, and rates of infants exposed to cocaine prenatally has been 
estimated to be between 2.6% and 11% of all live births. Ultra performance liquid 
chromatography (UPLC) is an emerging analytical technique which draws upon the principles of 
chromatography to run separations at higher flow rates for increased speed, while simultaneously 
achieving superior resolution and sensitivity. Extraction of both analytes was achieved using a 
preliminary protein precipitation followed by solid-phase extraction (SPE). Limits of detection 
for both analytes were 4 ng/g and the lower limit of quantitation (LLOQ) was 40 ng/g. The 
working calibration range was 40-1000 ng/g. The methodology exhibited high intra-run precision 
with CV values ranging from 1.6-9.2% for cocaine and 5.3-11.8% for benzoylecgonine. Inter run 
precision was evaluated and experiments produced CV values ranging from 3.9-5.0% for cocaine 
and 4.4-6.2% for benzoylecgonine. The increased speed and separation efficiency offered by 
UPLC, allowed for the separation and subsequent quantification of both analytes in less than 2 
minutes. Dramatic increases in separation speed such as those afforded by UPLC translate into 
increased samples per unit time in high throughput toxicology laboratories. Development of 
sensitive analytical methodologies capable of detecting low levels of such drugs in meconium 




Cocaine belongs to the tropane alkaloid family and is obtained from the leaves of the 
plant Erythroxylon coca. Although the leaves of Erythroxylon coca and other related species 
have been used by the Peruvian Indians for centuries to increase endurance and improve well-
being, the active ingredient cocaine, was not isolated until the mid nineteenth century. Albert 
Niemann, a graduate student at the University of Gottingen was the first person to devise and 
report a technique for the isolation of cocaine in 1860[204]. In 1884, 24 years after the first 
reported isolation of cocaine, Dr Karl Koller discovered that cocaine was an effective local 
anesthetic. In the years following Koller’s discovery, physicians around the world were 
employing cocaine as an anesthetic in ophthalmologic, dental, and general surgical procedures. 
Although analogues of cocaine such as procaine and lidocaine are still employed as anesthetic 
agents, the free distribution of cocaine was banned by the Harrison Narcotics Act in 1914. By the 
mid twentieth century the recreational use of cocaine had become a significant concern across 
socioeconomic lines. 
Cocaine is available on the street in either the base form (crack, free base) or as the 
hydrochloride salt. Although both forms of the drug are available in high purity for a similar 
street value, the free-base ‘crack’ cocaine is predominately used for smoking while cocaine 
hydrochloride is mainly employed for intravenous injection and nasal insufflation. 
The prevalence of cocaine use has increased substantially over the past two decades and 
in 1989 it was estimated that 50 million Americans has used cocaine at least once and 
approximately 8 million people were regular users of the drug[205]. More recent findings from 
the 2006 National survey on drug use and health (NSDUH) estimates 2,700 initiates to cocaine 
use per day based on the 977,000 persons aged 12 years or older who admitted to using cocaine 
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for the first time within the past twelve months[2]. The NSDUH estimates that in addition to the 
2.4 million frequent (i.e., at least twice weekly) users of cocaine, there are approximately 4.6 
million occasional users (i.e., once a month or less) of the drug, excluding individuals already in 
prison[2]. 
Although it is difficult to accurately determine the number of women who use cocaine 
during pregnancy, there is evidence to suggest that cocaine represents a significant proportion of 
the illicit substances which 4% of pregnant women admitted using during pregnancy in the 2006 
NSDUH [2, 8, 11, 206]. One such study, performed at a high-risk tertiary perinatal, reported that 
38% of infants tested positive for drugs, and 90% of those 773 infants were positive for 
cocaine[207]. In 1991 the Los Angeles County Office of Chief Medical Examiner-Coroner (LAC 
CMEC) reported that 40% of neonates dying within two days with no apparent cause of death 
had cocaine and/or benzoylecgonine in their blood[208]. Rates of infants exposed to cocaine 
prenatally has been estimated to be between 2.6% and 11% of all live births[11].  
Chemical extraction of benzoylecgonine from biological matrices is complicated by the 
amphoteric nature of the compound. While cocaine exists as a basic molecule and is easily 
extracted into organic solvent under alkaline conditions, benzoylecgonine exists as a zwitterion 
making it difficult to extract. Extraction of target analytes from biological matrices generally 
occurs following neutralization with an appropriate acid or base depending on the properties of 
the drug. Benzoylecgonine possesses two ionizable centers, one with acidic properties and one 
with basic properties making its neutralization difficult. Extraction design is further complicated 
by the need to simultaneously extract cocaine for analysis meaning that the method of choice 
must provide satisfactory recovery of both analytes.  
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Table 10 provides the chemical structures of cocaine and its primary metabolite, 
benzoylecgonine and describes certain physicochemical properties of each compound including 
molecular weights, molecular formulas, and pKa’s. 







Molecular weight 303.353 g/mol Molecular weight 289.33 g/mol 
Molecular formula C17H21NO4 Molecular formula C16H19NO4 




5.3 Mechanism of Action 
Cocaine is a naturally-occurring central nervous system (CNS) stimulant that interferes 
with the actions of dopamine, norepinephrine and serotonin in functioning nerves. Cocaine is 
classed as a sympathomimetic agent due to its ability to activate the sympathetic nervous system 
both centrally and peripherally[209]. Central stimulation of the sympathetic nervous system 
results from cocaine’s ability to selectively bind dopamine reuptake transporters (DATs) in the 
brain[204]. Clearance of dopamine at the synapse and subsequent termination of dopaminergic 
neurotransmission is achieved through reuptake into the presynaptic neuron which is mediated 
by DATs[210]. By binding to DATs, cocaine impairs the reuptake of dopamine into the 
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presynaptic neuron resulting in elevated dopamine levels in the central nervous system. Direct 
stimulation of the central nervous system by cocaine and other sympathomimetic agents also 
results in increased norepinephrine release from peripheral synapses. Cocaine not only facilitates 
increased release of norepinephrine peripherally it also acts to inhibit its reuptake at the synapses 
causing it to remain in the synaptic cleft for a prolonged period of time. As a result of cocaine’s 
ability to inhibit the reuptake of dopamine centrally and norepinephrine peripherally, the natural 
effect of these neurotransmitters is amplified. Excessive levels of CNS dopamine and peripheral 
norepinephrine account for the feelings of euphoria and increased alertness associated with 
cocaine use[209]. 
5.4 Effect of Prenatal Exposure 
Due to the popularity and prevalence of cocaine use in the USA, the vast majority of 
research conducted into the effects of maternal drug use has focused on cocaine. Prenatal cocaine 
use has been associated with premature labor, placental abruption, low birth parameters (weight, 
head circumference, length), microcephaly, congenital malformations, increased risk of sudden 
infant death syndrome (SIDS), spontaneous abortion, acute hypoxic-ischemic encephalopathy, 
cerebral hemorrhage or infarction, abnormal neonatal behavior, limb deformities[75, 83, 211, 
212]. 
5.5 History of Cocaine and Benzoylecgonine Detection in Meconium Specimens. 
The detrimental outcomes of prenatal cocaine exposure on developing children have long 
been realized. As a result of the widespread use of cocaine during pregnancy, many analytical 
methodologies describing the detection of cocaine and its inactive metabolite, benzoylecgonine, 
in meconium have appeared in the literature.  
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Browne and colleagues described a method for the detection of cocaine and its 
metabolites in meconium using HPLC and GC-MS. First-day meconium samples were subject to 
solid phase extraction followed by chromatographic separation and detection by either UV or 
MS. Although the authors reported the presence cocaine at concentrations ranging from 0.1µg/g 
to 0.78µg/g, no benzoylecgonine, ecgonine or ecgonine methyl ester was detected, prompting the 
authors to speculate that the metabolizing capabilities of the neonate may be limited[52]. 
Callahan and co-workers employed GC/MS for the identification of gestational cocaine exposure 
in the infants of 59 women who had been previously identified as cocaine users through hair 
analysis. The authors concluded that GC/MS analysis of meconium proved more sensitive than 
immunoassay analysis of urine and can detect fetal cocaine exposure which occurred in the last 
two trimesters of pregnancy[213].  
Clark et al employed solid phase extraction and GC/MS for the determination of cocaine 
and benzoylecgonine in methanolic extracts of meconium which had been screened using 
fluorescence polarization immunoassay (FPIA). The enhanced sensitivity of GC/MS enabled the 
authors to identify cocaine at concentrations as low as 0.25µg/g and benzoylecgonine at 
concentrations of 0.5µg/g[214]. Murphey and co-workers employed solid phase extraction 
columns with both cation exchange and hydrophobic properties for the simultaneous extraction 
of cocaine, benzoylnorecgonine, benzoylecgonine and norcocaine from meconium. Following 
extraction, analytes were identified using HPLC and limits of detection were 50ng/g for all 
analytes[215].  
Many of the reported methodologies for the determination of cocaine and its metabolites 
in meconium utilized solid phase extraction followed by GC/MS analysis. Solid phase extraction 
is generally required due to the complex nature of the meconium matrix. Liquid-liquid 
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extractions fail to remove many of the endogenous interferants present in the sample. GC/MS 
analysis was routinely utilized following SPE throughout the 1990s due to the separating power 
of gas chromatography and the unequivocal mass spectrometric identifications afforded my MS. 
Early reports of LC-MS/MS methods for the determination of cocaine and its metabolites in 
meconium began to appear in the literature at the turn of the century. Xia and colleagues 
employed a triple quadrupole mass spectrometer equipped with an electrospray ionization source 
for the determination of cocaine and several of its metabolites following LC separation. The 
authors conclude that the utilization of MS-MS both increases the selectivity of the assay and 
reduces sample preparation time as several metabolites of cocaine which are directly amendable 
to LC separation require additional derivatization for GC analysis[216]. Pichini and co-workers 
employed an ESI-LC/MS assay operating in SIM mode for the simultaneous determination of 
cocaine and opiates in meconium. Analytes were extracted using an initial liquid extraction into 
methanol or ammonium hydrogen carbonate buffer followed by a solid phase extraction for 
subsequent sample clean-up. Method validation included a linear dynamic range of 0.005 – 
1.00µg/g[217]. The same authors re-applied the validated LC-MS method two years later for the 
determination of two additional cocaine metabolites in meconium[218].  
To the best of the author’s knowledge, this is the first report of the application of UPLC-
MS/MS for the determination of cocaine and benzoylecgonine in meconium.  
Validation and implementation of UPLC-MS/MS methodologies capable of detecting 
low levels of common drugs of abuse in meconium will assist in providing more accurate 
information pertaining to the prevalence of prenatal drug exposure. The increased separation 
efficiency of UPLC provides the analyst with maximal separation power necessary to resolve 
endogenous sample components from target analytes. Increases in sensitivity, afforded by taller, 
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narrower peaks are also achieved with UPLC separations. As a result, low levels of target 
analyte, which would likely go undetected using traditional HPLC, will be detectable in the 
complex meconium matrix. The introduction of tandem mass spectrometry detection into routine 
meconium analysis provides obvious advantages such as enhanced selectivity relative to UV or 
single mass spectrometric detection. Increases in selectivity ensure that low concentrations of 
target analytes, which would normally be indistinguishable from endogenous interferences using 
HLPC-UV or GC/MS, are accurately identified. 
5.6 Experimental 
5.6.1 Chemicals and Reagents 
Cocaine, benzoylecgonine, cocaine-d3, and benzoylecgonine-d3 standards (1mg/mL in 
methanol) were obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported 
liquid-liquid extraction columns were purchased from Biotage (Charlottesville, VA). All solvents 
were HPLC grade and obtained from Fisher Scientific (Pittsburgh PA). 
5.6.2  Calibration Curve Matrix 
Meconium specimens which had previously screened negative for cocaine using a 50 
ng/g cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with both cocaine 
and benzoylecgonine to give concentrations of 15 ng/mL (n=5) and 125 ng/mL (n=5). Spiked 
meconium was then quantified using a calibration curve constructed in negative meconium and a 
calibration curve constructed in certified drug free whole blood. Quantitative results obtained 
using the meconium calibration curve showed excellent correlation (<15% CV) with those 
obtained using the calibration curve made up in negative blood and as a result, all subsequent 
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method validation experiments were performed using calibration curves prepared in certified 
negative blood.  
5.6.3 Working Standards 
Calibration curves were constructed using seven calibration standards prepared in 
certified drug free whole blood and all sample volumes were 1 mL. A working standard (500 
ng/mL) used to prepare calibration standards, was prepared by combining 250 µL of a stock 
solution (10 µg/mL) of cocaine and benzoylecgonine with 4.75 mL of deionized water. An 
internal standard solution (500 ng/mL) was prepared using 1 mg/mL standards of cocaine-d3 and 
benzoylecgonine-d3. 
5.6.4 Calibration Curves 
Calibration curves for all experiments were prepared according to Table 11. 
Table 11: Preparation of cocaine and benzoylecgonine calibration curves. 
Standard Concentration Volume of Working Standard Volume of Deionized water 
250 500 500 
100 200 800 
50 100 900 
25 50 950 
10 20 980 
5 10 990 
Negative 0 1000 
 
100µL of internal standard solution (500 ng/mL) was added to each sample including the blank 
and all samples were then vortexed for 30 seconds. 
5.6.5 Quality Control (QC) Standards 
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure 
the accurate identification and quantitation of validation specimens. A low QC (LQC) was 
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prepared at a concentration of 10 ng/mL and a high QC (HQC) at a concentration of 250 ng/mL. 
Quality control standards were injected immediately following the final point of the calibration 
curve and quantitation of each QC was required to be accurate within 20% of the expected 
nominal value to proceed with the analysis of validation specimens. 
5.6.6 Sample Preparation 
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with 
50:50 methanol/water to assist with the sonication procedure. Samples were shaken and 
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium sample was added to 
appropriately labeled culture tubes. Cocaine, benzoylecgonine and deuterated internal standards 
were added to samples which were then block vortexed for 5 minutes. Analytes were extracted 
by first adding 2 mL of cold acetonitrile while simultaneously vortexing each sample. Samples 
were then centrifuged for 10 minutes at 3000 rpm. Following centrifugation, the organic layer 
was transferred to a clean labeled large screw top test tube. 3 mL of 0.1 M phosphate buffer (pH 
6.0) was added to each sample followed by the addition of 1 mL of concentrated ammonium 
hydroxide. Samples were then vortexed by hand for 10-15 seconds followed by a 5 minute 
centrifugation at 3000 rpm.  
5.6.7 Solid Phase Extraction (SPE) 
Analytes were selectively extracted using a solid phase extraction employing UCT clean-
screen ZSDAU020 columns with reversed phase and ion-exchange retention mechanisms. 
Columns were first conditioned with sequential washes of methanol (3 mL), deionized water (3 
mL) and 0.1 M phosphate buffer, pH 6.0 (1 mL). All solvents were allowed to drip through the 
columns slowly under gravity and waste containers were interchanged accordingly. Following 
column conditioning, samples were poured onto the columns and allowed to drip through 
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unassisted for 15 minutes before any pressure was applied. Following sample loading, sequential 
wash steps were performed using deionized water (1 mL), 1.0 M HCl (1 mL), and methanol (3 
mL). All wash solvents were allowed to drip through the columns unassisted for 5-10 minutes 
after which time any remaining solvent was assisted through the columns using a positive 
pressure manifold. Following column wash steps, positive pressure was applied for 5-10 minutes 
to ensure complete elution of wash solvents. Waste containers were then exchanged for small, 
labeled elution test tubes and analytes were eluted with 3 mL of 78:20:2 (dichloromethane: 2-
propanol: ammonium hydroxide) elution solvent which was made fresh daily. Samples were 
dried down under a gentle steam of nitrogen and reconstituted in 200 µL of DI water:ACN 
(75:25). Samples were transferred to appropriately labeled plastic vials and injected for analysis. 
5.6.8 Liquid Chromatography 
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra 
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations 
were achieved on an ACQUITY UPLC™ HSS T3 column (2.1x 50mm) packed with 1.8µm 
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of 
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1% 
formic acid (solvent B). Analytes elution was achieved using the following step-wise binary 
elution gradient: Initial mobile phase composition was 75:25 (H2O:ACN). Initial conditions were 
held constant for 0.5 mins after which the composition of solvent B was linearly increased to 
50% over 1.5 mins, finally conditions were returned to their initial composition of 75:25 
(H2O:ACN) over the next 0.01 mins and held for 0.49 min to equilibrate the column before the 
next injection in the sequence. The total run time was 2.50 mins (Figure 17). Samples were 
maintained at 7.5°C in the sample organizer and sample injection volumes were 5µL for all 
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analyses. Flow rates were maintained at 0.5 mL/min for the first 0.50 mins after which they were 
increased to 0.6 mL/min for the remainder of the chromatographic separation. All flow was 
directed into the ESI source of the mass spectrometer. 
 
 
5.6.9 Mass Spectrometry 
Mass spectrometry conditions were as follows: capillary voltage 0.80 kV, cone voltage 
20 V, extractor voltage 3.0 V, RF lens voltage 0 V. The source temperature was 120°C while the 
desolvation temperature was set at 350°C. Cone gas was set at a flow of 100 L/Hr while the 
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.10 mL/min. Nitrogen 
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was 
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Figure 17: TIC from the UPLC separation of cocaine and benzoylecgonine. 
126 
 
used as the collision gas. Table 12 reports the mass transitions, dwell times, cone voltages, and 
collision energies for each of the analytes and their deuterated internal standards.  
Table 12: MS/MS parameters used for each analyte and deuterated internal standard. 
Compound Mass transition Purpose Cone (V) Collision (V) Dwell (secs) 
Cocaine 304.14 > 182.10 Quantifying ion 40 20 0.01 
Cocaine 304.14 > 150.16 Qualifying ion 40 20 0.01 
Cocaine-d3 307.15 > 184.96 Quantifying ion 30 20 0.01 
Benzoylecgonine 290.08 > 168.24 Quantifying ion 40 20 0.01 
Benzoylecgonine 290.08 > 104.78 Qualifying ion 40 40 0.01 
Benzoylecgonine-d3 293.11 > 170.98 Quantifying ion 40 20 0.01 
 
Figure 18 illustrates the fragmentation pathways for cocaine and benzoylecgonine under ESI 








Figure 18: Fragmentation pathways for Cocaine and Benzoylecgonine during tandem mass 
spectrometry experiments[219]. 
 
5.7 Results and Discussion 
5.7.2 Method Validation 
Preliminary equivalence studies indicated that calibration curves prepared in certified 
drug-free blood were suitable for the accurate quantification of cocaine and benzoylecgonine in 
the meconium matrix (Table13 & 14). The percent relative error (%RE) calculated for the 5 
HQCs and 5 LQCs was less than 1.6% for cocaine and 7.2% for benzoylecgonine, indicating a 
high degree of correlation between the two curves at both the high and low end of the calibration 





cocaine and benzoylecgonine, respectively. Mean relative error values for high quality control 
specimens were 1.3%, and 7.0% for cocaine and benzoylecgonine, respectively.  
Table 13: Cocaine equivalence studies using quantitative values obtained from calibration curves 
constructed in meconium (MC) and blood (BC). 
Cocaine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  14.1 14.3 1.40% 
HQC 120.1 118.6 1.30% 
NEG(B) 0 0.2 N/A 
NEG(M) 0.1 0.2 N/A 
*LQC and HQC concentrations represent mean values of 5 replicate analyses. 
Table 14: Benzoylecgonine equivalence studies using quantitative values obtained from 
calibration curves constructed in meconium (MC) and blood (BC). 
Benzoylecgonine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  15.9 16.4 3.0% 
HQC  134.7 125.9 7.0% 
NEG(B) 0 0.4 N/A 
NEG(M) 0.1 0 N/A 
*LQC and HQC concentrations represent mean values of 5 replicate analyses. 
The analytical methodology exhibited sufficient selectivity throughout studies using 
blank meconium specimens and QC standards which had been spiked with various exogenous 
interferences. Blank meconium specimens were analyzed to ensure that any response generated 
by the matrix alone corresponded to a concentration less than the LLOQ, while spiked samples 
were analyzed to assess the ability of the methodology to accurately and precisely quantitate the 
analyte in the presence of possible exogenous interferences (Table 15). Three blank meconium 
specimens were spiked with selectivity quality control standards (QCs) which had been 
previously prepared using various analytes commonly encountered in forensic specimens. The 
two remaining blank meconium specimens were spiked with opiates (codeine, morphine, 
hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6-monoacetylmorphine) and THC 
respectively, at concentrations corresponding to HQCs. The selectivity of the analytical 
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methodology in the presence of opiates and THC was investigated as these drugs are commonly 
encountered in forensic specimens at appreciable concentrations. 
Table 15: Exogenous compounds included in selectivity quality control standards. 
Standard Contents 
Selectivity QC 1 Carbamazepine, carbamazepine epoxide, felbamate, gabapentin, lamotrigine, 
levetiracetam, mephobarbital, naproxen, oxcarbazepine, phenytoin, primidone, 
topiramate, valproic acid, zonisamide 
Selectivity QC 2 Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine, 
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine, 
paroxetine, sertraline, venlafaxine 
Selectivity QC 3 Alprazolam, chlorpheniramine, citalopram, clonazepam, cyclobenzaprine, 
dextromethorphan, duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine, 
olanzapine, strychnine, zolpidem 
 
 Blank meconium specimens generated minimal detector responses corresponding to 
mean analyte concentrations 0.4 ng/mL for cocaine (Table 16), and 1.5 ng/mL for 
benzoylecgonine (Table 17) which were below the LLOQ of 10 ng/mL. Analysis of spiked 
standards prepared at the LLOQ, indicate that the methodology is selective for the analytes of 
interest, even in the presence of various exogenous interferences (Table 16 & 17). 
Table 16: Cocaine selectivity studies using blank meconium from five different sources and 
blank meconium specimens spiked with various exogenous interferences. 
 Cocaine Std  Std Conc (ng/mL) *Measured conc 
(ng/mL) 
Acceptable range Pass/Fail 
Blank samples 0 0.4 <10ng/mL Pass 
Spiked samples 10 10.3 10 +/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 17: Benzoylecgonine selectivity studies using blank meconium from five different sources 
and blank meconium specimens spiked with various exogenous interferences. 
Benzoylecgonine Std Std Conc (ng/mL) *Measured conc 
(ng/mL) 
Acceptable range Pass/Fail 
Blank samples 0 1.5 <10ng/mL Pass 
Spiked samples 10 11.6 10 +/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
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Accuracy studies performed by analyzing five replicates at three different concentrations 
spanning the calibration range yielded mean values of 254.9 ng/mL, 52.7 ng/mL, and 10.5 
ng/mL reflecting accuracies of 98%, 94.6%, and 95%, respectively for cocaine and 245.7 ng/mL, 
50.2 ng/mL, and 10.5 ng/mL reflecting accuracies of 98.3%, 99.6%, and 95%, respectively for 
benzoylecgonine (Table 18 & 19). Quantitation accuracies were greater than 94% for both 
analytes over the entire calibration range. 
Table 18: Cocaine accuracy studies. 
Cocaine Std Std Conc  *Measured value %RE 
High point  250 254.9 2.0% 
Midpoint  50 52.7 5.4% 
LLOQ  10 10.5 5.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 19: Benzoylecgonine accuracy studies. 
Benzoylecgonine Std Std Conc *Measured value %RE 
High point  250 245.7 1.7% 
Midpoint  50 50.2 0.4% 
LLOQ  10 10.5 5.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
 Both intra-batch and inter-batch precision studies indicated a high degree of precision 
over the three concentrations investigated with intra-batch CVs ranging from 1.6-9.2% with the 
mean being 4.5% for cocaine (Table 20), while CVs for benzoylecgonine ranged from 5.3-11.8% 
with a mean value of 7.4% (Table 21). Inter-batch precision produced CV values ranging from 
3.9-5.0% over the three concentration ranges for cocaine and from 4.4-6.2% over the three 





Table 20: Intra- and inter-batch precision studies for cocaine. 
Cocaine Std *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  254.9 258.1 275.9 255.0  261.0 3.9%  
CV 2.0% 1.6% 3.5% 2.9%     
Midpoint 52.7 48.3 48.8 49.6 49.9   4.0% 
CV 5.2% 4.6% 4.3% 2.4%     
LLOQ 10.5 10.6 10.0 9.5 10.2  4.9%  
CV 9.2% 6.8% 6.6% 4.4%     
*Reported concentrations are mean values of 5 replicate analyses. 
Table 21: Intra- and inter-batch precision studies for benzoylecgonine (BE). 
BE Std *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  245.7 264.4 245.5 230.8 246.6  5.6%  
CV 6.3% 7.9% 7.1% 5.9%     
Midpoint  50.2 49.4 52.4 47.0 49.8  4.4%  
CV 11.8% 5.5% 5.9% 7.2%     
LLOQ  10.5 10.5 10.9 9.4  10.3 6.2%  
CV 9.5% 8.6% 7.3% 5.3%    
*Reported concentrations are mean values of 5 replicate analyses. 
Analyte recovery was investigated over three concentrations which spanned the calibration range 
for each analyte and was found to have a mean value of 71.7% for cocaine (Figure 19) and 
10.2% for benzoylecgonine (Figure 20). Mean recoveries from triplicate analysis at the three 
concentration ranges investigated ranged from 68.3-77% for cocaine and 9.3-10.7% for 
benzoylecgonine representing good consistency and reproducibility even though the overall 
recovery of benzoylecgonine was poor. While poor recoveries for benzoylecgonine may be 
attributable to analyte loss during the solid phase extraction, further studies aimed at determining 

















Figure 20: Benzoylecgonine recovery at three concentrations over the linear range. 
 The limit of detection was determined to be 1 ng/mL for both cocaine and benzoylecgonine 
corresponding to a concentration of 4 ng/g in the meconium specimen prior to sonication. 
Unequivocal identification of analytes was not feasible at concentrations below 1 ng/mL due to 
significant fluctuation and inaccuracies in calculated ion ratios. Both cocaine and 
benzoylecgonine appear to be quite stable in the meconium matrix over the investigated 
calibration range when stored at 4°C. Quantitation accuracies during stability studies were 
greater than 84% and 93% for cocaine HQC and LQCs respectively, and greater than 95% and 












Development and validation of an accurate, selective, precise, and sensitive UPLC-ESI-
MS/MS method for the identification and quantification of cocaine and benzoylecgonine in 
meconium was achieved. For the purpose of improved selectivity, two MRM transitions were 
monitored for each analyte and quantifications was achieved using deuterated internal standards 
and a six point calibration curve. Injection volumes of 5 µL allowed for the accurate 
quantification of both analytes over the range 10 - 250 ng/mL, corresponding to concentrations 
of 40 - 1000 ng/g in the original meconium specimens. Significant gains in sample throughput 
are achieved with ultra performance liquid chromatography through rapid chromatographic 
separations made possible by sub 2 µm packing materials. This increased speed of analysis 
alleviates problems associated with extensive sample preparation and allows working toxicology 
laboratories to increase sample throughput without sacrificing the quality of the data. To the best 
of the author’s knowledge, this is the first report of a validated UPLC-ESI-MS/MS method for 
the quantitative analysis of cocaine and benzoylecgonine in meconium specimens. The validated 
methodology was implemented at AIT Laboratories (Indianapolis, IN) for the purpose of 
confirming the presence of cocaine and benzoylecgonine in authentic meconium specimens 
which had previously screened positive. From 07/01/08 – 03/06/2009 a total of 4036 meconium 
specimens were screened for cocaine/benzoylecgonine. Of those samples, 303 screened positive 
representing 7.5% of the total specimens. 71 of the 303 specimens were confirmed positive using 




Chapter 6: Detection and Quantification of Codeine, Morphine, 
Hydromorphone, and 6-Monoacetylmorphine (6-MAM) in Meconium using 
ISOLUTE HM-N Supported-Liquid Extraction Columns and UPLC-MS/MS 
6.1 Abstract 
A method for the extraction and quantification of codeine, morphine, hydromorphone, 
and 6-monoacetylmoprhine (6-MAM) from meconium specimens using supported-liquid 
extraction (SLE) columns and ultra performance liquid chromatography coupled to tandem mass 
spectrometry (UPLC-MS/MS) is described.  
Deaths resulting from heroin (diacetylmorphine) use have long been considered an 
epidemic and continue to plague society due to the addictive nature and abuse potential of the 
drug. While heroin remains a popular drug of abuse in today’s society, large increases in the 
prescriptive medical use of several opiate analgesics over the past ten years have been 
accompanied by increases in morbidity due to abuse, addiction, and diversion. Popular opiate 
analgesics commonly prescribed for the treatment of pain include morphine, codeine, 
hydrocodone, and hydromorphone.  
Meconium specimens were sonicated to maximize homogeneity of the sample and 
analytes were subsequently extracted from the matrix using ISOLUTE HM-N supported-liquid 
extraction (SLE) columns. Quantitation was performed using a Waters UPLC™ chromatograph 
coupled to a triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) 
source. Chromatographic separation was achieved in less than 5 minutes, data was acquired in 
the MRM mode and quantitation was achieved using multi point calibration curves. 
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The analytical methodology was deemed selective for the analyte of interest in the 
presence of exogenous interferences. Quantitation accuracy ranged from 90 – 100% for all four 
analytes over three concentrations spanning the calibration range. Intra-batch precision studies 
indicated high quantitative precision with CV values ranging from 1.2 – 10.7% for all analytes. 
Inter-batch precision was high over the entire calibration range with CV values ranging from 0.5 
– 6.1%. Analyte recovery ranged from 52.3 – 76.3% for all four analytes representing good 
extraction efficiencies. The limit of detection for all four analytes was 2.5 ng/mL, corresponding 
to a concentration of 10 ng/g prior to homogenization.  
By employing ISOLUTE HM-N supported-liquid extractions for the isolation of analytes 
in meconium, sample preparation time is greatly reduced without sacrificing analyte recovery. 
Ultra performance liquid chromatography allowed for the rapid chromatographic separation of 
all four analytes in less than 5 minutes and tandem mass spectrometric detection ensured 
increased sensitivity and selectivity relative to traditional techniques such as HPLC-UV and 
GC/MS. Development of analytical techniques requiring minimal sample preparation for the 
determination of opiates in meconium specimens will aid in the identification of infants 
prenatally exposed to drugs such as heroin, morphine, codeine, hydrocodone, and 
hydromorphone. 
6.2 Mechanism of Opiate Action 
Members of the opiate family mimic the effects of endogenous analgesics termed 
‘endogenous opioid peptides,’ which include β-endorphin, leu-enkephalin, met-enkephalin, 
dynorhpins, and the neoendorphins[220]. Such peptides are released by the body to regulate pain 
and it is this action which is mimicked by members of the opiate family which bind to specific 
receptors in the spinal cord and prevent the release of excitatory neurotransmitters[220]. In 
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combination to directly blocking the release of excitatory neurotransmitter in the spinal cord, 
opiates also act to inhibit the release of neurotransmitters in certain nerve fibers which are 
responsible for relaying pain signals to the spinal cord. The combination of central and 
peripheral inhibition results in a powerful analgesic effect common to all members of the drug 
class[220].  
The identification of specific receptors at which opiates bind was not reported until 1976 
when Martin and coworkers performed a detailed analysis of the neurophysiological and 
behavioral properties of several opiate compounds looking specifically for cross tolerance[221]. 
Studies suggested the presence of three types of opioid receptors which were subsequently 
named after the drugs used in the studies. The µ (mu) receptor was named after morphine, while 
the κ (kappa) receptor was named after ketocyclazocine and the σ (sigma) receptor after N-
allylnormetazocine. The σ receptor is no longer considered an opiate receptor. In 1977, 
Kosterlitz and coworkers identified the δ (delta) opiate receptor when they noticed that action of 
enkephalins on the vas deferens was relatively insensitive to naloxone[222].  
The existence of such receptors has always been theorized due mainly to the 
stereoselectivity of the opiates, the existence of antagonists and the differences in potencies 
throughout the opiate family. As already mentioned, opiates act by binding to one or multiple of 
the opiate receptors thereby preventing the transmission of second messenger signals associated 
with pain. Although the actual biochemical mechanism associated with this process is not fully 
understood, it is thought to involve changes in the coupling of a G-protein to the regulatory 
enzyme adenylate cyclase which in turn inhibits the actions of adenylate cyclase. Inhibition of 
the adenylate cyclase enzyme facilitates the opening of potassium (K+) ion channels and the 
simultaneous closing of calcium (Ca++) channels which results in the hyperpolarization of 
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neurons and the overall regulation of pain[223]. Most of the commonly prescribed opiates are 
full agonists at the mu receptor and many members of the opiate family act on all three receptors 
(Table 22).  
Table 22: Receptor activity for selected opiates and synthetic derivatives. 
Opiate Overall relationship 
µ (mu) receptor 
action 
δ (delta) receptor 
action 
κ (kappa) receptor 
action 
Morphine full agonist strong agonist weak agonist weak agonist 
Codeine full agonist weak agonist weak agonist no activity 
Methadone full agonist strong agonist weak agonist weak agonist 
Fentanyl full agonist strong agonist weak agonist no activity 
Buprenorphine partial agonist partial agonist no activity antagonist 
Pentazocine partial agonist antagonist weak agonist moderate agonist 
Naloxone antagonist antagonist antagonist antagonist 
 
Agonists for any of the three opiate receptors will possess some degree of analgesic inducing 
properties however additional side effects will vary somewhat depending on the individual 
receptor. Mu-specific agonists will cause powerful analgesia along with the euphoria responsible 
for the widespread abuse of opiates. The mu receptor is also responsible for many of the 
unwanted effects of opiates such as respiratory depression which is considered to be the main 
side effect of opiates associated with most overdoses. Drug induced respiratory depression 
occurs when the brain is unaware of accumulating levels of CO2 and subsequently 
understimulates the lung musculature[224]. The brain is unaware of such accumulation due to 
desensitization of the medulla which is responsible for determining the need to breathe deeper, 
faster, and more rhythmically in times of CO2 accumulation[224]. In addition to inducing 
respiratory depression, agonists at the mu receptor also produces miosis, reduction in motility of 
the GI system, and physiological dependence[220]. Agonists at the kappa receptor will induce 
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spinal analgesia, dysphoria, and sedation while opiate agonists at the delta receptor will mediate 
analgesia, additional respiratory depression, slight euphoria and dependence[220]. 
6.3 Introduction to Commonly Abused Opiates 
The opiates are a large family of drugs which are structurally and pharmacologically 
related to morphine. Morphine is the central member of the opiate family and is obtained from 
raw opium, which is the dried sap of the seed capsule in the opium poppy (Papaver somniferum). 
Raw opium is initially purified to refined opium which is a sticky gum exudate containing many 
alkaloids including morphine (~10%), codeine (~0.5%) and thebaine (~0.4%) which are 
subsequently extracted and prepared for medicinal purposes[220, 225]. Members of the opiate 
family include several semi-synthetic compounds such as codeine, oxycodone, dihydrocodeine, 
hydrocodone, and hydromorphone, which are derived from the morphine molecule through 
chemical modification[220].  
Several synthetic opiates, known more commonly as opioids, such as fentanyl, 
methadone, meperidine, propoxyphene and buprenorphine are also commonly prescribed for 
their analgesic properties. Although these compounds appear structurally unique relative to the 
morphine molecule, their three dimensional interaction with opioid receptors is very similar. 
Although the exact mechanism by which opiates act on the central nervous system (CNS) is still 
largely speculative, their pharmacological effect has been documented and sought after for over 
two hundred years[226].  
The interaction of opiates with specific receptors in the CNS is responsible for their 
central effects such as analgesia, drowsiness, mental dullness, changes in mood, and 
euphoria[220, 225, 227]. The pharmacological activity of opiates mimics that of endogenous 
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opioid peptides which are produced naturally in the body and interact with receptors throughout 
the nervous system and GI tract to alter the body’s response to painful stimuli[227]. Because of 
their ability to modulate pain and reduce suffering, opiates are an extremely important and 
widely prescribed class of drug throughout many fields of medicine. The ability of opiates and 
certain illicit derivatives (eg. heroin) to produce feelings of euphoria, also means that they are 
one of the most widely abused drug classes in today’s society.  
In 1999, the federally sponsored Drug Abuse Warning Network (DAWN) program 
indicated that heroin toxicity accounted for almost half (42%) of all narcotic-related deaths and 
41.3% of all reported drug-related deaths[204]. In 2006, a National Vital Statistics Report 
published by the US Department of Health and Human Services indicated that heroin related 
deaths were continuing to increase and that a total of 2,101 deaths were attributed to heroin 
overdose in 2002, representing a 17% increase from the previous year[228, 229]. As opiate 
related deaths continue to increase throughout the world, heroin is still considered the most 
prevalent opiate of interest in post mortem toxicology due to its widespread availability and 
ability to induce life threatening respiratory depression[230]. Following administration, heroin is 
rapidly converted via deacetylation to 6-monoacetylmorphine (6-MAM) and then to morphine 




Figure 21: Metabolism of heroin. 
 
The conversion of heroin to 6-monoacetlymorphine is complete within 10-15 minutes 
while the total conversion of heroin to morphine is completed within a few hours [204]. Due to 
its rapid biochemical transformation following administration, heroin has a similar excretion 
profile to morphine, although small amounts of 6-MAM are found in the urine of most heroin 
users[220]. The presence of 6-MAM in the urine distinguishes heroin use from morphine use and 
although the presence of trace levels of codeine are also consistent with heroin use (due to the 
presence of codeine in the heroin as an impurity), only the presence of 6-MAM can 
unequivocally identify the source of morphine as heroin. 6-MAM has also been shown to cross 
the placental membrane and accumulate in the meconium of infants exposed to heroin prenatally, 
and similar to urine, its identification in meconium provides definitive proof of maternal heroin 
use[92]. The detection of 6-MAM in the meconium of newborn infants is vital to distinguish 
morphine use from heroin use.  
Morphine is administered to pregnant women for several reasons such as the induction of 
spinal anesthesia[231], for the treatment of acute pancreatitis[232], and to provide improved 
labor and postcesarean analgesia[233] and while most sources of morphine will be administered 
Heroin 6-monoacetylmorphine Morphine 
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only hours prior to birth and will likely not present in the meconium of the newborn, the 
presence of 6-MAM will distinguish heroin use from any morphine use, licit or otherwise.   
Morphine (MS Contin, Kadian, Avinza) is one of the most widely prescribed opiates for 
the treatment of chronic pain due to its highly potent analgesic effects. Morphine is likely the 
most effective opiate for the treatment of severe pain and while its analgesic effects are well 
utilized in the field of pain management, its potent agonist activity at the mu receptor also 
induces euphoric effects which are sought after by addicts worldwide.  
Joranson and coworkers investigated trends in the medical use of morphine for the 
treatment of severe pain over a six year period. In 1990, approximately 2.2 million grams of 
morphine were prescribed to patients suffering from severe pain. Over the next six years, this 
number increased by 59% and by 1996, 3.5 million grams of morphine were being actively 
prescribed to patients across north America[234]. Although the authors conclude that the 
increasing use of medical morphine did not appear to contribute to the increasing health 
consequences of opiate analgesic abuse, a separate study published in the Journal of Addictive 
Diseases reports that the rate of morphine prescription (number of morphine prescriptions per 
10,000 patient encounters) increased 2.64 fold over the time period 1995-2004, while the rate of 
emergency department (ED) mentions for morphine simultaneously increased 1.16 fold[235].  
Since 1995, there has been an overall 86% increase in morphine use across the United 
States[235]. Morphine is largely metabolized by glucuronidation at the 3- and 6-positions to 
form morphine-3-glucuronide and morphine-6-glucuronide respectively, the latter of which has a 




Figure 22: Biotransformation and conjugation of morphine. 
 
Both free and conjugated forms of morphine have been shown to cross the placental barrier and 
accumulate in the meconium of prenatally exposed newborns[92]. Recent studies also suggest 
that morphine undergoes a minor metabolic transformation to hydromorphone in the cases of 
high dose, steady state patients (Figure 22)[236, 237]. Hydromorphone is considered a secondary 
metabolite of morphine that will not necessarily be detectable in the case of an acute overdose 
but may be present in the urine of patients taking large doses over significant periods of time at 
concentrations corresponding to 2-5% of the morphine. Hydromorphone has also been shown to 
cross the placental barrier and accumulate in the meconium of infants prenatally exposed to the 
drug or one of its metabolic precursors such as hydrocodone and morphine[92]. 
Hydrocodone (Vicodin, Lortab, Lorcet) is a popular, short acting, opiate analgesic 
prescribed for the treatment of mild pain and often formulated with non-opiate analgesics such as 




acetaminophen or salicylates. Such formulations provide increased analgesia via drug synergy 
and also to deter patients from overdosing by formulating the opiate with NSAIDS which have 
unpleasant side effects when taken in high doses.  
Wisniewski et al. investigated the relationship between the prescribing trends for 
hydrocodone products and the aggregate indicators of non-medical abuse such drug induced and 
drug-related emergency department (ED) visits, over an eight year time period[235]. Studies 
indicated that the number of prescriptions written per 10,000 patients increased 2.03 fold over 
the eight year period while the number of hydrocodone-related ED visits increased 1.60 
fold[235]. The rate of hydrocodone use has consistently increased since 1999 and in 2005, more 
prescriptions were written for hydrocodone/acetaminophen combination products than any other 
medication including drugs such as amoxicillin and atorvastatin[238].  
Hydrocodone is metabolized in man by O- and N-demethylation and reduction of the 6-
keto group[239]. Hydrocodone, like many drugs is metabolized by a large family of enzymes 
know as the cytochrome P450 (or CYP450) enzymes. The 2D6 isozyme of the CYP450 family, 
known as CYP2D6 is responsible for the O-demethylation of hydrocodone to hydromorphone, 





Figure 23: Metabolism of hydrocodone to hydromorphone. 
 
Rapid metabolizers have been shown to produce and excrete significantly more of a dose as 
hydromorphone than poor metabolizers[239].  
Hydromorphone (Dilaudid) is a strong opiate analgesic prescribed for the treatment of 
chronic pain. Hydromorphone is also the active metabolite of hydrocodone which undergoes O-
demethylation by CYP2D6 to form the active metabolite. Joranson and coworkers reported a 
19% increase in the medical use of hydromorphone from 1900 to 1996 at which time 141,325 
grams of the drug were being prescribed across the united states[234]. Hydromorphone is a 
potent opiate which has been responsible for fatalities at concentrations as low as 51 ng/mL and 
a particular review of hydromorphone related deaths in Ontario from 1985 to 2003 revealed that 
deaths attributed to hydromorphone toxicity involved concentrations ranging from 77 to 2684 
ng/mL[240]. Hydromorphone abuse is increasing in today’s society and its detection in 
meconium is of additional importance as it will also assist in identifying maternal hydrocodone 
use.  
Prenatal exposure to opiates has been associated with the following symptoms in infants: 
colic pains, agitation, irritability, high pitched cries, and long term withdrawal symptoms known 




Table 23 provides the chemical structures of morphine, codeine, hydromorphone, and 6-
monacetylmorphine along with certain physicochemical properties such as molecular weights, 
and pKa’s.  
Table 23: Chemical structures, molecular weights, molecular formulas, and pKa's of morphine, 






Molecular weight 285.34 g/mol Molecular weight 299.36 g/mol 
Molecular formula C17H19NO3 Molecular formula C18H21NO3 






Molecular weight 285.34 g/mol Molecular weight 327.37 g/mol 
Molecular formula C17H19NO3 Molecular formula C19H21NO4 




6.4 History of Opiate Detection in Meconium 
The detection of opiates in meconium has been the focus of far fewer research efforts 
than that of cocaine. The detection of opiates in meconium is becoming increasingly important as 
prescription opiates such as morphine, codeine, and hydrocodone are being abused as a result of 
their widespread availability on the street and cheap cost. Analytical methodologies capable of 
detecting opiates in meconium have been largely based on GC/MS technologies due to the 
selectivity afforded by MS.  
Moriya and co-workers successfully detected the presence of morphine in the stool of a 
41 day old infant at a concentration of 1340 ng/g following derivatization with trifluoroacetic 
anhydride and GC/MS analysis[85]. In an effort to increase the selectivity and sensitivity of 
meconium analysis which had been largely performed using radioimmunoassays, ElSohly et al 
employed GC/MS for the determination of several drug classes, including opiates, in 
meconium[243]. Pichini and co-workers employed an ESI-LC/MS assay operating in SIM mode 
for the simultaneous determination of opiates and cocaine in meconium. Analytes were extracted 
using an initial liquid extraction into methanol or ammonium hydrogen carbonate buffer 
followed by a solid phase extraction for subsequent sample clean-up. Method validation included 
a linear dynamic range of 0.005 – 1.00µg/g[217].  
Coles and co-workers reported the first tandem mass spectrometry method for the 
determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6-
acetylmorphine in meconium following liquid chromatographic separation. A decreased sample 
preparation time was achieved by eliminating the glucuronide hydrolysis step and employing a 
solid phase extraction in which the elution occurred directly into autosampler vials. LC-MS/MS 
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provided enhanced selectivity for the detection of the six opiates with a decreased interference 
rate of 3.9% compared to 13.6% for a previously established GC/MS method[92].  
To the best of the author’s knowledge, this is first report of the simultaneous detection of 
codeine, morphine, hydromorphone and 6-monoacetylmorphine in meconium using UPLC-
MS/MS. The implementation of UPLC methodologies into routine meconium analysis will 
increase the speed and efficiency of chromatographic separations allowing for more rapid 
separation of various opiate derivatives without the need for complex mobile phases. Combining 
the chromatographic advantages of UPLC with the increased selectivity of tandem mass 
spectrometry will result in more rapid, accurate, and sensitive identifications of various opiate 
derivatives in human meconium.  
6.5 Experimental 
6.5.1 Chemicals and reagents 
Codeine, morphine, hydromorphone, 6-monoacetylmorhine, codeine-d3, morphine-d3, 
hydromorphone-d3, and 6-monoacetylmorphine-d6 standards (1mg/mL in methanol) were 
obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported liquid-liquid 
extraction columns were purchased from Biotage (Charlottesville, VA). All solvents were HPLC 
grade and obtained from Fisher Scientific (Pittsburgh PA). 
6.5.2 Calibration Curve Matrix 
Meconium specimens which had previously screened negative for opiates using a 50 ng/g 
cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with codeine, morphine, 
hydromorphone, and 6-monoacetylmorphine to give concentrations of 10 ng/mL (n=5) and 500 
ng/mL (n=5). Spiked meconium was then quantified using a calibration curve constructed in 
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negative meconium and a calibration curve constructed in certified drug free whole blood. 
Quantitative results obtained using the meconium calibration curve showed excellent correlation 
(<15% CV) with those obtained using the calibration curve made up in negative blood and as a 
result, all subsequent method validation experiments were performed using calibration curves 
prepared in certified negative blood.  
6.5.3 Working Standards 
Calibration curves were constructed using eight calibration standards prepared in certified 
drug free whole blood and all sample volumes were 1 mL. Two working standards were used to 
construct the calibration standards, working standard 1 (500 ng/mL) was prepared by combining 
150µL of an amphetamine and methamphetamine stock solution (10µg/mL) with 2850µL of 
negative blood. Working standard 2 (50 ng/mL) was prepared by combining 300µL of working 
standard 1 with 2700µL of negative blood. An internal standard solution (500 ng/mL) was 
prepared using 1 mg/mL standards of codeine-d3, morphine-d3, hydromorphone-d3, and 6-
monoacetylmorphine-d6. 
6.5.4 Calibration Curves 
Calibration curves for all experiments were prepared according to Table 24.  
Table 24: Preparation of codeine, morphine, hydromorphone, and 6-monacetylmorphine 
calibration curves. 
Standard Concentration (ng/mL) Volume of Working Standard (µL) Volume of Negative Blood (µL) 
500 1000 (Std 1) 0 
250 500 (Std 1) 500 
100 200 (Std 1) 800 
50 1000 (Std 2) 0 
25 500 (Std 2) 500 
10 200 (Std 2) 800 
5 100 (Std 2) 900 




100µL of internal standard solution (500 ng/mL) was added to each sample including the blank 
and all samples were then vortexed for 30 seconds. 
6.5.5 Quality Control (QC) Standards 
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure 
the accurate identification and quantitation of validation specimens. A low QC (LQC) was 
prepared at a concentration of 10 ng/mL and a high QC (HQC) at a concentration of 500 ng/mL. 
Quality control standards were injected immediately following the final point of the calibration 
curve and quantitation of each QC was required to be accurate within 20% of the expected 
nominal value to proceed with the analysis of validation specimens. 
6.5.6 Sample Preparation 
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with 
50:50 methanol/water to assist with the sonication procedure. Samples were shaken and 
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium samples was added to 
appropriately labeled culture tubes. Codeine, morphine, hydromorphone, and 6-
monoacetylmorphine standards and deuterated internal standards were added to samples which 
were then block vortexed for 5 minutes. Samples were centrifuged for 5 minutes at 3500 rpm 
after which the supernatants were transferred to appropriately labeled culture tubes (12x75). 
Samples were then diluted with 2mL of deionized water and vortexed for 10-15 seconds. 
Samples were loaded into 5mL ISOLUTE HM-N supported liquid extraction columns and left to 
sit for 10 minutes. Analytes were initially eluted with 5 mL of ethyl acetate and after a 3 minute 
waiting period a second elution step was performed with 3 mL of ethyl acetate. Samples were 
dried down under a gentle stream of nitrogen and reconstituted in 200 µL of DI water. Samples 
were transferred to UPLC vials and injected. 
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6.5.7 Liquid Chromatography 
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra 
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations 
were achieved on an ACQUITY UPLC™ HSS T3 column (2.1x 50mm) packed with 1.8µm 
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of 
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1% 
formic acid (solvent B). Analyte elution was achieved using the following step-wise binary 
elution gradient: Initial mobile phase composition was 97:3 (H2O:ACN). The composition of 
solvent B was increased to 20% over the first 2.50 mins and then rapidly increased to 99% over 
the next 0.05 mins where it was held constant for 0.45 mins, finally conditions were returned to 
their initial composition of 97:3 (H2O:ACN) over the final 0.01 mins of the chromatographic 
run. The total run time was 3.01 minutes (Figure 24). Samples were maintained at 7.5°C in the 
sample organizer and sample injection volumes were 5µL for all analyses. Flow rates remained 




Figure 24: TIC from the UPLC separation of morphine, hydromorphone, codeine, and 6-
monoacetylmorphine (6-MAM). 
6.5.8 Mass Spectrometry 
Mass spectral conditions were as follows: capillary voltage 0.40 kV, cone voltage 48 V, 
extractor voltage 3.1 V, RF lens voltage 0.1 V. The source temperature was 150°C while the 
desolvation temperature was set at 450°C. Cone gas was set at a flow of 50 L/Hr while the 
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.18 mL/min. Nitrogen 
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was 
used as the collision gas. Table 25 reports the mass transitions, dwell times, cone voltages, and 









Table 25: MS/MS parameters used for each analyte and their deuterated internal standards. 
Compound Mass Purpose Cone (V) Collision (V) Dwell (secs) 
Codeine 300.01 > 164.90 Quantifying ion 45 40 0.02 
Codeine 300.01 > 215.00 Qualifying ion 45 22 0.02 
Codeine-d3 303.03 > 215.00 Quantifying ion 50 26 0.02 
Morphine 285.97 > 164.90 Quantifying ion 50 36 0.02 
Morphine 285.97 > 152.50 Qualifying ion 50 46 0.02 
Morphine-d3 288.89 > 200.90 Quantifying ion 50 26 0.02 
Hydromorphone 285.98 > 184.90 Quantifying ion 55 28 0.02 
Hydromorphone 285.98 > 156.80 Qualifying ion 55 40 0.02 
Hydromorphone-d3 288.97 > 184.90 Quantifying ion 50 30 0.02 
6-monoacetlymorphine 328.01 > 164.90 Quantifying ion 55 36 0.02 
6-monoacetlymorphine 328.01 > 210.90 Qualifying ion 55 26 0.02 















Figure 25 illustrates the fragmentation pathways for codeine, morphine, hydromorphone, and 6-









 Figure 25: Fragmentation pathways for morphine, codeine, hydromorphone, and 6-
monoacetylmorphine during tandem mass spectrometry experiments[244]. 
6.6 Results and Discussion 
6.6.1 Method Validation 
Initial equivalence studies indicated that calibration curves prepared in certified drug-free 
blood were appropriate for the quantitation of codeine, morphine, hydromorphone, and 6-
monoacetylmorphine quality control standards prepared in negative meconium. Accurate 
quantification of QCs and a high degree of correlation between the calibration curves prepared in 
blood and those prepared in meconium indicate that curves prepared in drug-free blood will 
enable accurate quantitations of analytes in authentic meconium specimens (Table 26-29). 



















constructed in blood and those constructed in meconium. Relative errors did not exceed 9% for 
LQC (10 ng/mL) standards while the relative error associated with quantitating HQC (500 
ng/mL) standards did not exceed 2.5% indicating a high degree of correlation for all four 
analytes. Calibration curves constructed in certified drug-free blood were employed for the 
remainder of validation experiments. 
Table 26: Codeine equivalence studies using quantitative values obtained from calibration curves 
constructed in meconium (MC) and blood (BC). 
Codeine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  10.6 9.8 8.2% 
HQC  506.8 507.2 0.1% 
NEG(B) 0.1 0 N/A 
NEG(M) 0.1 0 N/A 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 27: Morphine equivalence studies using quantitative values obtained from calibration 
curves constructed in meconium (MC) and blood (BC). 
Morphine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  9.0 9.2 2.2% 
HQC  504.7 517.2 2.4% 
NEG(B) 0 0 N/A 
NEG(M) 0 0 N/A 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 28: Hydromorphone equivalence studies using quantitative values obtained from 
calibration curves constructed in meconium (MC) and blood (BC). 
Hydromorphone Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  9.5 9.3 2.2% 
HQC  492.9 490.1 0.6% 
NEG(B) 0 0 N/A 
NEG(M) 0 0 N/A 





Table 29: 6-monoacetylmorphine (6-MAM) equivalence studies using quantitative values 
obtained from calibration curves constructed in meconium (MC) and blood (BC). 
6-monoacetylmorphine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  9.8 9.1 7.7% 
HQC  491.0 482.4 1.8% 
NEG(B) 0 0 N/A 
NEG(M) 0 0 N/A 
*Reported concentrations are mean values of 5 replicate analyses. 
The analytical methodology was deemed selective following the analysis of blank 
meconium specimens from five different sources and the accurate quantitation of five standards 
prepared at the LLOQ which had been spiked with various xenobiotics commonly encountered 
in forensic toxicology (Table 30).  
Table 30: Exogenous compounds included in selectivity quality control standards. 
Standard Contents 
Selectivity QC 2 Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine, 
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine, 
paroxetine, sertraline, venlafaxine
Selectivity QC 3 Alprazolam, chlorpheniramine, citalopram, clonazepam, cyclobenzaprine, dextromethorphan, 
duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine, olanzapine, strychnine, zolpidem 
Selectivity QC 4 Chlordiazepoxide, chlorpromazine, clozapine, diazepam, lorazepam, midazolam, norclozapine, 
nordiazepam, oxazepam, PMA, quetiapine, temazepam 
Selectivity QC 5 Amphetamine, benzoylecgonine, cocaethylene, cocaine, EDDP, ephedrine, MDMA, 
methadone, methamphetamine, norpropoxyphene, nortramadol, PCP, propoxyphene, tramadol 
Selectivity QC 6 Alfentanil, diphenhydramine, doxylamine, meperidine, normeperidine, orphenadrine, 
promethazine, propranolol, trazodone, trimipramine, verapamil 
 
Blank meconium matrices failed to generate a response for any of the four analytes investigated 
indicating that the method is sufficiently selective to eliminate the possibility of matrix 
interferences generating false positives (Table 31-34). Accurate quantitation of QC standards 
prepared at the LLOQ which had been spiked with various exogenous interferences commonly 
encountered in forensic specimens indicated that the methodology is selective for the analytes of 
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interest (Table 31-34). Quantitation accuracies ranged from 94% to 100% for codeine, 91% to 
96% for morphine, 94% to 97% for hydromorphone, and 92% to 99% for 6-
monoacetylmorphine. Quantitation accuracy at the LLOQ indicates a high degree of selectivity 
in the presence of exogenous interferences. 
Table 31: Codeine selectivity studies using blank meconium from five different sources and 
blank meconium specimens spiked with various exogenous interferences. 
Codeine Std Std Conc *Measured 
Conc 
Acceptable range Pass/Fail 
Blank samples 0 0 <10ng/mL Pass 
Spiked samples  10 10.0 10+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 32: Morphine selectivity studies using blank meconium from five different sources and 
blank meconium specimens spiked with various exogenous interferences. 
Morphine Std Std Conc *Measured 
Conc
Acceptable range Pass/Fail 
Blank samples 0 0 <10ng/mL Pass 
Spiked samples  10 9.3 10+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 33: Hydromorphone selectivity studies using blank meconium from five different sources 
and blank meconium specimens spiked with various exogenous interferences. 
Hydromorphone Std Std Conc *Measured 
Conc 
Acceptable range Pass/Fail 
Blank samples 0 0 <10ng/mL Pass 
Spiked samples  10 9.6 10+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 34: 6-monoacetylmorphine selectivity studies using blank meconium from five different 
sources and blank meconium specimens spiked with various exogenous interferences. 
6-monoacetylmorphine Std Std Conc Measured Conc Acceptable range Pass/Fail 
Blank samples 0 0 <10ng/mL Pass 
Spiked samples  10 10.1 10+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Accuracy of the methodology was investigated by analyzing five replicates over three 
concentrations spanning the calibration range. Accuracy was investigated at concentrations of 
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500, 50, and 10 ng/mL for all analytes. Mean values of 487.1 ng/mL, 50.2 ng/mL, and 9.7 ng/mL 
reflecting accuracies of 97.4%, 99.6%, and 97% were obtained for codeine (Table 35), while 
analysis of morphine standards yielded mean values of 478.6 ng/mL, 46.5 ng/mL, and 9.9 ng/mL 
corresponding to accuracies of 95.7%, 93%, and 99% (Table 36). High accuracies were also 
observed through the analysis of hydromorphone standards which produced mean values of 
493.9 ng/mL, 49.8 ng/mL, and 9.8 ng/mL corresponding to accuracies of 98.8%, 99.6%, and 
98% (Table 37). Analysis of 6-monoacetlymorphine QC standards prepared at concentrations of 
500, 50, and 10 ng/mL yielded mean values of 515.7 ng/mL, 52.0 ng/mL, and 9.8 ng/mL 
corresponding to accuracies of 96.9%, 96%, and 98% (Table 38). Quantitation accuracy over the 
calibration range was greater than 93% for all four analytes.  
Table 35: Codeine accuracy over three concentrations spanning the calibration range. 
Codeine Std Std Conc *Measured value %RE 
High point  500 487.1 2.6% 
Midpoint  50 50.2 0.4% 
LLOQ  10 9.7 3.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 36: Morphine accuracy over three concentrations spanning the calibration range. 
Morphine Std Std Conc *Measured value %RE 
High point  500 478.6 4.3% 
Midpoint  50 46.5 7.0% 
LLOQ  10 9.9 1.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 37: Hydromorphone accuracy over three concentrations spanning the calibration range. 
Hydromorphone Std Std Conc *Measured value %RE 
High point  500 493.9 1.2% 
Midpoint  50 49.8 0.4% 
LLOQ  10 9.8 2.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
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Table 38: 6-monoacetylmorphine accuracy over three concentrations spanning the calibration 
range. 
6-monoacetylmorphine Std Std Conc *Measured value %RE 
High point  500 515.7 3.1% 
Midpoint  50 52.0 4.0% 
LLOQ  10 9.8 2.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Intra- and inter-batch precision was investigated during method validation. Five 
replicates prepared at three different concentrations spanning the calibration range were analyzed 
and mean values were calculated for each concentration to determine the precision associated 
with the methodology. Quality control standards were prepared in negative meconium at 
concentrations of 10, 50, and 500 ng/mL for each analyte. Both intra- and inter-batch precision 
studies indicated a high degree of method precision over the investigated concentration range 
with intra-batch CVs ranging from 1.4-9.5% with a mean value of 2.9% for codeine (Table 39), 
while intra-batch morphine studies produced CVs ranging from 1.2-10.7% with a mean value of 
3.1% (Table 40). Analysis of hydromorphone QCs produced intra-batch CVs ranging from 1.4-
7.6% with a mean value of 3.3% (Table 41), while 6-monoacetylmorphine standards yielded 
CVs ranging from 1.3-10% with a mean value of 3.3% (Table 42). Method precision was high 
over the entire calibration range including the LLOQ where individual CVs did not exceed 
10.7% (Tables 39-42). Inter-batch precision calculations were performed to assess method 
precision over a four day period. CVs were calculated based on four-day mean values for QCs at 
concentrations of 500, 50, and 5 ng/mL and produced values of 3.3%, 4.5, and 4.7% respectively 
for codeine, 3.1%, 4.0%, and 4.7% for morphine, 3.1%, 2.3%, and 6.1% for hydromorphone, and 




Table 39: Intra- and inter-batch precision for codeine. 
Codeine Std *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  487.1 505.8 507.6 527.8 507.1 3.3% 
CV 1.4% 1.9% 1.7% 1.8%     
Midpoint  50.2 53.3 50.0 54.7 52.0 4.5% 
CV 1.6% 2.6% 1.5% 2.9%     
LLOQ  9.7 10.5 9.6 10.5 10.1 4.7% 
CV 4.9% 2.3% 2.6% 9.5%     
*Reported concentrations are mean values of 5 replicate analyses. 
Table 40: Intra- and inter-batch precision for morphine. 
Morphine Std *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  478.6 499.9 466.3 494.0 484.7  3.1%  
CV 1.4% 1.8% 1.5% 2.7%     
Midpoint  46.5 45.5 45.0 49.2 46.6  4.0%  
CV 2.7% 2.6% 3.0% 5.5%     
LLOQ  9.9 9.2 9.1 8.9 9.3  4.7%  
CV 1.2% 2.6% 1.6% 10.7%    
*Reported concentrations are mean values of 5 replicate analyses. 
Table 41: Intra- and inter-batch precision for hydromorphone. 
Hydromorphone 
Std
*Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  493.9 499.3 508.2 529.2 507.7 3.1% 
CV 2.5% 2.7% 4.4% 2.7%   
Midpoint  49.8 48.6 47.7 50.2 49.1 2.3% 
CV 2.0% 1.4% 3.4% 2.7%   
LLOQ  9.8 8.9 9.2 10.2 9.5 6.1% 
CV 2.6% 3.8% 3.4% 7.6%   
*Reported concentrations are mean values of 5 replicate analyses. 
Table 42: Intra- and inter-batch precision for 6-monoacetylmorphine (6-MAM). 
6-MAM Std *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  515.7 525.9 528.0 534.0 525.9 1.4% 
CV 1.3% 3.0% 2.2% 2.9%   
Midpoint  52.0 52.3 52.2 52.6 52.3 0.5% 
CV 2.2% 3.0% 4.1% 3.6%   
LLOQ  9.8 10.6 10.5 9.6 10.1 5.2% 
CV 1.9% 2.4% 2.6% 10.0%   
*Reported concentrations are mean values of 5 replicate analyses. 
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Analyte recovery was investigated over three concentrations by comparing the detector 
response of analyte at three different concentrations which had been added to, and extracted 
from, the meconium matrix. Analyte recovery was investigated by comparing peak areas of 
extracted samples at concentrations of 10, 50, and 500 ng/mL with unextracted samples which 
represented 100% recovery. Mean analyte recoveries over the three concentrations investigated 
were 64.3%, 52.3%, 55.9%, and 76.3% for codeine, morphine, hydromorphone, and 6-
monacetylmorphine respectively. Mean recoveries from triplicate analysis at the three 
concentrations investigated ranged from 61-69% for codeine (Figure 26), 47-61% for morphine 
(Figure 27), 48-64% for hydromorphone (Figure 28), and 68-84% for 6-monoacetylmorphine 
(Figure 29). 
 


















Figure 27: Morphine extraction recovery. 
 
 































Figure 29: 6-MAM extraction recovery. 
 
The limit of detection was 2.5 ng/mL for all four analytes corresponding to a concentration of 10 
ng/g in the original meconium specimen. Limits of detection were calculated based on 
acceptance criteria for retention times and ion ratios. At concentrations below 2.5 ng/mL 
unequivocal identification was not possible due to inaccurate ion ratios. Stability studies 
indicated that all four analytes were stable in the meconium matrix when stored long-term at 
4°C. High and low QC standards corresponding to the calibration range were subject to a 72 hour 
freeze-thaw cycle and analyzed following thawing on the third day. Quantitation accuracies 
during stability studies were greater than 97%, and 94% for codeine LQCs and HQCs 
respectively, greater than 98%, and 92% for morphine low and high QCs, greater than 98%, and 
99% for hydromorphone low and high QCs and greater than 96%, and 99% for 6-
monoacetylmorphine low and high QCs respectively. Accurate quantitations during stability 
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specimens and any accurate quantitation of the four analytes following thawing should be 
feasible. 
6.7 Conclusions 
Development, optimization and validation of a UPLC-ESI-MS/MS method allowed for 
the accurate, selective, precise, and sensitive determination of morphine, codeine, 
hydromorphone, and 6-monoacetylmorphine following supported liquid extraction from 
meconium specimens. Extraction of all four analytes from the meconium matrix using ISOLUTE 
HM-N supported liquid extraction columns significantly reduced sample preparation time while 
the rapid separations afforded by UPLC significantly reduced analysis time, allowing for 
increased sample throughput. The increased separation efficiency afforded by UPLC, combined 
with the inherent selectivity and sensitivity of tandem mass spectrometric detection is well suited 
to low level, multi-analyte determination in complex biological matrices such as meconium. 
Rapid UPLC separations combined with certain automated features of the Waters TQD 
instrument, significantly reduces method development and validation time, making the 
instrumental combination well suited to high throughput toxicology laboratories. Two MRM 
transitions were monitored for each analyte and quantifications were made using deuterated 
internal standards and seven point calibration curves. Detection limits for all four analytes was 
2.5 ng/mL in the homogenized extract, and injection volumes of 5 µL allowed for the linear 
quantification of analytes up to 500 ng/mL. To the author’s knowledge, this is the first validated 
UPLC-MS/MS methodology for the quantification of morphine, codeine, hydromorphone, and 6-
monoacetylmorphine in meconium specimens. 
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Chapter 7: Simultaneous Quantification of Amphetamine and 
Methamphetamine in Meconium Using ISOLUTE® HM-N Supported Liquid 
Extraction Columns and UPLC-MS/MS 
7.1 Abstract 
A procedure for the rapid extraction and quantification of amphetamine and 
methamphetamine from meconium using ISOLUTE HM-N supported liquid extraction columns 
and ultra performance liquid chromatography coupled with tandem mass spectrometry (UPLC-
MS/MS) is described. Due to the matrix complexity of meconium samples, extraction and 
sample preparation prior to instrumental analysis can prove difficult and time consuming. The 
present study introduces a novel sample preparation technique for the simultaneous 
quantification of amphetamine and methamphetamine in meconium using UPLC-MS/MS.  
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique 
which draws upon the principles of chromatography to run separations at higher flow rates for 
increased speed, while simultaneously achieving superior resolution and sensitivity.  
Extraction of both analytes was achieved using ISOLUTE HM-N supported liquid 
extraction columns containing a modified form of diatomaceous earth. Subsequent separation 
and quantification using ultra UPLC-MS/MS was achieved in less than 3 minutes. Limits of 
detection for amphetamine and methamphetamine were 4 ng/g and 1000 pg/g respectively. The 
lower limit of quantitation (LLOQ) was 20 ng/g. The methodology exhibited high intra run 
precision with CV values ranging from 1-9% for amphetamine and 1-6% for methamphetamine. 
Inter run precision experiments produced CV values ranging from 3-7% for amphetamine and 1-
6% for methamphetamine.  
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The reported methodology proved suitable for the accurate quantification of 
amphetamine and methamphetamine in meconium samples and greatly reduced sample 
preparation time normally required for traditional solid phase extraction. Development and 
validation of such analytical methodologies will prove beneficial for the identification of prenatal 
substance abuse which. 
7.2 Introduction 
Due to the increasing abuse and synthesis of amphetamine like stimulants, there is a 
desire among analytical chemists for sensitive methodologies capable of detecting low levels of 
these drugs in meconium. Such methodologies would aid in further understanding the effects of 
fetal exposure on newborns. Clefting, cardiac anomalies, and fetal growth reduction deficits have 
all been seen in infants exposed to amphetamines during pregnancy [245]. Animal studies 
involving prenatal exposure to amphetamines have allowed for the same observations and 
methamphetamine has been shown to cross the placenta within thirty seconds of intraperitoneal 
injection [246]. Methamphetamine is the most widely abused amphetamine and animal studies 
observed increased maternal and offspring mortality, retinal eye defects, cleft palate, rib 
malformations, decreased rate of physical growth, and delayed motor development associated 
with prenatal methamphetamine exposure [247-250]. Although peak concentrations are lower on 
the fetal side, slower elimination of the amphetamines means that the fetus is subject to 
prolonged exposure which can significantly impact neonatal health and development [246].  
In the first large scale investigation into the prevalence of methamphetamine use during 
pregnancy in areas of the United States where methamphetamine is a notable concern, it was 
found that 5.2 % of the 1632 subject mothers used methamphetamine at some point during their 
pregnancy [251]. The authors concluded that the methamphetamine exposed group was 3.5 times 
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more likely to be small for gestational age than the unexposed group [252]. Prenatal exposure to 
amphetamines has also been associated with behavioral problems, cranial abnormalities, 
increased incidence of premature delivery, placental abruption, increased rates of fetal distress, 
biliary atresia, and decreased growth parameters (weight, head circumference, length)[253, 254]. 
Table 43 provides the chemical structures of methamphetamine and amphetamine along with 
certain physicochemical properties such as molecular weights, and pka’s.  
Table 43: Chemical structures, molecular weights, molecular formulas and pKa's of 






Molecular weight 135.21 g/mol Molecular weight 149.23 g/mol 
Molecular formula C9H13N Molecular formula C10H15N 
pKa 9.80 pKa 10.1 
 
7.3 Mechanism of Action 
The amphetamines are similar to cocaine in their ability to modify the actions and levels 
of catecholamines. Amphetamines acts to stimulate the sympathomimetic nervous system both 
centrally and peripherally. This again is achieved through increasing levels of dopamine and 
norepinephrine, however, the mechanism by which the amphetamines achieve this differs 
slightly from other stimulants such as cocaine. Amphetamines are chemically similar to 
dopamine and norepinephrine allowing them to enter the presynaptic terminal assisted by protein 
molecules that would normally transport dopamine and norepinephrine back into the nerve 
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terminal from the synaptic cleft. Once in the presynaptic terminal, amphetamines acts to release 
dopamine and norepinephrine from vesicles resulting in increased levels of free catecholamines 
in the nerve ending. Amphetamines also inhibit monoamine oxidase (MAO), an enzyme 
responsible for the deactivation of free catecholamines in the presynaptic terminal. As a result, 
excess levels of dopamine and norepinephrine are transported out of the presynaptic terminal and 
into the synapse where they produce feelings of pleasure and euphoria.  
7.4 Effect of Prenatal Exposure 
Clefting, cardiac anomalies, fetal growth reduction deficits have all been seen in infants 
exposed to amphetamines during pregnancy, increased maternal and offspring mortality, retinal 
eye defects, cleft palate, rib malformations, decreased rate of physical growth, and delayed motor 
development have all been associated with prenatal exposure to amphetamines. Although peak 
concentrations are lower on the fetal side, slower elimination of the amphetamines means that 
the fetus is subject to prolonged exposure which can significantly impact neonatal health and 
development [245-250]. 
7.5 History of Amphetamine Analysis in Meconium (Literature Review) 
Meconium has become the specimen of choice for the detection of prenatal exposure to 
several drugs of abuse [255, 256]. There are several reasons for this, including the relatively 
simple and non-invasive procedure used to collect meconium samples, making it more successful 
than urine collection [70]. Meconium analysis also extends the window of drug detection to 
approximately the last 20 weeks of gestation as well as extending the window for specimen 
collection, as it is not fully evacuated until 125 hours post-natally [213, 257, 258].  
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Due to the complexity of the meconium matrix, analysis can prove difficult as sample 
preparation may require additional laborious steps to efficiently extract the desired analytes from 
the non-homogenous sample [259]. Ostrea et al. [260] employed a two stage extraction 
procedure for the detection of illicit drugs and other xenobiotics in newborn infants. Such 
procedures involve an initial liquid extraction from the meconium after which the organic layer 
is evaporated and reconstituted in phosphate buffer in preparation for solid-phase extraction. 
Conventional SPE columns require multi-step conditioning and subsequent aspiration before the 
sample can be introduced onto the column. Most SPE extraction procedures involve 2-3 
sequential washes before analytes are eluted with a suitable solvent made fresh daily. The 
combination of a two stage extraction involving a multi wash SPE procedure with the need to 
prepare elution solvents daily can prove very laborious in high throughput laboratories.  
ElSohly et al [243] achieved limits of detection of 50 ng/g for amphetamine and 
methamphetamine employing a multi-step liquid extraction procedure and GC/MS. Additional 
sample cleanup was achieved by incorporating a back extraction for the purpose of eliminating 
neutral molecules present in the matrix. Researchers at the National Institute on Drug Abuse 
(NIDA) recently developed the first reported tandem mass spectrometry method for the detection 
of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related 
(MDMA) analytes in human meconium. Specimens were homogenized and subject to solid 
phase extraction prior to chromatographic separation and mass spectrometric detection. The 
authors employed a triple quadrupole mass spectrometer equipped with an APCI source. 
Selective determination of the 10 analytes was achieved by monitoring two specific MRM 
transitions. The enhanced sensitivity of LC-MS/MS analysis relative to more traditional GC/MS 
analysis allowed for lower limits of quantitation in the range of 1.25 to 40 ng/ng while upper 
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limits of quantitation were set at 10,000 ng/g. Successful detection of p-
hydroxymethamphetamine, norephedrine and 4-hydroxy-3-methoxymethamphetamine in the 
meconium of a methamphetamine-exposed neonate was reported for the first time[93]. While 
such methodologies have allowed for the selective determination of amphetamines in meconium, 
sample preparation remains a time costly and limiting factor in the analysis of meconium. 
Laborious solid phase extractions following homogenization and initial liquid-liquid extractions 
can prove very time inefficient and greatly affect the turnaround time of high throughput 
toxicology laboratories.  
The aim of the present study was to develop a time and cost effective methodology for 
the preparation of meconium samples which would allow for the rapid and simultaneous 
quantification of amphetamine and methamphetamine in meconium. In this report, we describe 
the first application of supported liquid extraction columns for the preparation of meconium 
specimens prior to analysis and quantification by UPLC-MS/MS. ISOLUTE HM-N supported 
liquid extraction columns require no column conditioning and once the sample is introduced onto 
the column, elution is achieved with two washes of ethyl acetate. This is the first report of the 
use of UPLC-MS/MS for the determination of amphetamine and methamphetamine in 
meconium. 
7.6 Experimental 
7.6.1 Chemicals and reagents 
Amphetamine, methamphetamine, amphetamine-d6, and methamphetamine-d9 standards 
(1mg/mL in methanol) were obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N 
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supported liquid-liquid extraction columns were purchased from Biotage (Charlottesville, VA). 
All solvents were HPLC grade and obtained from Fisher Scientific (Pittsburgh PA). 
7.6.2 Calibration Curve Matrix 
Meconium specimens which had previously screened negative for amphetamines using a 
50 ng/g cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with both 
amphetamine and methamphetamine to give concentrations of 10 ng/mL (n=5) and 500 ng/mL 
(n=5). Spiked meconium was then quantified using a calibration curve constructed in negative 
meconium and a calibration curve constructed in certified drug free whole blood. Quantitative 
results obtained using the meconium calibration curve showed excellent correlation (<15% CV) 
with those obtained using the calibration curve made up in negative blood and as a result, all 
subsequent method validation experiments were performed using calibration curves prepared in 
certified negative blood.  
7.6.3 Working Standards 
Calibration curves were constructed using eight calibration standards prepared in certified 
drug free whole blood and all sample volumes were 1 mL. Two working standards were used to 
construct the calibration standards, working standard 1 (500 ng/mL) was prepared by combining 
150µL of an amphetamine and methamphetamine stock solution (10µg/mL) with 2850µL of 
negative blood. Working standard 2 (50 ng/mL) was prepared by combining 300µL of working 
standard 1 with 2700µL of negative blood. An internal standard solution (500 ng/mL) was 
prepared using 1 mg/mL standards of amphetamine-d6 and methamphetamine-d9. 
7.6.4 Calibration Curves 
Calibration curves for all experiments were prepared according to Table 44. 
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Table 44: Preparation of amphetamine and methamphetamine calibration curves. 
Standard Concentration (ng/mL) Volume of Working Standard (µL) Volume of Negative Blood (µL) 
500 1000 (Std 1) 0 
250 500 (Std 1) 500 
100 200 (Std 1) 800 
50 1000 (Std 2) 0 
25 500 (Std 2) 500 
10 200 (Std 2) 800 
5 100 (Std 2) 900 
Negative 0 1000 
 
100µL of internal standard solution (500 ng/mL) was added to each sample including the blank 
and all samples were then vortexed for 30 seconds. 
7.6.5 Quality Control (QC) Standards 
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure 
the accurate identification and quantitation of validation specimens. A low QC (LQC) was 
prepared at a concentration of 5.0 ng/mL and a high QC (HQC) at a concentration of 500 ng/mL. 
Quality control standards were injected immediately following the final point of the calibration 
curve and quantitation of each QC was required to be accurate within 20% of the expected 
nominal value to proceed with the analysis of validation specimens. 
7.6.6 Sample Preparation 
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with 
50:50 methanol/water to assist with the sonication procedure. Samples were shaken and 
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium samples was added to 
appropriately labeled culture tubes. Amphetamine and methamphetamine standards and 
deuterated internal standards were added to samples which were then block vortexed for 5 
minutes. Samples were centrifuged for 5 minutes at 3500 rpm after which the supernatants were 
transferred to appropriately labeled culture tubes (12x75). Sample recovery was optimized by 
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adding 500 µL of 2.0M NaOH to ensure that the analyte was present in its basic state. Samples 
were then diluted with 2mL of deionized water and vortexed for 10-15 seconds. Samples were 
loaded into 5mL ISOLUTE HM-N supported liquid extraction columns and left to sit for 10 
minutes. Analytes were initially eluted with 5 mL of ethyl acetate and after a 3 minute waiting 
period a second elution step was performed with 3 mL of ethyl acetate. 200 µL of 1% HCl was 
added to all eluates to ensure formation of the hydrochloride salts to reduce the possibility of 
analyte loss during evaporation steps. Samples were dried down under a gentle stream of 
nitrogen and reconstituted in 200 µL of DI water. Samples were transferred to UPLC vials and 
injected. 
7.6.7 Liquid Chromatography 
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra 
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations 
were achieved on an ACQUITY UPLC™ phenyl column (2.1x 50mm) packed with 1.7µm 
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of 
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1% 
formic acid (solvent B). Analyte elution was achieved using the following step-wise binary 
elution gradient: Initial mobile phase composition was 99:1 (H2O:ACN). The composition of 
solvent B was increased to 2% over the first 0.10 mins after which time it was linearly increased 
to 10% over 2.9 mins followed by an increase to 100% over 0.50 mins. Conditions were returned 
to their initial composition of 99:1 (H2O:ACN) over 0.50 mins and held for 1 min to equilibrate 
the column before the next injection. The total run time was 5 mins. Samples were maintained at 
10°C in the sample organizer and sample injection volumes were 1µL for all analyses. Flow rates 
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remained constant at 0.5 mL/min and all flow was directed into the ESI source of the mass 
spectrometer. 
7.6.8 Mass Spectrometry 
Mass spectrometry conditions were as follows: capillary voltage 0.60 kV, cone voltage 
22 V, extractor voltage 3.1 V, RF lens voltage 0.1 V. The source temperature was 150°C while 
the desolvation temperature was set at 350°C. Cone gas was set at a flow of 50 L/Hr while the 
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.18 mL/min. Nitrogen 
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was 
used as the collision gas. Table 45 reports the mass transitions, dwell times, cone voltages, and 
collision energies for each of the analytes and their deuterated internal standards.  
Table 45: MS/MS parameters used for each analyte and deuterated internal standard. 
Compound Mass transition Purpose Cone (V) Collision (V) Dwell (secs) 
Amphetamine 135.97 > 90.90 Quantifying ion 20 14 0.02 
Amphetamine 135.97 > 119.0 Qualifying ion 20 10 0.02 
Amphetamine-d6 141.94 > 93.00 Quantifying ion 20 16 0.02 
Methamphetamine 149.97 > 90.90 Quantifying ion 25 16 0.02 
Methamphetamine 149.97 > 119.0 Qualifying ion 25 12 0.02 
Methamphetamine-d9 159.03 > 92.90 Quantifying ion 25 18 0.02 
 
Figure 30 illustrates the fragmentation pathways for amphetamine and methamphetamine under 








Figure 30: Fragmentation pathways for amphetamine and methamphetamine during tandem mass 
spectrometry experiments[261]. 
 
7.7 Results and Discussion 
During direct infusion experiments, the most abundant product ion for both amphetamine 
and methamphetamine was identified as the m/z 90.90 ion (Figure 30). Subsequently, the mass 
transition from 135.97>90.90 was monitored as the quantifying trace for amphetamine and the 
mass transition from 149.97>90.90 was monitored as the quantifying trace for 
methamphetamine. In order to monitor these mass transitions, MS1 was set to pass masses of 
135.97 and 149.97 along with the parent masses of the deuterated internal standards. Following 
collision induced dissociation of the protonated molecular ions into their characteristic product 
ions, MS2 was set to transmit only product ions with m/z 90.90. To eliminate the potential 
effects of cross-talk between the identical fragment ions of amphetamine and methamphetamine, 





analytes. Due to their structural similarities, amphetamine and methamphetamine exhibit almost 
identical physicochemical properties. Initial UPLC experiments indicated that the baseline 
resolution of the two compounds could only be achieved with a non-traditional step-wise 
gradient.  
7.7.1 Chromatographic Separation of Amphetamine and Methamphetamine 
Preliminary chromatographic experiments aimed to chromatographically resolve 
amphetamine and methamphetamine to eliminate the possibility of ion ‘cross talk’ which can 
complicate the quantitation process. The initial elution gradient profile was as follows: 0 – 0.10 
min, 25% B; 0.10 – 3.0 min, 25 – 100% B; 3.0 – 3.5 min, return to initial conditions; 3.5 – 5.0 
min, equilibration of the column. The chromatographic separation under these conditions 




Figure 31: TIC of UPLC separation #1. Elution gradient failed to resolve amphetamine (Amp) 
and methamphetamine (Mamp). 
 
In order to achieve baseline resolution of amphetamine from methamphetamine, a second 
gradient profile was evaluated. The elution gradient profile was as follows: 0 – 0.10 min, 15% B; 
0.10 – 3.0 min, 15 – 100% B; 3.0 – 3.5 min, return to initial conditions; 3.5 – 5.0 min, 
equilibration of the column. The chromatographic separation of amphetamine and 
methamphetamine improved under these conditions however significant co-elution meant that 





Figure 32: TIC of UPLC separation #2. Elution gradient resulted in the co-elution of 
amphetamine (Amp) and methamphetamine (Mamp). 
 
Chromatographic resolution was improved using the second elution gradient profile in which the 
initial aqueous component was increased. In order to investigate the effect of increasing the 
aqueous component further, a third gradient profile was evaluated. The elution gradient profile 
was as follows: 0 – 0.10 min, 5 – 10% B; 0.10 – 3.0 min, 10 – 100% B; 3.0 – 3.5 min, return to 
initial conditions; 3.5 – 5.0 min, equilibration of the column. Chromatographic resolution was 






Figure 33: TIC of UPLC separation #3. Elution gradient was unable to resolve amphetamine 
(Amp) and methamphetamine (Mamp). 
 
As an increase in the initial aqueous component of the gradient profile did not significantly 
improve the chromatographic resolution, the effect of sustaining a slightly higher aqueous 
component in the early stage of the separation was investigated. The elution gradient profile was 
as follows: 0 – 0.10 min, 1% B; 0.10 – 3.0 min, 1 – 100% B; 3.0 – 3.5 min, return to initial 
conditions; 3.5 – 5.0 min, equilibration of the column. The higher aqueous composition again 
shifted the retention times of both analytes but did not significantly improve the chromatographic 






Figure 34: TIC of UPLC separation #4. Elution gradient was unable to resolve amphetamine 
(Amp) and methamphetamine (Mamp). 
 
In order to evaluate the separation power of a largely aqueous mobile phase, the elution gradient 
profile was modified to sustain a largely aqueous composition not only during the early stages of 
the separation but also throughout and beyond analyte elution. The elution gradient profile was 
as follows: 0 – 0.10 min, 1 – 5% B; 0.10 – 3.0 min, 5 – 10% B; 3.0 – 3.5 min, 10 – 90% B; 3.50 
– 4.50 min, return to initial conditions; 4.5 – 5.5 min, equilibration of the column. While 
chromatographic resolution of amphetamine and methamphetamine was achieved using the 
highly aqueous mobile phase, significant peak broadening, especially in the case of 







Figure 35: TIC of UPLC separation #5. Elution gradient resulted in significant peak broadening. 
 
In order to minimize peak broadening while still achieving baseline resolution, the following 
elution gradient profile was evaluated: 0 – 0.10 min, 1 – 2% B; 0.10 – 3.0 min, 2 – 10% B; 3.0 – 
3.5 min, 10 – 100% B; 3.50 – 4.0 min, return to initial conditions; 4.0 – 5.0 min, equilibration of 
the column. The elution gradient maintained a higher aqueous component during the initial stage 
of the separation and increased the organic component during the ramp between 3.0 and 3.5 
minutes. Band broadening was significantly reduced without significantly altering retention 
times (Figure 36). Both analytes eluted in less than three minutes and the total run time was five 






Figure 36: TIC of UPLC separation #6. Elution gradient allowed for the baseline resolution of 
amphetamine (Amp) and methamphetamine (Mamp). 
 
7.7.2 Method Validation 
Equivalence studies were performed to investigate the accuracy of employing calibration 
curves constructed in certified drug-free blood for the purpose of quantifying analytes in the 
meconium matrix. Five LQC and five HQC standards were prepared and quantified using a 
calibration curve constructed in negative whole blood, and a calibration curve constructed in 
meconium which had previously screened negative for the analytes of interest. The relative error 
of the two quantitative values was calculated for each QC and used to determine the level of 
agreement between the two calibration curves. Relative error did not exceed 2% indicating a 
high degree of correlation between calibration curves constructed in blood and calibration curves 
constructed in meconium for the purpose of quantifying amphetamine and methamphetamine in 





to generate accurate quantitations when applied to the meconium matrix which is encouraging. 
Calibration curves constructed in certified drug-free blood were deemed suitable for the 
quantitation of amphetamine and methamphetamine in the meconium matrix and were 
subsequently employed for the remainder of validation experiments. 
Table 46: Amphetamine equivalence studies using quantitative values obtained from calibration 
curves constructed in meconium (MC) and blood (BC). 
Amphetamine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  10.0 10.1 1.0% 
HQC  513.4 506.7 1.3% 
NEG(B) 0 0 N/A 
NEG(M) 0 0 N/A 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 47: Methamphetamine equivalence studies using quantitative values obtained from 
calibration curves constructed in meconium (MC) and blood (BC). 
Methampheatmine Std *BC (ng/mL) *MC (ng/mL) %RE 
LQC  9.8 9.4 4.3% 
HQC  538.7 503.3 7.0% 
NEG(B) 0 0 N/A 
NEG(M) 0 0 N/A 
*Reported concentrations are mean values of 5 replicate analyses. 
The analytical methodology was deemed selective following the analysis of five 
meconium blanks and five QC standards prepared at the LLOQ which had been spiked with 
various exogenous interferences commonly encountered in forensic specimens (Table 48). Blank 
meconium specimens were analyzed to ensure minimal analyte response was generated from any 
endogenous matrix components. Analysis of five LLOQ specimens which had been spiked with 
potential interfering species was performed to ensure selectivity at the low end of the calibration 




Table 48: Exogenous compounds included in selectivity quality control standards. 
Standard Contents 
Selectivity QC 1 Carbamazepine, carbamazepine epoxide, felbamate, gabapentin, lamotrigine, 
levetiracetam, mephobarbital, naproxen, oxcarbazepine, phenytoin, primidone, topiramate, 
valproic acid, zonisamide 
Selectivity QC 2 Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine, 
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine, 
paroxetine, sertraline, venlafaxine 
Selectivity QC 3 Alprazolam, chlorpheniramine, citalopram, clonazepam, cyclobenzaprine, 
dextromethorphan, duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine, 
olanzapine, strychnine, zolpidem 
 
Analysis of blank meconium specimens indicated that endogenous matrix components 
are capable of generating only minimal detector responses which correspond to concentrations 
well below the LLOQ. Analyte responses during the analysis of blank samples did not exceed 
0.2 ng/mL for either analyte (Tables 49 and 50). Results indicate that false positives arising from 
endogenous matrix interferences are unlikely. Analysis of QC standards prepared at the LLOQ, 
which had been spiked with various exogenous interferences, indicated that accurate and 
selective identification of amphetamine and methamphetamine was possible even in the presence 
of various other xenobiotics. Quantitation accuracies of spike QC standards ranged from 96% to 
100% for amphetamine and 94% to 98% for methamphetamine (Table 49 & 50). Accurate 
quantitations at the LLOQ for both analytes were possible due to the high selectivity of the 
tandem mass spectrometric methodology. Selectivity studies indicate that false positives due to 





Table 49: Amphetamine selectivity studies using blank meconium from five different sources 
and blank meconium specimens spiked with various exogenous interferences. 
Amphetamine Std Std Conc 
(ng/mL) 
*Measured Conc (ng/mL) Acceptable range Pass/Fail 
Blank samples 0 0.1 <5ng/mL Pass 
Spiked samples 5 5.0 5+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 50: Methamphetamine selectivity studies using blank meconium from five different 
sources and blank meconium specimens spiked with various exogenous interferences. 
Methamphetamine Std Std Conc *Measured Conc (ng/mL)  Acceptable range Pass/Fail 
Blank samples 0 0.2 <5ng/mL Pass 
Spiked samples 5 5.2 5+/- 20% Pass 
*Reported concentrations are mean values of 5 replicate analyses. 
The accuracy of the analytical method was investigated by analyzing five replicate QC 
standards over three different concentrations spanning the calibration range. Accuracy was 
assessed by calculating the closeness of the mean test results to the known standard 
concentration. Mean values were determined using five replicates prepared at concentrations of 
500, 50, and 5 ng/mL. Mean values of 491.1 ng/mL, 50.8 ng/mL, and 4.8 ng/mL were obtained 
from replicate analysis of amphetamine standards at concentrations of 500, 50, and 5 ng/mL 
respectively, representing accuracies of 98.2%, 98.4%, and 96% (Table 51). Replicate analysis of 
methamphetamine QCs prepared at concentrations of 500, 50, and 5 ng/mL produced mean test 
values of 530.9 ng/mL, 53.2 ng/mL, and 4.7 ng/mL respectively, representing accuracies of 






Table 51: Amphetamine accuracy studies. 
Amphetamine Std Std Conc (ng/mL) *Measured value (ng/mL) %RE 
High point  500 491.1 1.8% 
Midpoint  50 50.8 1.6% 
LLOQ  5 4.8 4.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Table 52: Methamphetamine accuracy studies. 
Methamphetamine Std Std Conc (ng/mL) *Measured value (ng/mL) %RE 
High point  500 530.9 6.2% 
Midpoint  50 53.2 6.4% 
LLOQ  5 4.7 6.0% 
*Reported concentrations are mean values of 5 replicate analyses. 
Precision of the analytical methodology was investigated by analyzing five replicate QC 
standards at concentrations of 500, 50, and 5 ng/mL over four consecutive days. Both intra- and 
inter-batch studies indicated high method precision (CVs <8.5%). Intra-batch precision studies 
yielded CVs ranging from 1.4%-8.5% for amphetamine and 0.7%-5.4% for methamphetamine 
indicating high intra-batch precision over the entire calibration range. (Table 53 & 54). Inter-
batch precision studies were also promising with four-day CVs of 3.9%, 2.0%, and 6.2% for 
amphetamine QCs prepared at concentrations of 500, 50, and 5 ng/mL, while analysis of 
methamphetamine standards over the four day time period produced CVs of 1.9%, 3.7%, and 
5.3% for the 500, 50, and 5 ng/mL QCs respectively (Table 53 & 54).  
Table 53: Intra- and inter-batch precision studies for amphetamine. 
Amphetamine *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  491.1 494.7 530.1 523.8 509.9  3.9%  
CV 1.6% 3.2% 2.7% 1.4%     
Midpoint  50.8 49.8 51.3 48.9 50.2  2.0%  
CV 1.8% 1.9% 1.4% 5.3%     
LLOQ  4.8 4.6 5.1 5.3 5.0  6.2%  
CV 5.6% 8.5% 4.5% 2.6%    
*Reported concentrations are mean values of 5 replicate analyses. 
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Table 54: Intra- and inter-batch precision studies for methamphetamine. 
Mamp *Day 1 value *Day 2 value *Day 3 value *Day 4 value 4 day mean 4 day CV 
Highpoint  530.9 507.7 519.9 524.9  520.9 1.9% 
CV 1.6% 1.6% 0.7% 3.2%     
Midpoint  53.2 49.7 52.3 49.3 51.1   3.7% 
CV 0.9% 1.6% 2.7% 4.3%     
LLOQ  4.7 4.6 4.9 5.2  4.9 5.3%  
CV 3.8% 5.4% 2.7% 2.9%    
*Reported concentrations are mean values of 5 replicate analyses. 
 Recovery of amphetamine and methamphetamine from the meconium matrix using the 
HM-N supported-liquid extraction technique was investigated to determine the efficiency of the 
extraction. Extraction efficiency was assessed by comparing the detector response for 
unextracted standards prepared at concentrations of 500, 50, and 5 ng/mL with the detector 
response for extracted standards prepared at the same concentrations. Standards were prepared in 
triplicate and peak area responses for unextracted standards represented 100% recovery. Peak 
area responses for extracted standards were then used to calculate recovery. Mean analyte 
recoveries over the three concentrations investigated were 52% for amphetamine and 52.7% for 
methamphetamine (Figure 37 & 38). Mean analyte recoveries for triplicate standards at each of 
the three concentrations ranged from 49-57% for amphetamine and 47-58% for 
methamphetamine. Analyte recovery was extremely consistent and precise and recoveries of 






Figure 37: Amphetamine recovery. 
 
 































The limit of detection was 1.0 ng/mL for amphetamine and 0.250 ng/mL for methamphetamine 
corresponding to concentrations of 4.0 ng/g and 1 ng/g in the meconium specimen prior to 
sonication. Limits of detection were calculated based on acceptance criteria for retention times 
and ion ratios. At concentrations below 1 ng/mL for amphetamine and 0.250 ng/mL for 
methamphetamine, unequivocal identification was not possible due to inaccurate ion ratios. 
Stability studies indicated that amphetamine and methamphetamine are both stable in the 
meconium matrix when stored long-term at 4°C. Stability studies were performed by preparing 
High and low QC standards which were subsequently subject to a 72 hour freeze-thaw cycle and 
analyzed following thawing on the third day. Quantitation accuracies during stability studies 
were greater than 98% and 99% for amphetamine LQCs and HQCs respectively, and greater than 
98%, and 99% for methamphetamine low and high QCs respectively. High accuracy and 
precision during stability studies indicated that current storage temperature and conditions are 
appropriate for the accurate analysis of authentic meconium specimens. 
7.8 Conclusions 
Meconium is a complex biological matrix that can indicate prenatal exposure to drugs of 
abuse. Unfortunately, meconium specimens require extensive sample pre-treatment before they 
are suitable for instrumental analysis. Extensive sample preparation can prove detrimental to 
sample turnaround time in high throughput toxicology laboratories. ISOLUTE HM-N supported 
liquid-liquid extraction columns provide an attractive sample pre-treatment technique for the 
extraction of amphetamine and methamphetamine from meconium specimens. ISOLUTE HM-N 
columns are designed to deal with difficult matrices such as sonicated meconium specimens 
which can sometimes cause traditional SPE columns to plug due to sample turbidity. Rapid and 
selective extraction of both analytes was possible with the columns and subsequent separation 
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and quantitation was achieved in less than 5.0 min using UPLC-MS/MS. Two MRM transitions 
were monitored for each analyte and quantifications were made using deuterated internal 
standards and seven point calibration curves. Limits of detection were 1 ng/mL and 250 pg/mL 
for amphetamine and methamphetamine, respectively. Injection volumes of 1 µL allowed for the 
linear quantitation of analytes over the range 5 ng/mL – 500 ng/mL. To the author’s knowledge, 
this is the first validated UPLC-ESI-MS/MS methodology for the quantitation of amphetamine 
and methamphetamine in meconium specimens. The proposed methodology could greatly reduce 
the sample preparation time for meconium testing which is becoming an extremely important 
tool for the identification of prenatal exposure to drugs of abuse. The validated methodology was 
implemented at AIT Laboratories (Indianapolis, IN) for the purpose of confirming the presence 
of amphetamine and methamphetamine in authentic meconium specimens which had previously 
screened positive. From 07/01/08 – 03/06/2009 a total of 4036 meconium specimens were 
screened for amphetamine/methamphetamine. Of those samples, 138 screened positive 
representing 3.4% of the total specimens. 37 of the 138 specimens were confirmed positive using 










Chapter 8: Investigations into the Application of Desorption Electrospray 
Ionization (DESI) for the Rapid Screening of Meconium Specimens 
8.1 Abstract 
The current study investigates the suitability of desorption electrospray ionization (DESI) 
for the purpose of screening human meconium samples for several cocaine, amphetamine, and 
opiate derivatives. DESI offers the advantage of ambient sampling meaning that specimens can 
be directly analyzed following limited sample preparation. Due to the complex nature of the 
human meconium matrix, significant sample preparation is often required before specimens can 
be screened using traditional immunoassay techniques. Traditional immunoassay techniques 
such as ELISA, EMIT, and RIA are designed for qualitatively detecting analytes in common 
biological matrices such as serum and urine. Direct application of such techniques to the analysis 
of more complex matrices, such as meconium, can result in inaccurate results and a high rate of 
false-positives. The suitability of the DESI-MS/MS method for screening meconium specimens 
was investigated by analyzing 21 authentic specimens that had previously screened positive for 
either cocaine or amphetamines using an immunoassay screen. Direct comparison of the 
immunoassay screening results with those obtained using the DESI-MS/MS method indicates 
that the mass spectral method greatly enhances selectivity and decreases the rate of false 
positives. Investigations into the suitability of DESI-MS/MS for screening meconium specimens 
aimed to reduce both the degree of sample preparation and also the number of false-positive 




8.2.1 Desorption Electrospray Ionization (DESI) 
Desorption electrospray ionization is achieved by directing a fine spray of electrically 
charged droplets at an ambient object of interest. When the fine spray of droplets hits the surface 
of interest, desolvated ions created from small organic molecules as well as large biomolecules 
are released. Analytes initially leave the surface of interest entrained within small, progeny 
droplets which subsequently evaporate to produce analyte ions. Desorbed ions are subsequently 
vacuumed through air into a conventional mass spectrometer (Figure 39)[262].  





DESI was first described in 2004 by Cooks et al who employed the technique for the 
ionization of peptides and proteins from metal, polymer, and mineral surfaces[263]. The 
distinguishing feature of DESI is that is allows for the collection of mass spectral data under 
ambient conditions. Approximately two decades prior to the introduction of DESI by Cooks and 
co-workers, two new ionization methods were introduced almost simultaneously and have since 
had an enormous impact on the utilization of mass spectrometry in biology and the life 
sciences[264]. One of these methods, employed primarily for the analysis of solids, is a 
desorption ionization (DI) technique known as matrix assisted laser desorption ionization 
(MALDI)[265]. The second technique, applicable to the analysis of solutions is electrospray 
ionization (ESI)[266]. Although ionization techniques based upon matrix-assisted laser 
desorption and electrospray ionization have origins dating back some thirty years, the 
recognition of their potential for the analysis of large biomolecules has only been realized 
recently[267]. Both MALDI and ESI are soft ionization techniques meaning that ions produced 
using either method will possess low internal energies and thus undergo little 
fragmentation[138]. Both methods exhibit very high ionization efficiencies and allow for very 
precise Mr measurements. DESI combines experimental features of both ESI (see section 2.7.6) 
and MALDI (see section 8.2.2) and a thorough understanding of both techniques is required to 
fully recognize the potential applications of DESI in the fields of biology, chemistry, forensics, 
and toxicology. 
8.2.2  Matrix Assisted Laser Desorption Ionization (MALDI) 
Matrix assisted laser desorption ionization (MALDI) was first described in 1985 by Karas 
et al. who employed the technique for the ionization of organic molecules while simultaneously 
studying the influence of the wavelength on laser desorption[268]. Since its introduction some 
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twenty years ago, MALDI, along with ESI has become the heart of virtually all proteomic 
experiments due to its ability to provide the key tools essential for the analysis of proteins[138]. 
Although the exact mechanism of ionization and desorption during MALDI experiments remains 
debatable, it is widely accepted that the transfer of energy to an organic matrix causes rapid 
thermal heating of molecules and eventually leads to desorption of both matrix and analyte ions 










Figure 40: Schematic representation of MALDI ionization region (Adapted from 
www.magnet.fsu.edu/.../ionization_maldi.html). 
 
While theories regarding the mechanistic pathway of MALDI remain largely divergent, 
significant convergence in one area has resulted in the widely accepted theory that MALDI 
ionization occurs via a two step process, involving initial matrix (primary) ionization followed 
by analyte (secondary) excitation and ionization.  
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 MALDI is achieved by co-crystallizing a sample with a thousand-fold excess (minimum) 
of an organic matrix on a metal target. A pulsed laser is then focused onto the surface of the 
matrix-analyte solid solution[269]. The organic matrix is chosen based on its ability to absorb 
energy at the wavelength corresponding to the laser being employed[270]. Frequency coupling 
between the incoming laser and the matrix chromaphore causes rapid vibrational excitation 
leading to localized disintegration of the solid solution. Laser ablative induced disintegration of 
the solid solution surface results in the ejection of ‘clusters’ composed of analyte molecules 
surrounded by matrix (primary) ions[271]. Following evaporation of matrix molecules, free gas-
phase analyte molecules occupy the ablation plume where they undergo ionization through 
proton transfer reactions with the photo-excited matrix molecules[271]. It is these analyte 
(secondary) ions which are then extracted and separated in the mass spectrometer based on their 
mass to charge ratios[272]. 
Considerable time and effort has been expended into the further development and 
application of MALDI, however, minimal progress has been made in the understanding of its 
mechanistic principles. Without a thorough mechanistic understanding of the processes behind 
MALDI analysts may be unequipped to handle the difficulties often associated with absolute 
sensitivity, variable response factors, range of applicability and reproducibility[273]. This lack of 
mechanistic understanding is evident in the literature by the predominately empirical approach 
toward MALDI research and utilization. While the empirical approach to MALDI continues to 
dominate in fields such as proteomics and biomolecular analysis, others have concentrated 
research efforts on further understanding experimental variables. One study aims to 
quantitatively predict or interpret observed mass spectra as a function of experimental variables 
such as, matrix choice, analyte physical and chemical properties, concentrations, preparation 
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method, laser characteristics, local environment and ion extraction method, by drawing on the 
mechanistic principles behind the technique[273]. Studies exploring mechanistic theory and 
evaluating proposed models of MALDI will aid in its practical applications and provide a better 
understanding of factors capable of affecting relative and absolute signal intensities[273].  
MALDI has quickly found notoriety as an analytical tool for the characterization of 
peptides and proteins. Coupled to the appropriate mass analyzer, MALDI allows for the accurate 
mass analysis of low-picomole amounts of biomolecules with molecular weights exceeding 100 
kDa. MALDI offers the inherent advantage of generating low charge state ions from samples 
containing appreciable levels of commonly encountered buffers and salts which can significantly 
affect ionization efficiencies when employing alternative techniques. The use of a pulsed laser 
during MALDI experiments results in the production of packets of ions rather than a continuous 
beam as in the case of ESI[138].  
The mass spectra of ions generated by MALDI are typically measured using a time-of-
flight mass spectrometer. This is primarily due to the fact that time-of-flight mass analyzers are 
immediately compatible with the pulsed generation of high-energy ions and provide a 
theoretically unlimited mass range[270]. Each pulse of laser radiation generates packets of ions 
in a relatively short (≈5cm) source region. An electrical potential contained in the source region 
then accelerates the ions to a fixed kinetic energy before allowing them to traverse the field-free 
drift region of the TOF mass spectrometer. Ions ultimately arrive at the detector following a drift 
time that is dependent on their mass. The drift time or TOF of each packet of MALDI generated 
ions is measured by an internal clock which is triggered by the laser pulse, making time-of-flight 




8.2.3 History and Background of Meconium Screening 
Screening techniques employed for the purpose of identifying drugs of abuse in 
meconium have largely utilized immunoassay analysis. The large majority of meconium studies 
published in the scientific literature have utilized either radioimmunoassay or enzyme 
immunoassay techniques. Immunoassays are based on an interaction between a drug (antigen) 
and specific antibody. When the drug of interest is recognized by the antibody, the subsequent 
interaction produces an antigen-antibody complex which is then separated from the remainder of 
the reaction mixture. The endpoint of the reaction, whether it be radioactivity in the case of 
radioimmunoassays or enzymatic activity in the case of enzyme immunoassays, is then measured 
and provides an indication of the quantity of drug present[39].  
Radioimmunoassays (RIA) are performed by first generating a known quantity of 
radiolabeled antigen. This is normally achieved using radioactive isotopes of iodine attached to 
tyrosine. The radioactive labeled antigen then competes with the wild antigen (the drug of 
interest) for a limited number of binding sites in an antibody[39]. As the concentration of drug in 
the sample increases, the amount of bound radioactive antigen decreases due to fewer available 
binding sites in the antibody. The concentration of the drug can be estimated using a dose-
response curve generated by analyzing standards of known concentrations[39]. RIA has been 
widely employed for the detection of drugs of abuse in meconium and the vast majority of 
methods published prior to 1990 relied heavily in this technique[243]. The main drawback 
associated with RIA is the hazard and cost of preparing, handling, and disposing of the 
radioactive labeled antigen. RIA still finds widespread use in clinical laboratories, however, the 
majority of studies involving the detection of drugs of abuse in meconium published in the last 
fifteen years have utilized enzyme immunoassay.  
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Enzyme linked immunosorbent assay (ELISA) is the most commonly employed enzyme 
immunoassay for various reasons including its inherent sensitivity, ability to handle multiple 
samples, and safe reagents. ELISA operates on the same principles as RIA in that the drug of 
interest competes with an enzyme labeled antigen for a limited number of binding sites in the 
antibody. Antigen labels are non-radioactive and are linked to an enzyme while the antibody is 
immobilized into a solid support[39]. The enzyme used to label the antigen is chosen based on its 
ability to produce a colored product from a colorless substrate. This color reaction between the 
enzyme and the substrate is the endpoint of the assay and can be used to estimate the 
concentration of drug in the sample. Due to the competitive binding nature of the assay, the 
concentration of the drug is inversely proportional to the concentration of the enzyme labeled 
antigen that is bound to the antibody[39].  
Enzyme multiplied immunoassay technique (EMIT) also finds widespread use as a 
screening tool for drugs of abuse in biological specimens. EMIT is similar to ELISA in that the 
antigen is again linked to an enzyme however it is the activity of this enzyme that indicates the 
presence or absence of a drug class. The enzyme used to label the antigen is inactivated upon 
binding with the antibody meaning that enzymatic activity will be higher in the presence of the 
drug due to competitive binding mechanisms. The total amount of drug present in the sample is 
directly proportional to the enzymatic activity which is measured as the product of a reaction. 
Enzymatic activity is the endpoint of the assay and indicates the total amount of drug in the 
sample[39].  
Unlike the National Institute on Drug Abuse protocol regulating urine testing, meconium 
analysis is not government regulated and many of the testing techniques have been directly 
adapted from pre-existing urine assays with the assumption that specific analysis procedures 
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have no significant impact on results[275]. Due to the complex nature of the meconium matrix 
and the lack of research detailing its composition, the presence of endogenous compounds 
capable of generating false positives must be considered. False positive results arise when 
endogenous or exogenous components of the sample are erroneously recognized as the drug of 
interest by the testing technique. Recognition of the interfering compound as the drug of interest 
generates a positive result in the true absence of the drug. Specimens that screen positive should 
be subject to subsequent confirmation testing utilizing mass spectrometry where feasible.  
The superior selectivity of mass spectrometry provides the analyst with structural 
information for the drug of interest, eliminating the possibility of false positives. Incorrect 
recognition of interferences as the drug of interest may be due to similarities in chemical 
structure or simply to the lack of selectivity afforded by most immunoassay techniques. 
Situations in which the drug of interest is present but not detected by the technique are referred 
to as false negative results and must also be considered when adapting pre-existing testing 
techniques to the analysis of complex matrices such as meconium. False negative results must 
also be considered when adapting a pre-existing extraction technique to a new matrix. Many of 
the extraction techniques employed for the confirmation testing of drugs in meconium have been 
directly adapted from pre-existing blood assays. Inappropriate or inefficient extraction of drugs 
from meconium can result in a negative confirmation result through analyte loss.  
Although many studies involving the detection of drugs of abuse in meconium by way of 
immunoassay techniques appeared in the literature in the late 1980s and early 1990s, it was not 
until 1995 that the issue of false-positive and false-negative rates was addressed by Moore et al. 
from the US Drug Testing Laboratories in Chicago. Moore and coworkers investigated the rates 
of both false-negative confirmation results arising from inefficient extraction of drugs, and false-
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positive results arising from screen-only testing[275]. Experiments were aimed at determining 
whether differences exist between published screening procedures and to determine whether 
reporting screen-only data is reliable and acceptable. The authors compared three published 
procedures for the determination of abused drugs in meconium to determine the false-negative 
rates associated with various screening methods. Following this, additional experiments were 
performed with the aim of calculating the rate of false-positives by determining the actual 
number of immunoassay screen-positive samples which were subsequently confirmed negative 
by GC-MS. False-positive rates were investigated to assess the accuracy of screen-only results 
which are often the only results generated by hospital laboratories. The use of screen-only results 
for decision making is unethical and in the case of meconium analysis, can have devastating 
consequences not only for mothers, but also for children and other family members [275]. 
Although all negative specimens were correctly screened negative, results indicated that the three 
screening techniques differed substantially in their ability to detect the drugs of abuse in pre-
determined positive samples. Only 19.6% of the positive samples were identified using one 
method while the remaining two methods had success rates of 54.5%, and 100%. Results 
indicate that considerable time and effort is required during method development and 
optimization to minimize the potential for false-negative screen results. Experiments aimed at 
determining the rate of false-positives illustrated the importance of confirmation testing as only 
53.3% of samples which screened positive were subsequently confirmed positive, indicating a 
false-positive rate of 46.7%[275]. The greatest discrepancies between screen and confirmation 
data occurred with the amphetamine drug class in which only 25.7% of positive screens were 
confirmed positive by GC-MS. Of the 228 specimens that screened positive for cocaine 
metabolites, only 59.2% were confirmed positive. The opiate drug class had a similar false-
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positive rate with 56.7% of positive screens confirming positive[275]. To some degree, high 
false-positive results can be attributed to the presence of various over the counter (OTC) and 
prescription medications which contain cross-reacting substances, however, confirmation testing 
to distinguish these compounds from drugs of abuse is essential to make ethical and accurate 
decisions[275].  
The suitability of immunoassay screening kits for the detection of drugs of abuse in 
meconium was also investigated by ElSohly and coworkers in 1999[243]. The authors aimed to 
develop and validate methods for meconium sample preparation prior to screening and 
confirmation testing while simultaneously evaluating the suitability of two different 
immunoassays for the purpose of screening for various drugs of abuse in meconium[243]. 
Experiments involved subjecting ninety five meconium specimens to the screening procedures 
and confirming any presumptive positives using GC-MS to determine the rate of false-positives. 
False-negative rates were also investigated by subjecting seventy meconium specimens for each 
drug class to confirmation analysis regardless of screening results. While immunoassay 
technologies did not generate any false-negative results, rates of false-positives were again 
alarming and ranged from 15% for opiates, to 100% for amphetamines[243]. The authors 
highlight the importance of carrying out GC-MS confirmation of positive screens prior to 
reporting results due to the high rate of false-positives.  
Rates of false-positive results in authentic meconium specimens were also monitored at 
AIT Laboratories (Indianapolis, IN) for the cocaine and amphetamine drug classes. Following 
the implementation of UPLC-MS/MS methodologies for meconium confirmation analysis (see 
chapters 5 & 7), the rate of false-positives was monitored over an eight month period 
(07/01/2008 – 03/01/2009). All specimens were screened using ELISA and the false-positive rate 
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was determined by calculating the percentage of positive screens that were subsequently 
confirmed negative. During the eight month time period a total of 4036 meconium specimens 
were screened for amphetamines and cocaine. Of the 303 samples that screened positive for 
cocaine/benzoylecgonine, 71 were confirmed positive representing a false-positive rate of 76%. 
Of the 138 samples that screened positive for amphetamines, only 37 were confirmed positive 
representing a false-positive rate of 73%.  
Based on results from the reported studies investigating the suitability of immunoassays 
for the purpose of screening meconium, it is evident that reporting screen-only results is both 
unethical and inaccurate due to the high rate of false-positive results. False-positive results not 
only complicate decision making processes for health care professionals, they also result in 
additional costs for the toxicology laboratory through unnecessary confirmation analysis. While 
the confirmation analysis is of extreme importance in the case of false-positives, such testing 
requires expensive reagents for suitable sample preparation and additional expenses associated 
with labor. Confirmation analysis is an expensive procedure for laboratories utilizing state of the 
art technologies such as LC/MS/MS for the purpose of providing enhanced sensitivity. 
Traditional confirmation techniques such as GC-MS require substantial sample preparation such 
as liquid-liquid or solid phase extraction of the drug from the meconium matrix, purification of 
the extract, and derivatization of the analyte, all of which require expensive chemical reagents. In 
addition to the cost of reagents, sample extraction and preparation prior to instrumental analysis 
can be very labor intensive consuming both time and labor costs for the toxicology laboratory.  
False-positive results associated with immunoassays are inevitable due to the inferior 
selectivity associated with the technique and the complexity of the biological samples being 
analyzed. Laboratories employing confirmation testing for the purpose of unequivocally 
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identifying the drug of interest recognize the potential for false-positives, however, the ability of 
immunoassays to screen out a large majority of negative samples in a cost effective manner 
somewhat offsets this disadvantage. High throughput production laboratories view immunoassay 
screening kits as a cheap, quick, reliable and effective way to screen biological samples for drugs 
of abuse, however, the potential for high rates of false-positive results means that laboratories 
must carefully monitor the time and cost associated with performing such assays. From a 
production standpoint, there is little value in dedicating resources to performing immunoassay 
screening tests that generate a large number of false-positive results requirin expensive 
confirmation testing.  
While it is widely accepted that screen testing will never possess the selectivity of 
confirmation analysis, laboratories must continue to monitor the effectiveness of screening 
techniques with respect to their intended purpose. An immunoassay screen test generating a 
100% false-positive rate is obviously not serving its purpose as an effective way to screen 
samples, and careful monitoring of the costs associated with avoidable confirmations relative to 
the effectiveness of the screen will allow the laboratory to assess the overall value of the 
technique. 
Sample preparation prior to immunoassay analysis can be laborious depending on the 
specific screening technique, the analyte of interest and the biological matrix in which it exists. 
ElSohly et al. proposed a procedure for the preparation of meconium extracts for immunoassay 
analysis[243]. The authors investigated several procedures for the extraction of drugs from the 
meconium matrix prior to immunoassay analysis. Many of these methods were deemed to be 
inefficient, inconsistent, impractical, or generally problematic and therefore useless for 
meconium extractions[243]. Reduced sensitivity, maximal background signals leading to invalid 
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results, low recoveries, and colored extracts unsuitable for analysis were some of the problems 
encountered throughout investigations into multiple sample preparation techniques. The final 
extraction method was developed based on the observations from previous trials and is outlined 





Figure 41: Proposed procedure for the preparation of meconium extracts for immunoassay 
analysis (Adapted from ElSohly et al., 1999). 
 
The procedure proposed by ElSohly and coworkers for the preparation of meconium extracts for 
immunoassay analysis is laborious and a represents a significant sample work up. The 
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performance of an immunoassay test requiring such extensive sample preparation should be 
monitored closely to ensure that unnecessary confirmations as a results of false-positives are 
minimal. The value of an immunoassay screening test which requires significant sample 
preparation and generates a large number of false-positives is arguably negligible, and 
investigations into alternate screening techniques more suited to the analysis at hand may prove 
beneficial for laboratories experiencing this problem.  
Commercially available immunoassay screening kits are designed for the detection of 
drugs in blood and/or urine and care must be taken when adapting such methodologies to 
alternate matrices. Alternate toxicology samples such as amniotic fluid, tissue, fly larvae, and 
meconium are complex biological matrices rich in interfering species of both endogenous and 
exogenous origin. The suitability of immunoassay based testing for such specimens must be 
carefully evaluated as the potential for false-positive results will be much higher in the complex 
matrix. More alarming than the possibility of false-positive results which generate additional 
costs for the toxicology laboratory is the possibility of false-negative results.  
False-negative results arise when screening kits are unable to detect a drug of interest, 
and can arise due to matrix complexity or sensitivity issues. False-negative results are a major 
concern for toxicology laboratories as testing is normally discontinued following a negative 
screen. In the case of a false-positive, subsequent confirmation testing utilizing mass 
spectrometry will indicate the true absence of the drug, however, in the case of a false-negative, 
there is no confirmation test. Following a negative screen, specimens are simply reported 
negative and discarded following a standard storage period. As a result, laboratories must ensure 
that screening techniques employed for the purpose of identifying drugs of abuse are suitable for 
the analysis at hand. While false-positive results generate additional costs for the laboratory 
207 
 
through unnecessary confirmation testing, false-negatives mean that drug use goes undetected. In 
the case of meconium specimens, false-negative results mean that maternal drug use goes 
undetected and the drug-exposed child is denied the treatment and care that is normally provided 
following authoritative intervention in such cases.  
Due to the increasing utilization of alternate toxicological specimens for the 
determination of drugs of abuse, the use of alternate screening techniques more suited to such 
complex biological matrices must be investigated. Immunoassay based technologies are likely to 
generate higher rates of false-positives when used for the analysis of more complex species due 
to the lack of selectivity associated with the technique. As the number of endogenous interfering 
species in the matrix increases, the accuracy of the immunoassay is likely to decrease as the 
inferior selectivity of the technique will be exploited to a greater extent than with traditional 
blood or urine based specimens. The use of mass spectrometry for screening purposes would 
alleviate many of the problems associated with immunoassay based techniques by affording 
inherent selectivity and eliminating the possibility of false-positive results.  
8.2.4  Mass Spectrometry as a Screening Tool 
Investigations into the use of mass spectrometry as a screening tool for drugs of abuse in 
biological specimens date back to the late 1970s. Thompson described one of the earliest GC-MS 
methodologies developed as a screening tool for the detection of anticonvulsant drugs in 
urine[276]. Sample preparation involved evaporating a small aliquot of urine (50-200 µL), and 
permethylating the residue with methylsulfinylmethide carbanion and methyl iodide. Product 
mixtures were resolved using GC allowing the authors to identify drug metabolites, mono-, di-, 
and trisaccharides, and organic acids, including fatty acids and glucuronides based on mass 
spectral data.  
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Wilson and coworkers described a GC-MS methodology employing chemical ionization 
mass fragmentography for the purposes of simultaneously identifying seven secondary and 
tertiary tricyclic antidepressants in plasma[277]. Sample preparation involved a one step liquid-
liquid extraction into hexane which was subsequently injected onto the chromatograph. The 
authors present the methodology as a suitable technique for monitoring therapeutic 
concentrations and for screening plasma samples in suspected overdose cases where the drug of 
abuse has not been identified.  
In 1980, Dugal et al detailed the methodological aspects of a computerized system for the 
gas chromatographic screening and primary identification of several CNS stimulants and 
narcotic analgesics in human urine[278]. Sample preparation involved a relatively simple liquid-
liquid extraction followed by sample derivatization. Analytes were screened using selective 
nitrogen detection. The authors conclude that the methodology is suitable for the purposes of 
screening several drugs and their respective metabolites in a short amount of time.  
Broad based screening methodologies utilizing gas chromatography coupled to one of 
several detection systems continued to appear in the literature in the years following this early 
work. The vast majority of methodologies employed mass spectrometry for the purpose of 
unequivocally identifying analytes based on EI fragmentation patterns and library matching. 
While GC-MS methodologies offer fast analysis times and mass spectrometric detection for the 
screening of acidic, basic, and neutral compounds, and sample preparation can prove laborious 
and reduce the overall effectiveness of the screening technique.  
Due to the nature of the column packing in gas chromatographs, samples must be 
introduced onto the column in an organic solvent of minimal polarity. Many methodologies 
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described in the literature satisfied this requirement by buffering the sample matrix with a base 
and extracting basic analytes into organic solvents suitable for direct injection. In addition, many 
compounds are too polar and/or do not possess sufficient volatility for direct GC-MS analysis. 
To alleviate such problems, many compounds must be chemically derivatized prior to GC-MS 
analysis. Sample derivatization is performed to decrease the polarity and/or increase the 
volatility of an analyte which does not naturally lend itself to analysis by GC-MS. The 
incompatibility of GC-MS with aqueous solvents combined with the need for chemical 
derivatization complicates sample preparation and means that significant sample 
preparation/clean up is required to simply screen the specimen. While sample preparation for 
broad based GC-MS screening can be laborious due to the nature of the chromatographic system, 
the advantage of obtaining mass spectral screening data often offsets this disadvantage. As a 
result, many laboratories employ GC-MS for the purpose of screening for general unknowns. 
Figure 42 describes a typical sample preparation procedure for a broad based GC-MS screen. 
 
Figure 42: Extraction flow chart for a broad based GC-MS screen. 
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Investigations into the use of LC-MS and LC-MS/MS for the purpose of general unknown 
screening began to appear in the scientific literature in the early 1980s. One of the earliest reports 
described the use of a triple quadrupole mass spectrometer for the rapid screening and 
confirmation of up to fifty analytes in a single sample of equine blood, serum, and urine in less 
than two minutes[279]. The enhanced sensitivity afforded by the tandem mass spectrometer 
enabled the authors to achieve detection limits in the ng/mL to µg/mL range for most analytes. 
The authors conclude that the use of LC-MS/MS technology for the purpose of screening 
provides a fast, sensitive technique for the accurate determination of selected drugs and 
metabolites in blood urine and serum.  
Chromatographic resolution is not always necessary when employing mass spectrometry 
for the purpose of screening, provided the instrument possesses the capability to operate in SIM, 
SRM, or MRM mode. As a result, technologies such as GC/MS and LC/MS/MS have the 
capability to simultaneously screen for large numbers of drugs without the need for baseline 
resolution by monitoring selected ion transitions. Monitoring the presence or absence of 
compounds based on an ion trace rather than retention time means that rapid chromatographic 
separations are possible as extracted ion traces provide accurate qualitative data even in cases of 
chromatographic co-elution. Mass spectrometers coupled to liquid chromatographs offer 
additional advantages over GC/MS technologies as aqueous extracts of biological samples can be 
analyzed directly due to the column chemistry of the separation and the sophisticated nature of 
the LC/MS interface.  
The ability of LC/MS and LC/MS/MS technologies to simultaneously screen for large 
numbers of drugs following minimal sample preparation and rapid LC separation was the driving 
force for the large number of methodologies appearing in the literature in the following years. 
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The majority of methods described rapid, broad based screens for drugs of abuse in biological 
samples. In 1987, Straub and coworkers described the use of tandem mass spectrometric 
techniques for the purpose of rapid structural elucidation and metabolite quantification in 
complex sample matrices[280]. The authors report the ability of tandem mass spectrometers to 
serve as separation devices as well as tools for structural elucidation. Studies employed 
desorption ionization techniques and primary metabolites along with drug conjugates were 
identified using an appropriate combination of neutral loss and precursor ion scans[280]. Jones 
and colleagues from the facility of advanced instrumentation employed tandem mass 
spectrometry for the purpose of screening mercapturates in urine following ionization in the 
negative ion mode[281]. The authors employed neutral loss scanning to screen urine samples for 
the presence of mercapturates in the low nanogram per milliliter range. Identifications were 
made based on the simple daughter ion spectra of the deprotonated molecular ions. In the same 
year, Brzezinka and colleagues also employed the neutral loss scanning mode of a tandem mass 
spectrometer for the purpose of screening serum samples for the presence of barbiturates[282]. 
Subsequent confirmation testing and quantification was performed using MRM and limits of 
detection were reported to be better than one microgram per milliliter for most analytes.  
Weinmann and Svoboda employed solid phase extraction followed by flow injection 
analysis (FIA) with ionspray-ionization and tandem mass spectrometry for the simultaneous and 
quantitative screening of illicit drugs in serum and urine[283]. Experiments were performed on 
an API 3000 triple quadrupole instrument and MS/MS analysis was performed by sequentially 
isolating the precursor ions of the analytes and their deuterated standards with subsequent 
fragmentation and monitoring of one fragment ion for each substance[283]. The authors 
conclude that the increased speed, sensitivity, selectivity, and accuracy afforded by the tandem 
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mass spectrometer offers many advantages over traditional screening methodologies for the 
simultaneous determination of different drugs and metabolites in biological samples. Nordgren 
and co-authors evaluated the usefulness of LC-MS/MS for the purpose of screening urine 
samples for the designer amphetamines MDA, and MDMA[284]. Qualitative identifications 
were based on the detection of selected positive ions following APCI and studies were performed 
to assess the accuracy of the technique compared to immunochemical methodologies. Studies 
involved the analysis of 1000 clinical patient samples of which the LC-MS/MS methodology 
was able to identify four times as many positive samples as the immunochemical technique. The 
authors conclude that LC-MS/MS offers an attractive alternative to immunochemical techniques 
for drugs of abuse screening[284].  
In 2004, Eichhorst and colleagues published one of the earliest studies aimed at directly 
comparing LC-MS/MS with more traditional screening techniques such as GC-MS and ELISA 
for the purpose of detecting methylphenidate in urine samples[285]. The use of LC-MS/MS for 
screening urine samples was investigated in the hope of replacing less reliable, more expensive, 
and time consuming screening techniques such as GC/MS with a combined one-step screening 
and confirmation LC-MS/MS method. Implementation of the rapid LC-MS/MS method enabled 
the authors to achieve enhanced sensitivity, selectivity and reliability while simultaneously 
reducing the cost per sample.  
In 2005, Mueller and co-workers described a broad based multi-target screening (MTS) 
procedure for the detection of over 300 forensically relevant drugs in blood and urine using a 
hybrid triple-quadrupole linear ion trap mass spectrometer (QTrap)[197]. This was one of the 
earliest studies employing the various scanning capabilities of a tandem mass spectrometer for 
the purpose of screening such a large number of drugs in a single LC-MS/MS run. A multiple 
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reaction monitoring (MRM) scan and an enhanced product ion (EPI) scan were performed in an 
information-dependant acquisition (IDA) experiment. The MRM survey scan contained 298 
transitions for the 301 selected substances and three deuterated internal standards. In order to 
perform the EPI scan, Q3 was used as a linear ion trap to scan product ions. Drug identification 
was carried out by a library search with a newly developed MS/MS library based on EPI 
spectra[197]. Authors conclude that the developed methodology is useful for the rapid detection 
or exclusion of over 300 drugs in a blood, plasma, or serum extract. Limitations to the 
methodology include the cycle time required to perform both MRM and EPI experiments and 
multiple collision energies and the limited number of data points obtained across 
chromatographic peaks with 5ms dwell times.  
Nordgren and coworkers also employed a triple quadrupole mass spectrometer to 
simultaneously screen for 23 analytes in urine samples by monitoring the presence or absence of 
a single ion transition in the multiple reaction monitoring mode[286]. In a study of 3000 human 
urine samples, the methodology correctly identified the presence of at least one substance 65% 
of the time. Authors conclude that while the LC-MS/MS methodology offers a sensitive, robust 
alternative to more traditional screening techniques, future studies should consider incorporating 
additional ion transitions into the criteria for a positive result to decrease the number of false 
positive results obtained when monitoring only a single transition. Allen and coworkers 
investigated the usefulness of LC-MS/MS for the purpose of screening oral fluid samples for 
opiates, cocaine, methadone, and benzodiazepines and directly compared the method with the 
pre-existing ELISA method[287]. Individual analytes were again identified using multiple 
reaction monitoring and analysis of 72 patient samples indicated that the LC-MS/MS method 
compares favorably with the more traditional immunoassay based techniques. The authors 
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conclude that the tandem mass spectrometric method offers a more flexible, selective and 
sensitive alternative for screening oral fluid samples than ELISA due to the large number of 
individual drugs and metabolites that can be detected from a single sample injection.  
In the years to follow, several reports appeared in the literature describing the use of 
tandem mass spectrometers; mainly triple quadrupoles and quadrupole – ion trap hybrids 
(QTrap), for the purpose of screening large numbers of drugs and metabolites in biological 
specimens[168, 170, 183, 288-291]. Several research groups investigated the applications of 
exact mass measurements for the purposes of forensic drug screening [292-294]. Studies 
involved the use of time-of-flight (TOF) mass spectrometry coupled with either LC or UPLC for 
the purpose of measuring exact mass. While the exact mass measuring capabilities of TOF mass 
spectrometry have long been utilized in new drug discovery and ADME studies, several early 
reports describing the use of TOF for forensic drug screening indicate the widespread 
applicability of the technique for general unknown screening. Time of flight mass spectrometry 
provides high resolution exact mass measurements while minimizing both sample preparation 
time and cost of analysis when compared to GC/MS or ELISA technologies. Development of 
analyte libraries based on exact mass and retention time provides the analyst with a powerful 
technique for the purpose of general unknown screening. Screening techniques based on triple 
quadrupole technologies such as TQDs or QTraps only possess the capability to screen for 
analytes which exist in a predetermined MRM library. This is due to the fact that MRM studies 
must first be performed on standard materials to identify characteristic fragmentation patterns 
suitable for analyte identification. Once the information has been experimentally determined, 
parameters can be incorporated into the pre-existing MS/MS method to screen for the new 
analyte. Addition of new analytes to pre-existing TQD or QTrap methodologies directly affects 
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sensitivity as dwell times must be minimized to obtain sufficient data points across 
chromatographic peaks. While screening technologies based on TOF mass spectrometry may 
also utilize analyte library searches for the purpose of analyte identification, additional analytes 
which do not exist in the library may be identified based on exact mass. While analyte 
identifications based on LC-TOF or UPLC-TOF are generally made based on a combination of 
retention time and exact mass, qualitative data based solely on exact mass can be extracted post-
run from data which has already been analyzed.  
Over the past twenty years, the potential applications of mass spectrometry as a screening 
tool have been investigated by many research groups. While the vast majority of methods have 
utilized triple quadrupole technologies or hybrid tandem mass spectrometers, recent studies has 
paved inroads into the use of alternate mass spectrometric methods requiring minimal sample 
preparation and little, if any, chromatographic separation. Mass spectrometric techniques 
requiring minimal sample preparation and no chromatographic separation will undoubtedly be 
the subject of rigorous future research efforts as the potential to reduce analysis time and 
increase the number of samples screened per unit time offers many advantages for high 
throughput toxicology laboratories. 
8.2.5 Principles of Desorption Electrospray Ionization (DESI) 
Desorption electrospray ionization allows ambient sampling for mass spectrometric 
analysis by using an electrospray of aqueous droplets which act to desorb analytes from a surface 
of interest. Analyte leaves the surface of interest entrained in small, progeny droplets (solvated) 
which subsequently evaporate resulting in analyte ion production.  Desorbed gas-phase ions are 
then transferred to a mass spectrometer through an atmospheric pressure ion-transfer tube[263]. 
DESI is a multistep process which is initiated by producing primary charged droplets through an 
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electrospray source. Primary droplets are then projected toward the surface of interest where they 
collide and produce smaller droplets through collision-induced breakup. Secondary charged 
droplets, which are produced during this interaction, are then transported, along with ablated 
materials and free ions, through an atmospheric pressure interface and into a mass spectrometer 
(Figure 39)[295].  
DESI eliminates the need to introduce the sample into a region of vacuum or an 
inaccessible region closely coupled to a vacuum system meaning that the sample can be moved 
continuously or reoriented in space while collecting mass spectral data[263]. As previously 
mentioned, DESI experiments combine features of ESI with those of desorption ionization 
methods such as MALDI. An electrospray emitter, similar to those employed in traditional ESI 
experiments, is used to generate gas phase solvent ions, ionic clusters, and charged microdroplets 
which are directed as the surface of the sample. Several kilovolts of electrical charge are applied 
to the spray solution and pneumatic nebulization is used to assist with solvent desolvation. 
Electrosprayed microdroplets of the aqueous spray solution, normally containing additives which 
ensure maximal analyte ionization, act as projectiles and subsequently generate gas-phase ions 
when directed at the surface of interest through electrostatic and pneumatically assisted 
desorption mechanisms[263, 264]. The interaction of the spray with the surface of interest results 
in the ionization of analytes present on the sample exterior.  
Analyte ions are then transported from ambient pressure conditions into a standard 
atmospheric pressure interface mass spectrometer[295]. The interrogating solution often consists 
of a water-alcohol mixture but may be modified with reagents such as acids or bases to enhance 
analyte ionization[295]. This spray solution is then electrohydrodynamically nebulized and 
directed at the surface of interest[295]. Unlike electrospray ionization (ESI) where the sample is 
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dissolved in the spray solvent, analytes to be analyzed using DESI are present in solid materials 
or liquids which have been deposited onto suitable surfaces allowing for direct analysis without 
the need for extensive sample preparation[295].  
The DESI spray solvent is an extremely important variable which can significantly affect 
the intensity and stability of analyte signal. Spray solvent composition requires careful 
consideration during method development as analytes must be somewhat soluble in the spray and 
its composition must be such that adequate droplet desorption can occur[296, 297]. Manicke and 
coworkers investigated the effect of spray solvent composition on signal intensity and stability 
by directing various sprays at a sample surface and monitoring the resultant ion current for the 
molecular ion. The authors directly compared five spray solvents comprised of different 
proportions of water and methanol[298]. The authors discovered that signal decay occurred more 
slowly with time as the proportion of water in the spray solvent increased. The increased rate of 
signal decay when using higher proportions of organic solvent can be attributed to the higher 
solubility of the analyte in the spray. In the presence of increased methanol content, more analyte 
is likely to be soluble in the spray leading to more efficient desorption from the surface and 
maximum ion signal. Increased sample solubility in the methanol rich solvent leads to maximum 
signal intensity at early time points with subsequent large decreases in signal due to depleted 
analyte concentrations at the exterior of the sample[298]. Maximum signal intensities were not 
significantly different for spray solvents consisting of 100% methanol, 75% methanol, and 50% 
methanol suggesting that additional factor others than analyte solubility are responsible for 
maximal desorption from the sample surface. This is in fact the case as increases in the organic 
component of the spray causes changes in solvent properties which work to negate the effect of 
increased analyte solubility. An example of these phenomena is the effect which increasing 
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organic solvent has on spot size which represents the area of analyte that is sampled. As the 
concentration of methanol increases, the spot size and therefore the area of analyte sampled 
decreases due to the lower surface tension of the liquid. Experiments also indicate that when the 
amount of water in the spray solvent exceeds 50% there is a significant decrease in the maximum 
signal intensity. This is consistent with the theory that the analyte will be less soluble in the 
aqueous spray, however, poor droplet desorption due to unfavorable viscosity may also 
contribute to decreased signal intensity[298]. The authors conclude that a 1:1 methanol/water 
(vol/vol) solution typically provided the best combination of signal intensity and stability for the 
analytes of interest[298].  
The exact composition of the solvent spray can be varied significantly depending on the 
analytical application of the experiment. Spray solvents consisting of high water content are 
often employed for MSn experiments which require more stable, longer lasting signal to 
complete mass spectral data acquisition. Similarly, high contents of methanol may be 
incorporated into the spray solvent for DESI experiments requiring high spatial resolution, such 
as molecular imaging. Spray solvents with higher fractions of methanol are more suited to such 
analyses as the high organic content reduces the spot size and provides greater spatial 
resolution[298]. Physical characteristics of the spray have also been investigated using phase 
Doppler anemometry (PDA) and experiments indicate that droplet sizes average 2-4 µm, and at a 
distance of 2 mm from the spray source, velocities range between 100-200 ms-1[295, 297].  
Venter and coworkers employed PDA for the purpose of determining the size and 
velocities of droplets involved in DESI experiments to further understand the likely ionization 
mechanisms behind the technique[295]. In contrast to desorption techniques which involve the 
production and acceleration of particles in the vacuum region of a mass spectrometer, such 
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massive cluster bombardment (MCI), droplet impact/secondary ion mass spectrometry (EDI), 
and secondary ion mass spectrometry (SIMS), DESI occurs at atmospheric pressure. Ionization 
mechanisms are therefore likely to be very different to vacuum techniques as fast moving 
droplets will be slowed by aerodynamic drag forces due to their interaction with surrounding gas 
molecules[295]. It is for this same reason that DESI if finding an increasing number of 
applications in the forensic and clinical toxicology laboratory.  
Samples analyzed by DESI are done so in the open environment of the laboratory which 
enables easy access during analysis for manipulation or higher throughput. Samples are also 
analyzed directly with little to no sample preparation, further alleviating problems associated 
with sample preparation for traditional instrumental analysis. While investigating the physical 
properties of droplets generated in DESI experiments, Venter and coworkers note that the kinetic 
energies per impacting water molecule are quite low and indicate that sputtering through 
momentum transfer during collisions or ionization via alternate electronic processes is 
unlikely[295]. The authors evaluate the validity of several proposed ionization mechanisms 
including droplet pick-up, chemical sputtering, evaporation followed by gas-phase ionization, 
and shockwave ionization by measuring the size and velocities of both inbound electrosprayed 
droplets and droplets leaving the sample exterior. Experimental evidence acquired throughout the 
study indicates that the droplet pick-up model may be the major process leading to the ionization 
of analytes during DESI experiments. The droplet pick-up model is believed to take place during 
the brief contact time that exists when impinging droplets collide with the sample surfaces and 
analytes are extracted into the departing droplet or droplet fragments. Following the salvation of 
condensed phase analytes by impinging droplets, typical electrospray ionization processes are 
thought to occur[295]. 
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The DESI ion source is comprised of two main parts, the sprayer assembly and the 
surface assembly which are both mounted on the base of the ion source (Figure 43).  
 
Figure 43: Schematic representation of the DESI ion source illustrating geometric parameters α 
(incident angle), β (collection angle), d1 (tip-to-surface distance), and d2 (MS inlet-to-surface 
distance) (Adapted from Takats et al. 2005). 
 
The sprayer is mounted to, and controlled from, a vertical rotating stage which is mounted onto a 
three dimensional linear moving stage. Linear motion is used to modify the sprayer-to-MS or 
sprayer-to-surface distance and to compensate for the different angles at which the sprayer is 
used[264].  
Parameters associated with the geometry of the ion source, the solvent spray, and the 
sample surface, all affect the analytical performance of DESI and each require consideration and 
optimization during method development. Of greatest importance are the geometric parameters 
(α, β, d1, d2; Fig 45), gas and liquid flow rates, voltages, solvent composition, deposition solvent, 
and surface composition, temperature, and potential[264]. The geometric parameters, α, and d1 
have a direct effect on the efficiency of the ionization process, while parameters, β and d2 have 
important effects of the collection efficiency, and therefore the sensitivity of the method. Cooks 
and coworkers indicate that the optimal settings for β and d2 are generally 5-10° and 0-2 mm, 




respectively[264]. Generally, low d1 values are preferred and are normally combined with large α 
values, although a dramatic increase in chemical noise is observed when α exceed 80°[264].  
The design of DESI instruments is complicated by the challenge of providing efficient 
ion transfer from the ion source to the fore vacuum region of the mass spectrometer without 
modifying the pumping capacity of the vacuum system[264]. Metal capillaries are most widely 
employed for the transfer of ions to the mass spectrometer as capillaries containing insulators can 
experience significant charge buildup on the inner surface resulting in poor ion transmission. 
While metal capillaries do not experience this same phenomenon, extensive neutralization of 
analyte ions can occur which leads to poor transmission efficiencies. 
Spectral characteristics of DESI are very similar to those of ESI in that spectra feature 
multiply charged ions, adducts, complexes, and abundant protonated molecular ions. Strong 
similarities between the two techniques are attributed to the similarities in the latter stages of ion 
formation. The drop pick-up ionization mechanism thought to occur in DESI experiments 
assumes that following analyte solvation by impinging droplets, analyte is incorporated into 
droplets and ionization occurs via traditional ESI mechanisms involving analyte-containing 
charged droplets[264].  
8.3 Experimental 
8.3.1 Chemicals and Reagents 
All drug standards and deuterated internal standards (1mg/mL in methanol) were 
obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported liquid-liquid 
extraction columns were purchased from Biotage (Charlottesville, VA). All solvents were HPLC 
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grade and obtained from Fisher Scientific (Pittsburgh PA). All DESI experiments were 
performed using Omni Slides™ from Prosolia (Indianapolis, IN). 
8.3.2 Electrospray Solvent Preparation 
 The spray solvent used for all experiments was an acetonitrile/water (80:20) mixture 
containing 0.1% (v/v) formic acid. 
8.3.3 DESI Source and Mass Spectrometry Conditions 
All experiments were performed on the Thermo TSQ Quantum Discovery MAX triple 
quadrupole mass spectrometer equipped with the Omni Spray® ion source (Prosolia, Inc., 
Indianapolis, IN). Omni Spray® ion source operating parameters were as follows: Nitrogen was 
used as the nebulizing gas and was applied to the spray head at a regulated pressure of 125 psi. 
The solvent was sprayed under the influence of 5 kV at a flow rate of 5 µL/min. The gas jet was 
composed of electrosprayed aqueous microdroplets, and free gas-phase ions were directed onto 
the surface at an incident angle of 55° to the normal. The vertical distance from the end of the 
solvent capillary to the top of the disposable surface was 2 mm. The inlet of the mass 
spectrometer was maintained at a temperature of 300°C. Total analysis time for each sample was 
approximately 13 seconds with a surface scan rate of 200 µm/s. 
8.3.4 Sample Preparation 
All samples were spotted directly onto Omni Slides™ using a 2µL Eppendorf pipette. 
Samples were left to dry under ambient conditions and analyzed directly using the DESI source. 
8.3.5 DESI Analysis of Standards 
Preliminary DESI experiments involved the analysis of amphetamine, methamphetamine, 
cocaine, benzoylecgonine, morphine, codeine, and hydromorphone standards (1mg/mL in 
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methanol) for the purpose of developing and optimizing mass spectrometric conditions. The 
DESI-MS/MS instrument used for all experiments is analogous to the triple quadrupole 
instrument described previously except that the electrospray ionization source is replaced by the 
DESI source which allows for ambient sampling. Precursor ions for MRM experiments are first 
generated by the DESI source before entering the vacuum region of the triple quadrupole mass 
spectrometer where they undergo collision induced dissociation in Q2 while Q1 and Q3 are used 
as mass filters. In order to develop and optimize the MS/MS method, drug standards (1mg/mL in 
methanol) were spotted onto Omni Slides™ and analyzed directly. These preliminary studies are 
analogous to infusion experiments using the ESI-MS/MS in which the collision gas is turned off 
to allow the precursor ions generated by the DESI source to reach the detector and produce a 
recordable signal. Precursor ions for all seven analytes were protonated molecular ions generated 
by the soft DESI technique (Table 55).  
Following identification of the molecular ion signal, an auto tune was completed for each 
analyte which involved adjusting collision energies to maximize the signal for the product ions 
generated in the collision cell. The mass transition from the protonated molecular ion [M+H]+ to 
the most abundant product ion was designated the qualifying ion transition and was used for all 
positive identifications (Table 55). Following auto tuning of each analyte, the optimized 
parameters were used to construct the MS/MS method which was then used to acquire data in the 
MRM mode. Table 55 reports the mass transitions, collision energies and tube lens voltages for 





Table 55: Optimized MS/MS parameter employed for all DESI experiments. 
Analyte Parent mass (m/z) Product ion (m/z) Collision energy (V) Tube lens (V)
Amphetamine 136 91 26 82 
Methamphetamine 150 91 22 81 
Cocaine  304 182 30 128 
Benzoylecgonine  290 168 79 118 
Codeine  300 165 30 128 
Morphine  286 152 20 124 
Hydromorphone  286 185 24 134 
 
 Figure 44 shows the mass spectral responses for all seven analytes which were spotted in 
consecutive channels of the Omni Slide™.  
Figure 44: Mass spectral responses for all seven analytes using DESI-MS/MS. 
 
RT: 0.00 - 1.68 SM: 3G




































































































TIC F: + c NSI SRM ms2 
136.000 [86.000-96.000]  MS  
ICIS 062308-standards 1
NL: 1.30E5
TIC F: + c NSI SRM ms2 
150.000 [86.000-96.000]  MS  
ICIS 062308-standards 1
NL: 7.52E6
TIC F: + c NSI SRM ms2 
304.000 [177.000-187.000]  
MS  ICIS 062308-standards 1
NL: 2.45E6
TIC F: + c NSI SRM ms2 
290.000 [163.000-173.000]  
MS  ICIS 062308-standards 1
NL: 3.75E5
TIC F: + c NSI SRM ms2 
300.000 [160.000-170.000]  
MS  ICIS 062308-standards 1
NL: 3.52E5
TIC F: + c NSI SRM ms2 
286.130 [147.000-157.000]  
MS  ICIS 062308-standards 1
NL: 6.31E5
TIC F: + c NSI SRM ms2 
286.270 [180.000-190.000]  










In order to determine the suitability of the DESI-MS/MS method for the analysis of authentic 
meconium specimens, several spiked samples were prepared and analyzed.  
8.3.6 Direct Analysis of Spiked Meconium Specimens 
Several meconium specimens which had undergone no sample preparation other than the 
initial homogenization step were spiked with appropriate analytes and analyzed directly using the 
DESI-MS/MS method. Experiments aimed to investigate the suitability of the DESI-MS/MS 
method for the direct analysis of meconium specimens having undergone minimal sample 
preparation. 
8.3.7 Sample Preparation 
Meconium specimens which had previously screened negative at AIT Laboratories 
(Indianapolis, IN) were spiked with varying amounts of analyte to give concentrations 
corresponding to the top point of calibration curves used in previous ESI-MS/MS experiments 
(Table 56). Concentrations were chosen arbitrarily for the purpose of evaluating the sensitivity of 
the DESI-MS/MS methodology. Prior to spiking, sample preparation of the meconium 
specimens was limited to the initial homogenization process required for immunoassay 
screening. Analytes of interest were then spiked directly into the homogenate at appropriate 
concentrations (Table 56). 
Table 56: Analyte concentrations chosen for initial DESI-MS/MS experiments. 
Sample  Analytes Concentration (ng/mL) 
1 morphine, codeine, hydromorphone 500 
2 amphetamine, methamphetamine 500 
3 cocaine, benzoylecgonine 250 




Negative meconium specimens (1 mL) were spiked with appropriate volumes of analyte, 
vortexed and spotted directly onto Omni Slides™. Samples were left to dry under ambient 
conditions and analyzed directly. 
8.3.8 Preliminary Results 
Extremely poor analyte signals were observed for all analytes prepared in the blank 
meconium matrix and analyzed directly (Figure 45). 
Figure 45: Analyte signals following direct analysis of spiked meconium samples. 
 
Preliminary experiments were aimed at evaluating the usefulness of DESI-MS/MS for the 
purpose of screening meconium specimens which had undergone little to no sample pre-
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treatment. While the use of mass spectrometry for screening offers several advantages over 
traditional techniques, sample pre-treatment must be kept minimal in order for the technique to 
prove both time and cost effective. Poor signal intensities (Figure 45) indicated that significant 
matrix effects were likely suppressing mass spectral signal and that further sample clean up 
would be required to achieve the desired screening sensitivity. In order to evaluate the matrix 
effect on signal intensity, DESI spectra of neat drug standards were directly compared to samples 
prepared in blank meconium (Figures 46-48) at the same concentration. Experiments were 
performed by directly spotting neat drug standards on the first four channels of the Omni Slide™ 
and the meconium matrix containing the same concentration of analyte on the last four channels. 
By comparing analyte signal intensities from the neat drug standards relative to the spiked 











Figure 46: Effect of meconium matrix on morphine, hydromorphone, and codeine signal. Mass 
spectral signals for neat drug standards prepared at 500 ng/mL can be seen in channels 1-4 while 
analyte signals for spiked meconium standards containing 500 ng/mL of each analyte can be seen 
in channels 5-8. 
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Figure 47: Effect of meconium matrix on amphetamine and methamphetamine signal. Mass 
spectral signals for neat drug standards prepared at 200 ng/mL can be seen in channels 1-4 while 
analyte signals for spiked meconium standards containing 200 ng/mL of each analyte can be seen 
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Figure 48: Effect of meconium matrix on cocaine and benzoylecgonine signal. Mass spectral 
signals for neat drug standards prepared at 200 ng/mL can be seen in channels 1-4 while analyte 
signals for spiked meconium standards containing 200 ng/mL of each analyte can be seen in 
channels 5-8. 
 
Figures 46-48 clearly illustrate the effect of the complex meconium matrix on the analyte 
signal. While signal intensities were reasonable for all analytes sampled as dilute drug standards, 
signals all but diminished when analytes were sampled at the same concentrations in the 
meconium matrix. The negative effect of the meconium matrix on analyte signal intensity meant 
that additional sample preparation/cleanup was required to achieve the desired screening 
sensitivity. Multiple sample preparation techniques were investigated in the hope that mass 
spectral responses for all analytes could be significantly enhanced without the need for extensive 
sample preparation. 
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8.3.9 Meconium Sample Preparation Method #1 
Meconium specimens employed for all DESI-MS/MS experiments were accurately 
weighed and diluted by a factor of 3 (w/v) with 50:50 methanol/water to assist with the 
sonication procedure required for immunoassay screening. In an attempt to clean up the sample 
and increase sensitivity by eliminating some of the matrix effects, the following sample 
preparation procedure was applied to blank meconium specimens that had been spiked with 
appropriate analytes: 
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile 
2. Vortex sample for 45 seconds 
3. Centrifuge sample for 2 minutes at 3000 rpm 
4. Transfer 500 µL of the organic layer to clean test tube and evaporate to dryness 
5. Reconstitute in 50µL of ACN and spot 2µL directly onto Omni Slide™ for analysis 
Following sample preparation, reconstituted samples were directly spotted onto the surface of the 
Omni Slide™. Resulting analyte signals for the amphetamines and cocaine derivatives can be 




Figure 49: DESI-MS/MS signal for the amphetamines following limited sample preparation 
according to sample preparation method #1. 
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Figure 50: DESI-MS/MS signal for cocaine and benzoylecgonine following limited sample 
preparation. 
 
Signal intensities for both amphetamine and methamphetamine were only marginally enhanced 
following the additional sample cleanup (Figure 49). The combination of precipitating out many 
of the endogenous proteins and concentrating the sample by drying down appears to have 
eliminated some of the matrix components responsible for signal suppression and slightly 
increased sensitivity. While the additional sample cleanup appears to slightly increase the mass 
spectral response for both analytes, the signal to noise (S/N) ratio is still very low making 
identification of the sample spots very difficult (Figure 49). The added step of concentrating the 
analyte has obvious advantages with regard to sensitivity, however, the process of drying down 
and reconstituting can be time consuming and laborious and must be kept minimal, if not 
completely eliminated, during screening procedures. Introducing such steps into screening 







associated with sample preparation. Screening techniques should provide accurate, qualitative 
information without the need for extensive sample preparation. 
Although signal intensities for benzoylecgonine remained very poor (Figure 50), the 
additional sample clean up appears to have significantly enhanced the DESI-MS/MS response 
for cocaine. While sensitivity has long been recognized as a downfall associated with ambient 
pressure ionization techniques, preliminary data reveals yet another complicating factor which 
needs to be addressed when developing and optimizing experimental protocols for DESI. Figures 
49 and 50 clearly illustrate the potential for sample redistribution leading to a continuous analyte 
response over the entire surface of the Omni Slide™. If sample spots remained confined to the 
sample wells on the surface of the Omni Slide™ a distinct number of analyte responses 
corresponding to the number of spotted samples would be observed. The continuous analyte 
response seen in Figure 50 indicates that the meconium matrix may be susceptible to 
redistribution on the surface of the Omni Slide™ leading to indistinguishable sample spectra.  
During initial experiments involving the Omni Slides™, it was repeatedly noted that 
samples prepared in the meconium matrix did not adhere very well to the surface of the slide. 
This observation provides a likely explanation for the sample redistribution seen in Figure 50. 
When meconium based samples are spotted onto the Omni Slide™, they redistribute outside the 
boundaries of the sample channel. In addition to this phenomenon, spray solvents tend to 
dissolve on the surface on Omni Slides™ causing further sample redistribution which can lead to 
cross contamination from one sample channel to the next.  
Poor signal intensities were again observed for codeine, morphine, and hydromorphone 
even following additional sample cleanup. This factor, combined with the significant signal 
235 
 
enhancements noticed for amphetamine, methamphetamine, and cocaine following identical 
sample cleanup, suggest that the poor sensitivities associated with several morphine derivatives 
may be due to limitations of the ionization process itself rather than matrix components causing 
suppression.  
Interestingly, sample redistribution leading to indistinguishable analyte responses did not 
appear to be in issue during the analysis of drugs standards prepared in methanol (Figure 44). 
This observation suggests that a more efficient sample preparation capable of removing 
additional matrix components may reduce the extent of sample redistribution on the hydrophobic 
surface of the Omni Slide™ which can lead to contamination in surrounding sample channels. 
Various techniques for reducing the degree of sample redistribution require investigation, 
however, significant enhancements in sensitivity need first be achieved before the DESI-MS/MS 
methodology can be considered useful for any practical screening applications. Meconium 
sample preparation method #2 was developed for the purpose of increasing sensitivity and 
possibly reducing the degree of sample redistribution. 
8.3.10 Meconium Sample Preparation Method #2 
Preliminary experiments indicate that the removal of complex matrix components 
causing signal suppression will not only increase sensitivity for all analytes but may also 
decrease sample redistribution on the hydrophobic surface of the Omni Slide™ which can lead to 
sample redistribution and indistinguishable analyte responses. In order to evaluate the use of an 
additional filtration step for sample cleanup, sample preparation method #2 was investigated. In 
addition to the protein crash employing cold acetonitrile it was hoped that by filtering the organic 
phase through 0.1µm Durapore PVDF filter units, additional sample cleanup would be achieved 
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leading to greater signal intensities and less sample redistribution. Samples were prepared as 
follows: 
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile 
2. Vortex sample for 45 seconds 
3. Centrifuge sample for 2 minutes at 3000 rpm 
4. Filter organic layer through Durapore PVDF 0.1µm filter units 
5. Spot 2 µL directly onto Omni Slide™ for analysis 
Four sample spots of meconium matrix prepared according to meconium sample preparation 
method #2 were analyzed directly adjacent to neat drug standards (positive control) prepared at 
appropriate concentrations. Positive quality control (QC) specimens had been prepared by 
diluting neat drug standards (1 mg/mL in methanol) to appropriate screening concentrations. 
Experiment were designed to evaluate the usefulness of analyzing positive controls prior to 
scanning authentic patient samples for the purpose of identifying true positive samples through 
direct comparison of analyte responses. Samples were spotted onto the Omni Slides™ according 
to Figure 51. 
 
Figure 51: Previously prepared positive quality control (QC) samples were spotted in the first 




Figure 52 illustrates the analyte responses for a cocaine/benzoylecgonine quality control 
standard prepared at 50 ng/mL spotted in channels 1-2 and analyte responses for a blank 
meconium specimen spiked with cocaine and benzoylecgonine at a concentration of 250 ng/mL 
and spotted in sample channels 3-6. All positive quality control standards were prepared from 
neat drug standards (1 mg/mL in methanol) through serial dilutions.  
 
Figure 52: Sample channels 1-2 represent analyte responses for a cocaine and benzoylecgonine 
quality control (QC) standard (50 ng/mL) while sample channels 3-6 were spotted with spiked 
meconium samples (250 ng/mL). 
 
Cocaine and benzoylecgonine signals appear to have been significantly enhanced using the 
additional filtration step described in sample preparation method #2. The filtration removal of 
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endogenous compounds in the meconium matrix has greatly enhanced the benzoylecgonine 
signal which was undetectable using sample preparation method #1. While the non-linear 
response between the quality control standard (50 ng/mL) and the spiked meconium (250 ng/mL) 
indicates that there is still some degree of signal suppression, the additional filtration step 
appears to have reduced this effect and enhanced overall sensitivity. The additional preparation 
step has also appears to have reduced the degree of sample redistribution. This is evident by the 
distinct analyte responses corresponding to individual sample spots on the surface of the Omni 
Slide™. 
Figure 53 shows the mass spectral response of a cocaine/benzoylecgonine positive 
control prepared at 50 ng/mL and spotted in channels 1-3 and analyte responses for a blank 




Figure 53: Mass spectral responses for a cocaine/benzoylecgonine positive control (50 ng/mL) in 
channels 1-3 and analyte responses for a blank meconium specimen spotted in channels 4-6. 
 
Blank meconium specimens spotted in channels 4-6 were negative for cocaine and 
benzoylecgonine when scanned using the 2 MRM transition MS/MS method.  
Figure 54 shows the mass spectral response of an amphetamine/methamphetamine 
positive control sample prepared at a concentration of 50 ng/mL and spotted in channels 1-2 and 
analyte responses for a meconium specimen spiked with amphetamine and methamphetamine at 
a concentration of 500 ng/mL and spotted in channels 3-6. 
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Figure 54: Mass spectral response of an amphetamine/methamphetamine positive control sample 
(50 ng/mL) spotted in channels 1-2 and analyte responses for a meconium specimen spiked with 
amphetamine and methamphetamine (500 ng/mL) in channels 3-6. 
 
Meconium sample preparation method #2 also enhanced the mass spectral response for 
amphetamine and methamphetamine in the meconium matrix (Figure 54). While both analytes 
were detected in the meconium matrix using the initial sample preparation method, sensitivities 
were poor and appear to have been greatly enhanced with the additional filtration step. The S/N 
ratio has been increased using sample preparation method #2 and the amphetamine signals are 
now more clearly distinguished from background noise. Distinct analyte signals for amphetamine 
and methamphetamine are also seen in Figure 54 indicating that sample redistribution has been 
minimized/eliminated using the new preparation method. Although analyte signals are 
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significantly enhanced following the additional filtration step, direct comparison of the signals 
from the 50 ng/mL quality control and the 500 ng/mL spiked sample indicate that matrix effects 
still exist. 
Figure 55 shows the mass spectral signals for an amphetamine/methamphetamine 
positive control (50 ng/mL) spotted in sample channels 1-2 and analyte responses for a blank 
meconium specimen prepared according to sample preparation method #2 and spotted in 
channels 3-6. 
 
Figure 55: Mass spectral response of an amphetamine/methamphetamine positive control sample 
(50 ng/mL) spotted in channels 1-2 and analyte responses for a blank meconium specimen 
spotted in channels 3-6. 
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Blank meconium specimens spotted in sample channels 3-6 did not generate any 
appreciable analyte response for either amphetamine or methamphetamine (Figure 55). 
Figure 56 shows the mass spectral response for an opiate positive control specimen (500 
ng/mL) spotted in sample channels 1-2 and analyte responses for a blank meconium specimen 
spiked with morphine, codeine, and hydromorphone at a concentration of 500 ng/mL. 
 
Figure 56: Mass spectral response of an opiate positive control sample (500ng/mL) spotted in 
channels 1-2 and analyte responses for a meconium specimen spiked with opiates (500 ng/mL) 
and spotted in channels 3-6. 
 
Extremely poor analyte signals were again observed for all opiate analytes in both the spiked 
meconium specimen and the positive quality control specimen. Poor analyte signals observed for 
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the 500 ng/mL neat drug standard supported earlier hypotheses that chemical properties of the 
opiates combined with DESI mechanisms may be responsible for the low analyte signals as 
opposed to matrix effects. While evidence of matrix suppression does exist, the inferior 
sensitivity of the opiates relative to the amphetamine and cocaine derivatives suggests that the 
morphine derivatives may not readily lend themselves to DESI, leading to inefficient ion 
formation. Efficient extraction and desorption of the analyte from the surface of interest is vital 
for any DESI experiment. Without efficient extraction and desorption from the surface, analyte 
ionization will be limited leading to decreased sensitivities. Studies indicate that efficient 
recovery of opiate derivatives from the meconium matrix may not be feasible using DESI. 
Although signal intensities were consistently poor for all opiate derivatives, significant 
signal enhancement for the amphetamine and cocaine derivatives indicated that the sample 
filtration step reduced signal suppression and increased overall sensitivity. In order to evaluate 
the increased sensitivity afforded by filtering the organic phase, meconium specimens were 
prepared with and without the filtration step and analyzed side by side. Positive quality control 
specimens prepared through serial dilutions of neat drug standards were again analyzed prior to 
authentic specimens to assist with positive identifications. All positive quality control specimens 
were spotted in sample channel 2 while channels 1 and 3 were left empty. Meconium samples 
prepared using sample preparation method #1 were spotted in sample channels 4-6 and 
meconium samples prepared using the additional filtration step described in sample preparation 
method #2 were spotted in sample channels 7-9. Figure 57 shows the mass spectral responses of 
amphetamine and methamphetamine standards (a-b) as well as benzoylecgonine and cocaine 
standards (c-d) which were spotted in channel 2. Channels 4-6 were spotted with meconium 
which had been spiked with amphetamine and methamphetamine and prepared according to 
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sample preparation method #1. Channels 7-9 were spotted with meconium which had been 
spiked with amphetamine and methamphetamine and prepared according to sample preparation 
method #2. The MS/MS method consisted of four MRM transitions, one for each of the analytes. 
Side by side analyses were performed to determine the extent to which the additional filtration 
step increases overall sensitivity. 
 
Figure 57: Mass spectral responses of amphetamine and methamphetamine standards (a-b) as 
well as benzoylecgonine and cocaine standards (c-d) spotted in channel 2. Mass spectral 
responses in channels 4-6 represent meconium samples which had been spiked with 
amphetamine and methamphetamine (500 ng/mL) and prepared according to sample preparation 
method #1. Mass spectral responses in channels 7-9 represent meconium specimens which had 
been spiked with amphetamine and methamphetamine (500 ng/mL) and prepared according to 
sample preparation method #2.  
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Both the amphetamine and cocaine positive quality control specimens were prepared at a 
concentration of 25 ng/mL. Rows a-b in Figure 57 show the mass spectral responses for the 
positive quality control specimen (sample channel 2) and a meconium specimen spiked with 
amphetamine and methamphetamine at a concentration of 500 ng/mL (channels 4-9). Samples 
spotted in channels 7-9 had undergone additional filtration to remove matrix components 
responsible for signal suppression. Only a small increase in signal intensity is seen for the 
filtered samples indicating that the time expended performing the filtration step may not provide 
significant increases in sensitivity to warrant its inclusion in the method.  
In an attempt to further enhance sensitivity, the mass spectrometry method was separated 
into two separate methods each containing 2 MRM transitions. By separating the mass spectral 
method into two components, each consisting of 2 MRM transitions, it was hoped that dwell 
time, and therefore sensitivity, could be maximized. The MS/MS method was divided into two 
separate methods, one containing the MRM transitions for amphetamine and methamphetamine, 
the other containing MRM transitions for cocaine and benzoylecgonine. Meconium specimens 
which had been spiked with amphetamine and methamphetamine were first analyzed using the 
combined MS/MS method (Figure 57) and then using the specific 
amphetamine/methamphetamine method (Figure 58). Specimens which had been spiked with 
cocaine and benzoylecgonine were first analyzed using the combined MS/MS method (Figure 
59) and then using the specific cocaine/BE method (Figure 60). It was hoped that by reducing the 
number of MRM transitions within each mass spectral method, improvements in sensitivity 
would be observed. Any gains in sensitivity would obviously come at the cost of analysis time, 
as samples would require analysis by two specific mass spectral methods as opposed to one 




Figure 58: Mass spectral responses for amphetamine and methamphetamine with the 
amphetamine/methamphetamine specific MS/MS method containing 2 MRM transitions. Sample 
channel 2 contains a positive quality control specimen prepared at 25 ng/mL. Sample channels 4-
6 contain meconium matrix spiked with amphetamine and methamphetamine (500 ng/mL) and 
prepared according to sample preparation method #1. Sample channels 7-9 contain meconium 
matrix spiked with amphetamine and methamphetamine (500 ng/mL) and prepared according to 
sample preparation method #2.  
 
 
Figure 59 shows the mass spectral responses for amphetamine and methamphetamine in both the 
positive quality control specimen and the spiked meconium matrix. Mass spectral responses were 
obtained using the amphetamine specific MS/MS method containing one MRM transition for 
each analyte. Small improvements in signal intensities were observed for amphetamine and 
methamphetamine when scanning with the 2 MRM transition method. 
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Figure 59: Mass spectral responses of amphetamine and methamphetamine standards (a-b) as 
well as benzoylecgonine and cocaine standards (c-d) spotted in channel 2. Mass spectral 
responses in channels 4-6 represent meconium samples which had been spiked with cocaine and 
benzoylecgonine (250 ng/mL) and prepared according to sample preparation method #1. Mass 
spectral responses in channels 7-9 represent meconium specimens which had been spiked with 
cocaine and benzoylecgonine (250 ng/mL) and prepared according to sample preparation method 
#2.  
 
While mass spectral responses for cocaine and benzoylecgonine in the meconium matrix 
(sample channels 4-9) were relatively low in intensity, significant signal enhancement was 
observed for specimens which had been filtered through Durapore PVDF 0.1µm filter units 
(sample channels 7-9). Figure 59 indicates that filtration of the acetonitrile layer following 
protein precipitation may aid in the removal of endogenous compounds responsible for the 
suppression of cocaine and benzoylecgonine signals. Filtration of the organic layer did not 
appear to enhance the amphetamine/methamphetamine signal to the same degree, however, small 
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increases in the cocaine/BE signals were more easily observed due to the complete absence of 
signal in unfiltered samples.  
 
Figure 60: Mass spectral responses of benzoylecgonine and cocaine standards (a-b) spotted in 
channel 2. Mass spectral responses in channels 4-6 represent unfiltered meconium samples 
which had been spiked with cocaine and benzoylecgonine and analyzed using the cocaine/BE 
specific MS/MS method consisting of one MRM transition for each analyte. Mass spectral 
responses in sample channels 7-9 represent filtered meconium specimens analyzed by the same 
method. 
 
The increased mass spectral responses observed in Figure 60 for cocaine and 
benzoylecgonine indicate that better sensitivities may be afforded by the 2 MRM transition 
method. Further studies into the extent of this signal enhancement are required to evaluate the 
suitability of employing multiple mass spectral methods when scanning authentic samples. While 
reducing the number of transitions in a mass spectral method allows for longer dwell times and 
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greater sensitivity, separating a comprehensive MS/MS method into multiple methods containing 
fewer MRM transitions can be both time and cost ineffective. If a specimen is to be screened for 
the presence of amphetamines and cocaine, analysis time will be minimized using a mass 
spectral method that simultaneously screens for both drug classes. Separating this comprehensive 
method into two separate MS/MS methods would allow for slightly greater sensitivities, but 
would also mean that samples would need to be analyzed twice, once for each method. This 
would have obvious drawbacks in high throughput toxicology laboratories as analysis time 
would be essentially doubled. The advantage of scanning each sample spot twice would be the 
increase in sensitivity afforded by the MS/MS method comprising fewer MRM transitions.  
Detailed experiments aimed at evaluating the disadvantages of increased analysis time 
versus the advantages of increases sensitivities must be performed before conclusions can be 
drawn. The analysis of dilute drug standards prior to authentic patient samples appears to 
significantly aid in the identification of true positives. Due to the complex nature of the 
meconium specimens, low level background signal is often observed when analyzing blank 
specimens. Differentiating between background signal attributable to endogenous matrix 
components and true positive samples can be difficult without the use of a positive quality 
control specimen to act as a reference. By analyzing positive quality control specimens prepared 
at appropriate concentrations prior to authentic patient samples, it is hoped that low level 




8.4 Qualitative Determination of Amphetamine, Methamphetamine, Cocaine, and 
Benzoylecgonine in Authentic Meconium Specimens using DESI-MS/MS. 
In order to evaluate the usefulness of DESI-MS/MS for screening authentic meconium 
specimens for drugs of abuse, direct comparative studies were performed with existing 
immunoassay techniques. While preliminary experiments involving spiked meconium specimens 
are satisfactory for ‘proof of concept’ studies, no insight into the overall applicability of the 
method can be gained until it is applied to authentic samples.  
8.4.1 Experimental Design 
Authentic meconium specimens (n=21) which had previously screened positive at AIT 
Laboratories (Indianapolis, IN) for amphetamine and/or cocaine were selected for the studies 
aimed at directly comparing the screening accuracy of DESI-MS/MS to the pre-existing 
immunoassay technique. Immunoassay screening results are shown in Table 57. All specimens 
chosen for this study were leftover from routine analysis performed at AIT Laboratories. 
Samples were selected based solely on initial screening results and were given arbitrary 
identification numbers to ensure that all samples were blinded and could not be connected to 








Table 57: Immunoassay screening results for experimental specimens. 
Specimen # Amphetamine screen (ELISA) Cocaine/BE screen (ELISA) 
1 Positive Negative 
2 Positive Negative 
3 Negative Positive 
4 Negative Positive 
5 Positive Negative 
6 Negative Positive 
7 Positive Negative 
8 Negative Positive 
9 Negative Positive 
10 Negative Positive 
11 Negative Positive 
12 Positive Negative 
13 Negative Positive 
14 Positive Negative 
15 Negative Positive 
16 Positive Negative 
17 Negative Positive 
18 Positive Negative 
19 Positive Positive 
20 Positive Positive 
21 Negative Positive 
 
Ten specimens screened positive for amphetamines using the immunoassay screening 
technique while thirteen of the meconium specimens screened positive for 
cocaine/benzoylecgonine (Table 57). All specimens (n=21) were then screened using the DESI-






8.4.2 Sample Preparation for DESI-MS/MS Screening Experiments 
Sample preparation for DESI-MS/MS screening was as follows: 
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile 
2. Vortex sample for 45 seconds 
3. Centrifuge sample for 2 minutes at 3000 rpm 
4. Filter organic layer through Durapore PVDF 0.1µm filter units 
5. Transfer and spot 1.5 µL of the acetonitrile phase directly onto the Omni Slide™ 
By eliminating the dry down and reconstitution steps, sample preparation was significantly 
reduced. Following sample preparation, samples were spotted onto the Omni Slides™ according 
to the Figure 61.  
 
Figure 61: Positive quality control specimens were spotted in channel 2 and analyzed first to aid 
with positive identifications. Authentic meconium specimens were then spotted in every second 
sample channel to reduce the possibility of sample redistribution. 
8.4.3 Preparation of Positive Quality Control Specimens 
Positive quality control specimens were again employed for the purpose of aiding in 
positive identifications. In order to more accurately compare analyte signals from positive 
quality control specimens to authentic patient specimens, all positive controls were prepared in 
blank meconium and subjected to the same sample preparation as authentic specimens. 
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Preparation of the amphetamine positive control involved spiking the blank meconium matrix 
with amphetamine and methamphetamine at concentrations of 25 ng/mL. Similarly, the cocaine 
positive control was prepared by spiking the blank meconium matrix with cocaine and 
benzoylecgonine at a concentration of 25 ng/mL. By subjecting the positive controls to the same 
sample preparation as authentic specimens, resulting analyte signals of positive controls will 
more accurately reflect drug concentrations in patient samples. While unextracted drug standards 
used in previous experiments were suitable for differentiating an analyte response from 
background noise, extracted positive QC standards prepared in the meconium matrix will 
provide more accurate indications as to the presence or absence of a drug in the matrix. 
 8.4.4 DESI-MS/MS Parameters 
All DESI source and mass spectrometric parameters were identical to those described in 
sections 8.3.1 – 8.3.3. Optimized MS/MS parameters for amphetamine, methamphetamine, 
cocaine, and benzoylecgonine can be found in Table 55. Analysis time was approximately 15 
seconds per sample. 
8.4.5 DESI-MS/MS Screening Results 









Table 58: DESI-MS/MS screening results for authentic meconium specimens (n=21) screened 
for amphetamines and cocaine. 
Specimen # Amphetamine screen (DESI) Cocaine screen (DESI) 
1 Positive Negative 
2 Negative Negative 
3 Negative Negative 
4 Negative Positive 
5 Positive Negative 
6 Negative Positive 
7 Negative Negative 
8 Negative Negative 
9 Negative Negative 
10 Negative Negative 
11 Negative Positive 
12 Negative Negative 
13 Negative Negative 
14 Positive Negative 
15 Negative Negative 
16 Negative Negative 
17 Negative Negative 
18 Negative Negative 
19 Negative Negative 
20 Negative Negative 
21 Negative Positive 
 
Fewer positive results were observed with the DESI-MS/MS screening method. Three 
specimens screened positive for amphetamines while only four specimens screened positive for 
cocaine/benzoylecgonine (Table 58). Specimens which screened positive using the DESI-
MS/MS method also screened positive on the immunoassay. In order to determine the accuracy 
of each screening method, all specimens were subject to confirmation analysis using UPLC-
MS/MS methods described in chapters 5 & 7. Confirming the presence or absence of each 
analyte using UPLC-MS/MS allowed for a more critical evaluation of each screening method 
with respect to accuracy, selectivity, and sensitivity. Tables 59 and 60 contrast the screening 
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results the immunoassay based screen and the DESI-MS/MS screen with confirmed results, 
respectively.  
Table 59: Immunoassay (ELISA) screening results for 21 authentic meconium specimens. 




Rate of false 
positives 
Rate of false 
negatives 
Amphetamines 10 1 90% 0% 
Cocaine 13 4 69% 0% 
 
Table 60: DESI-MS/MS screening results for 21 authentic meconium specimens. 




Rate of false 
positives 
Rate of false 
negatives 
Amphetamines 3 1 67% 0% 
Cocaine 4 4 0% 0% 
 
All specimens were first screened for amphetamines and cocaine using immunoassay and 
DESI-MS/MS and then subject to confirmation analysis using UPLC-MS/MS to validate the 
reliability of each screening technique. Of the 21 meconium specimens making up the 
experimental sample set, only 5 were confirmed positive for either amphetamines or cocaine. 
Four specimens were confirmed positive for cocaine and/or benzoylecgonine while only one 
specimen was confirmed positive for amphetamine (Tables 59 and 60). The 5 positive samples 
screened positive using both the immunoassay technique and the DESI-MS/MS technique, 
indicating that neither method is susceptible to generating false negatives. While both methods 
successfully identified all true positives, the DESI-MS/MS method appeared to offer far greater 
selectivity than the immunoassay based screen. Of the 10 specimens that screened positive for 
amphetamines using immunoassay, only 1 specimen was confirmed positive representing a 90% 
false positive rate. Of the 13 specimens that screened positive by immunoassay for cocaine, only 
four were confirmed positive representing a 69% false positive rate. When screened using DESI-
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MS/MS the false positive rates for amphetamines and cocaine were drastically reduced to 67% 
and 0%, respectively. The enhanced selectivity afforded by the mass spectrometry based screen 
significantly reduced the number of positive screens. Only 3 of the 21 specimens screened 
positive for amphetamines using the DESI-MS/MS method compared to 10 positives seen with 
the immunoassay based screen (Table 59 and 60). Similarly, only 4 of the 21 specimens screened 
positive for cocaine using the DESI-MS/MS method compared to 13 positive seen with the 
immunoassay technique (Table 59 and 60). Of the 3 samples that screened positive for 
amphetamines using DESI-MS/MS, one was confirmed positive. All four specimens that 
screened positive for cocaine using DESI-MS/MS were confirmed positive. Sensitivity of the 
DESI-MS/MS method for amphetamine and methamphetamine in the meconium matrix was 
quite poor making identification of positive specimens difficult. Amphetamine and 
methamphetamine signal intensities in positive control specimens were not dissimilar to the 
signals observed in negative specimens (Figure 62). Regions between integrated signals in 
Figure 62 represent baseline signal. Amphetamine and methamphetamine signal intensities in 
positive control specimens were approximately equal to the baseline signal making the 




Figure 62: Show the mass spectral responses for amphetamine (a) and methamphetamine (b) in 
the positive quality control and four negative specimens. Signal intensities for the positive 
controls were not dissimilar to those of negative specimens. 
 
Signal intensities for cocaine and benzoylecgonine in positive specimens were significantly 
greater than those observed for positive quality control specimens, allowing for easy 
identification (Figure 63). The signal to noise ratio for cocaine and benzoylecgonine in both 
positive quality control specimens and authentic specimens was far greater than those observed 
for the amphetamines. This increase in the S/N ratio made identification of the cocaine 
derivatives much easier than the amphetamines. The sensitivity of the DESI-MS/MS method for 
cocaine and benzoylecgonine is encouraging and indicates that accurate and reliable screening is 
possible following limited sample preparation.  
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Figure 63: Shows the mass spectral responses for benzoylecgonine (a) and cocaine (b) in a 
positive quality control specimen, three negative specimens (1, 2, and 3) and a true positive 
specimen (4). Intense analyte signals in all true positives allowed for easy identification. 
 
Studies indicate that mass spectrometry based screening techniques, such as the DESI-MS/MS 
method, could greatly reduce the number of false positive samples and prove more cost effective 
than traditional immunoassay techniques. The increased selectivity of the DESI-MS/MS screen 
is hardly surprising considering mass spectrometry has long been employed for confirmatory 
testing following a positive immunoassay screen. Confirmation analysis requires enhanced 
selectivity for the purpose of accurately identifying and quantifying individual analytes 
following a presumptive positive. The potential advantages of mass spectrometry based 
screening techniques have long been recognized, however, due to extensive sample preparation 
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requirements, and cost of analysis, mass spectrometry is generally not well suited to high 
throughput screening. DESI-MS/MS appears to be more suited to high throughput screening as 
samples can be analyzed under ambient conditions following minimal sample preparation. While 
further studies are required to evaluate the sensitivity of DESI-MS/MS relative to immunoassay 
techniques, the methodology appears to offer superior selectivity without the need for extensive 
sample preparation. Such techniques would prove useful for the analysis of alternate biological 
matrices that have traditionally required significant sample preparation prior to instrumental 
analysis.  
8.5 Conclusions 
While further studies are required to evaluate the suitability of the DESI-MS/MS 
technique for the detection of analytes other than cocaine and amphetamine derivatives, 
preliminary studies indicate that the method may be well suited to the high throughput screening 
of meconium samples. Implementation of mass spectrometry based screening techniques such as 
DESI-MS/MS will greatly enhance screening selectivity and reduce the number of false positive 
results commonly observed with immunoassay based techniques. 
 Immunoassay screening techniques are well suited to the analysis of traditional 
biological specimens such as serum and urine, however, these techniques are limited in their 
capability to accurately identify target analytes in more complex matrices such as meconium. 
Furthermore, the turbid nature of meconium specimens often means that significant sample 
preparation is required before the matrix can be analyzed using immunoassay screening 
techniques. Development of a DESI-MS/MS method for screening meconium specimens aimed 
to alleviate existing problems surrounding immunoassay analysis by increasing screening 
selectivity and allowing for ambient sampling of meconium specimens following limited sample 
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preparation. When applied to the analysis of 21 authentic meconium specimens, the DESI-
MS/MS method significantly reduced the rate of false positives compared to immunoassay 
analysis and allowed for the accurate identification authentic meconium specimens containing 
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